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Dementia is a disorder characterized by cognitive impairments and/or behavioral 
disturbances that interfere with the ability of daily functioning.1 Alzheimer’s disease (AD) 
is the most common cause of dementia, characterized by progressive memory loss and 
other cognitive impairment including language, executive functions and visuospatial 
skills.2 In contrary, frontotemporal dementia (FTD) is the second most common cause 
of dementia before the age of 65 years, predominantly characterized by behavioral 
disturbances and/or language deficits.3 Genetic factors are involved in both AD and 
FTD, with a high heritability up to 50% in FTD.4 High penetrant mutations in presenilin 
1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) are major genetic 
causes of autosomal dominant early-onset AD (EOAD).5 Mutations in microtubule 
associated protein tau (MAPT), progranulin (GRN) and hexanucleotide repeat expansion 
within the non-coding region of the chromosome 9 open reading frame 72 (C9orf72) 
are responsible for the majority of FTD cases.6 Although the majority of familial AD and 
FTD cases have been explained by these genetic mutations, there still exists familial 
cases with unidentified mutations. Currently, no cure is available for both diseases. 
Studying genetic factors provide us knowledge about the disease mechanism, which 
is essential for the development of new therapeutic strategies.
During the last decade, genetics in AD and FTD have made major steps, predominantly 
by introducing genome-wide association studies (GWAS) and next-generation 
sequencing (NGS) studies in the genetic research, explaining a subset of the missing 
heritability.6, 7 In contrary to GWAS studying common risk factors with a small effect 
contributing to the development of disease, NGS has enabled us to investigate the 
effect of rare variants with larger effect size.8 Whole exome sequencing (WES), a NGS 
technique focusing on protein-coding regions of the genome, is a cost-effective 
approach to identify mutations with probable damaging effect on the protein function. 
In this chapter we review the genetics forms in AD and FTD with their corresponding 
clinical and pathological features.
Whole exome sequencing (WES)
NGS using parallel sequencing approach to sequence exomes, specific loci or genomes, 
has enabled us to investigate the involvement of rare variants in distinct disease traits.8 
WES, a high throughput sequencing method sequencing protein-coding regions, 
may identify the underlying genetic defect, particularly in small families or single 
patients in which traditional linkage analysis is troublesome. In the last decade, WES 
has successfully identified novel mutations in AD and FTD.6, 9 However, WES has some 
limitations: 1. A high error rate due to sequencing errors or incorrect base calling 
compared to traditional Sanger sequencing. 2. Some genetic variants, such as copy 
number variants, variants in non-coding sequences or repeat expansions cannot be 
10 | Chapter 1
detected. 3. Rare variant analysis is challenging due to low statistical power due to minor 
allele frequencies, population stratification and false positive findings.7 For the latter 
issue, burden tests that compare the cumulative frequency by collapsing rare variants 
in a single gene or a specific genomic region could partly solve power issues, although 
large sample sizes are still needed to detect signals which sustain multiple testing.10
Alzheimer’s disease
AD is clinically characterized by progressive memory loss and other cognitive impairment 
including language, executive functions and visuospatial skills.1 Memory impairments is 
the most common initial clinical presentation of AD, but atypical presentation including 
behavioral changes, language and dysexecutive problems are also observed, and varied 
from 6-14% of AD cases.2 Neuropathologically, depositions of extracellular amyloid 
plaques and intracellular neurofibrillary tangles are the pathological hallmarks of the 
disease.11 AD is subdivided into EOAD and late-onset AD (LOAD) using a cut-off age 
of 65 years. EOAD accounts for about 1-2% of AD cases, and in around 13% of these 
cases an autosomal dominant pattern of inheritance is found.5 Although a subset of AD 
families with an autosomal dominant inheritance has been explained by single gene 
mutation (also referred as Mendelian forms), the majority of AD cases are genetically 
complex involving an interaction between genetic and environmental factors.12 An 
overview of gene defects associated with AD is presented in Table 1.
Table 1. Genes associated with Alzheimer’s disease
Gene Gene locus Inheritance EOAD/LOAD Type of mutation
Implicated disease 
pathway
PSEN1 14q24.2 AD EOAD missense APP processing
PSEN2 1q42.13 AD EOAD missense APP processing
APP 21q21.3 AD EOAD missense, copy 
number variation
APP processing
APOE 19q13.32 Risk factor LOAD missense Lipid metabolism
TREM2 6p21.1 Risk factor LOAD missense Immune response
PLD3 19q13.2 Risk factor LOAD missense Lipid metabolism, 
immune response




ABCA7 19p13.3 AD or risk factor EOAD/LOAD loss of function and 
missense
Lipid metabolism
UNC5C 4q22.3 Risk factor LOAD missense Neuronal 
development
AKAP9 7q21.2 Risk factor LOAD missense Signal transduction
AD, autosomal dominant; EOAD, early-onset Alzheimer’s disease; LOAD, late-onset Alzheimer’s disease.
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Mendelian forms in AD
Highly penetrant mutations in PSEN1, PSEN2 and APP with an autosomal dominant 
pattern of inheritance explain for approximately 5-10% of EOAD patients,5, 13-15 and were 
rarely found in LOAD patients.16 To date, more than 280 mutations have been found in 
PSEN1, PSEN2 and APP genes (www.molgen.ua.ac.be/ADMutations).17
APP
The APP gene is located at chromosome 21, and produces different transcripts by 
alternative splicing.18 The protein APP is cleaved into fragments via non-pathogenic 
pathway (by α and γ-secretases) and amyloidogenic pathway (by β- and γ-secretases). 
Missense and copy number mutations in APP have been reported, and account for less 
than 1% of the EOAD cases.5, 17 The majority of the APP mutations are located at the 
γ-secretases cleavages sites or on exons 16 and 17. However, recessive mutations (A673V 
and E693Δ) have also been reported in families with AD.19, 20 The clinical phenotypes 
of APP mutations carriers include AD and/or cerebral amyloid angiopathy (CAA),21 and 
the age at onset varies from 32-64 years.22 Neuropathologically, increased amyloid 
beta 40 (Aβ40) deposits in the cerebral vessels consistent with diagnosis of CAA have 
been observed.21
PSEN1 and PSEN2
PSEN1 is located at chromosome 14, and its homologue PSEN2 is located at chromosome 
1. Both genes encode for integral membrane proteins that contain nine transmembrane 
domains with a hydrophilic intracellular loop region.23 PSEN1 and PSEN2 are both key 
components of γ-secretases, which processes APP by cleaving into amyloid beta (Aβ) 
fragments.18 Mutations in these genes impair the proteolytic activity of γ-secretases, 
resulting in elevated amyloid-beta 42 (Aβ42) and a higher Aβ42/Aβ40-ratio. 
Mutations in PSEN1 are the most common cause of EOAD accounting for 6% of the 
cases.5 More than 200 mutations in PSEN1 have been reported including missense, 
insertions and deletions.17 In contrary, only 16 pathogenic PSEN2 mutations have been 
identified so far, and accounts for approximately 1% of EOAD.5 Mutations in PSEN1 and 
PSEN2 are highly penetrant, although risk factors and nonpathogenic variants are also 
reported in these genes.24 Variable age at onset among the mutation carriers ranging 
from 23 to 71 years had been reported, even within families with the same mutations.22 
Overall, younger age at onset has been reported for PSEN1 carriers (with mean 43 
years) than for PSEN2 carriers (with mean 58 years). Clinical heterogeneity is frequently 
reported including initial memory impairment, behavioral problems and language 
impairment.25, 26 In PSEN1 carriers, atypical cognitive presentations and pyramidal signs 
are more frequently observed in mutations beyond codon 200, while mutations before 
codon 200 were more frequently associated with younger age at onset.26 
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Neuropathologically, PSEN1 and PSEN2 mutation carriers often have greater amount 
of neocortical senile plaques and higher Aβ42/Aβ40 ratio than sporadic AD cases.27 
Furthermore, cotton wool plaques, which are large amyloid aggregates lacking the 
distinct amyloid core and prominent dystrophic neurites, are more frequently seen in 
PSEN1 mutations carriers with spastic paraparesis than sporadic cases.27, 28
Genetically complex forms
APOE
Apolipoprotein E (APOE) gene is located at chromosome 19, and contains three isoform 
that differ at amino acid residues 112 and 158: APOE ε2, APOE ε3 and APOE ε4.23 APOE 
ε4 is associated with an increased risk for developing LOAD compared to individuals 
with the most common genotype APOE ε3, with three-fold increased risk of AD for 
individuals carrying one ε4 alleles to ten-fold increased risk for those with two ε4 
alleles.18 Furthermore, APOE ε4 also increased risk in EOAD patients who carry at least 
one copy of ε4, and in particularly who have a positive family history.5 Although APOE 
ε4 is associated with an increased risk to develop AD, carrying this allele is neither 
necessary nor sufficient to cause AD. Up to 75% of the people who carry one allele 
of APOE ε4 did not develop AD.29 In contrary, APOE ε2 has a protective effect against 
AD by lowering the risk to 0.6 times in homozygous state compared to the common 
genotype.30 
Various studies have replicated the relationship between APOE and AD including its 
clinical and pathological correlation.31, 32 The number of APOE ε4 alleles is associated 
with an earlier age at onset, and an increased rate of cognitive and functional decline. 
Furthermore, APOE ε4 carriers with AD showed a higher rate of atrophy of the entorhinal 
cortex and hippocampus than APOE ε4 non-carriers with AD. Pathologically, more 
(neuritic) senile plaques have been found in the brains of AD cases carrying at least one 
copy of APOE ε4 than non-carriers, and this number is even higher among AD cases 
carrying two copies of APOE ε4.32
SORL1
The gene Sortilin-related receptor 1 (SORL1) encodes for sorting-related receptor with 
A-type repeats, and is involved in neuronal sorting process including intracellular 
transport, which is important for APP processing and the generation of AB peptides.33 
Genetic association of SORL1 variants with AD was initially reported as a risk factor for 
LOAD in a case-control study,34 and this increased risk has been further replicated in 
other GWAS and meta-analysis.35-38 In the WES era, rare coding variants in SORL1 have 
been found to be enriched in AD cases compared to controls, and in particularly, rare 
protein truncating variants (PTV) have been exclusively found in AD cases.39-41
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Although rare coding missense variants in SORL1 have been reported in patients with 
EOAD as well as LOAD, little is known about the damaging effects and the disease 
penetrance of the reported variants. Only a few studies reported co-segregation of 
rare variants in SORL1 in small families.41, 42 Two possible pathomechanisms of SORL1 
mutants have been hypothesized, possibly depending on mutation type: 1) impaired 
sorting of full-length APP into the retromer-recycling endosome pathway; 2) failure to 
slow trafficking of APP to cell surface.33, 43 
The clinical presentation of SORL1 carriers included classical phenotype of AD with 
memory impairment, although early neuropsychiatric and parkinsonian features have 
also been reported.42, 44 
Rare variants associated with AD risk
Large collaborative efforts in GWAS has successfully identified multiple genetic loci, 
associated with increased risk of AD.45-47 However, these genetic loci, usually containing 
several genes, have only a small effect on AD risk with odd ratios < 2, and emerging 
evidence suggested the existence of rare variants with larger effect size which is 
associated with AD risk. A detailed list of the identified genetic loci can be found at 
www.Alzgene.org. 
Since the implementation of next generation sequencing, multiple rare variants 
with larger effect size associated with AD have been found.48 Triggering Receptor 
Expressed on Myeloid Cells 2 (TREM2) variants have been implicated to increase AD 
risk in two independent studies,49, 50 and the variant p.Arg47His has been replicated 
in many studies.38, 51-54 TREM2 is highly expressed by microglial cells in the brains,49, 55 
and is involved in the regulation of phagocytosis, inhibition of inflammatory signaling, 
cytokine production and secretion in microglia.56 Evidence indicated that mutation in 
TREM2 could result in an impaired clearance of Aβ and microglia activation.57 
Loss of function variants in ATP Binding Cassette Subfamily A Member 7 (ABCA7), a gene 
initially identified in GWAS studies,45 was discovered to be associated with increased 
AD risk in Icelandic population.58 Sequential analysis in several case-control studies has 
confirmed an enrichment of loss of function variants in AD patients comparing with 
controls.59-62 
Rare coding variants in Phospholipase D3 (PLD3) has been implicated to increase 
the risk of LOAD by demonstrating of cosegregation of PLD3 in two large AD families 
using WES followed by genetic association in large case-controls series.63 However, 
this genetic association could not be replicated with either EOAD or LOAD in most of 
the studies.64-68 Sequencing studies have also linked rare variants in genes like UNC5C 
and AKAP9 with risk of AD, but these association is uncertain due to limited replication 
studies and functional experiment.69, 70
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Frontotemporal dementia
FTD is the second most common presenile form of dementia, and is characterized by 
progressive behavioral changes, executive deficits and/or language impairment. Arnold 
Pick has reported the first patient with FTD in 1892, who described a patient with 
progressive aphasia, dementia and lobar atrophy.71 In 1911, Alois Alzheimer referred 
the neuropathological features as Pick bodies and named the clinicopathological entity 
as Pick Disease.72
The prevalence of FTD ranges from 1 to 26 per 100,000 inhabitants with age of 65 or 
younger,73-76 and a frequency of 2.7 per 100,000 inhabitants has been reported in the 
Netherlands.77 The average age at onset is around 50-60 years, and higher age at onset 
of over 70 years has been reported in 10% of the FTD cases.4
Clinical features
FTD is clinically divided into three subtypes: behavioural variant, progressive non-fluent 
aphasia (PNFA) (also known as non-fluent variant PPA) and semantic dementia (SD) (also 
known as semantic variant PPA).4 The latter two and together with logopenic aphasia 
are classified as primary progressive aphasia (PPA). Behavioral variant FTD (bvFTD) is 
characterized by early behavioural changes and impairment in executive functions. 
Patients with PNFA present with slow, labored and halting speech accompanied with 
agrammatism.3 In contrast, patients with SD usually have an impaired word finding 
difficulties and word comprehension but a fluent speech. Motor neuron disease (MND) 
can occur in conjunction with FTD in about 10% of all cases, and is more often observed 
in bvFTD, and rarely in PPA. Furthermore, early parkinsonian symptoms including 
corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) like symptoms 
has been found in up to 20% of patients with FTD. 
Neuropathology
The term frontotemporal lobar degeneration (FTLD) encompasses the pathological 
entity of clinical FTD subtypes, characterized by atrophy of predominantly the frontal 
and temporal lobes.78 The pathology of FTLD is heterogeneous, and can be classified 
into distinct subtypes based on the aggregation of intracellular or intranuclear disease-
specific protein (also referred as inclusions).78, 79 Based on these inclusion and molecular 
defects, FTLD can be classified into four main subtypes: FTLD with tau (FTLD-Tau) in 
~40 % of the cases, transactive response DNA-binding protein of 43 kDa (FTLD-TDP) 
in ~50% of the cases, FET protein (including Fused in Sarcoma (FUS), Ewing Sarcoma 
(EWS) and TATA binding associated factor 15 (TAF-15)) protein aggregation (~5-10%) 
and FTLD-ubiquitin proteasome system (UPS) (<1%).80, 81  
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The main neuropathological finding of FTLD-tau is aggregation of hyperphosphorylated 
tau (ptau) protein in the neuronal and glial cells,80 also called as tauopathy, produced 
by alternative splicing of exon 2, 3 and 10 of the microtubule associated tau (MAPT) 
gene, and accounts for ~40% of all FTLD cases. 
FTLD-TDP-43 has been suggested as the most common FTLD-type representing 
approximately 50% of the FTLD cases.80, 82 The hallmarks of FTLD-TDP are neuronal 
cytoplasmic inclusions (NCI) and dystrophic neurites (DN) which are immunoreactive 
(IR) for TDP-43, ubiquitin and p62. Four different FTLD-TDP subtypes (A-D) has been 
proposed based on the morphology and distribution of these TDP-43 IR aggregates: 
Type A is characterized by abundance of short DN, compact NCI and lentiform neuronal 
intranuclear inclusions (NII), predominantly in the second layer of the neocortex; Type 
B represents cases with diffuse granular NCI and a few DN which are distributed in all 
layers; Type C cases show long thick DN with a few NCI in all layers; Type D cases have 
abundant lentiform NII and short DN in the neocortex, but only rare NCI. Although the 
majority of the FTLD-TDP cases could be classified into one of these TDP subtypes, a 
combination of different FTLD-TDP subtypes has been observed in up to 19% of the 
FTLD-TDP cases.80, 81 Additionally, a small number of cases has been found characterized 
by granulofilamentous neuronal inclusions, abundance of grains and oligodendroglial 
inclusions referred to as TDP type E.83
The remaining FTLD cases (~10%) are subdivided into FTLD-FET or FTLD-UPS, and are 
characterized by tau- and TDP43-negative, but ubiquitin positive inclusions. 
Genetics of FTLD
A positive family history, defined as at least one affected first-degree family member 
with dementia, ALS or Parkinson’s disease, has been reported in 30-50% of patients with 
FTD.4 A positive family history has been more commonly observed in bvFTD cases than 
SD and PNFA. An autosomal dominant mode of inheritance has been reported between 
10-27% of patients with FTD. A mutation in one of the three genes are the major genetic 
causes in FTD, inherited in autosomal dominant mode: MAPT,84 GRN85, 86 and C9orf72.87, 88 
Table 2 lists the causative genes reported in FTLD.
MAPT
The MAPT gene is involved in microtubules stabilization, and was identified as the 
first genetic cause for familial FTD.84 Two possible mechanisms has been suggested 
for pathological deposits of ptau in MAPT mutations: 1) some mutations disrupt the 
binding of tau protein to microtubules and thereby reduce microtubule assembly; 2) 
other mutations affect the splicing regulation of tau protein resulting in an imbalance 
of 3R:4R tau isoform ratios.89 Over 44 different pathogenic MAPT mutations have 
been reported (http://www.molgen.ua.ac.be/FTDmutations), predominantly located 
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between exon 9 and exon 13.17, 90 The frequency of MAPT mutations varied from 5% to 
20% in familial cases depending on the geographical distribution.6, 91-93 
The clinical presentation of MAPT mutations carriers is heterogeneous, with bvFTD 
as the most common phenotype, and less commonly memory impairment, semantic 
deficits and extrapyramidal symptoms.6 Some MAPT mutations carriers presented with 
prominent atypical parkinsonism resembling PSP and CBS, such as p.S303S and p.S305S 
mutations.90 The penetrance of the mutations is high, but unaffected mutation carriers 
have been reported.94, 95 The age at onset varied from 45 to 65 years.88
Table 2. Genes associated with frontotemporal dementia
Gene
Gene 
locus Inheritance Phenotype Pathology
Implicated disease 
pathway
MAPT 17q21.1 AD FTD, PSP, CBS Tau Toxic aggregation 
(defect in neuronal 
cytoskeleton)
GRN 17q21.32 AD FTD, CBS TDP type A Autophagy, Lysosomal 
pathway, inflammation
C9orf72 9q21.2 AD FTD and/or ALS TDP type A 
and/or B
Toxic RNA or repeat 
dipeptides aggregation
CHMP2B 3p11.2 AD FTD UPS Autophagy, Lysosomal 
pathway
TARDBP 1p36.22 AD FTD and/or ALS TDP unspecified DNA/RNA metabolism
VCP 9p13.3 AD IBMPFD, FTD 
and/or ALS
TDP type D Autophagy





AD FTD and/or ALS unspecified RNA metabolism; direct 
interaction with TDP-43
CHCHD10 22q11.23 AD FTD and/or ALS unspecified Mitochondrial 
dysfunction, synaptic 
integrity
TBK1 12q14.2 AD FTD and/or ALS TDP type A or B Autophagy, 
inflammation
OPTN 10p13 AR FTD and/or ALS TDP type A Autophagy
UBQLN2 Xp11.21 AD FTD and/or ALS unspecified Autophagy
FUS 16p11.2 AD ALS (and FTD) FUS DNA/RNA metabolism
TMEM106B 7p21.3 Risk factor FTD NA Regulation of 
lysosomal function and 
progranulin pathways
AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AR, autosomal recessive; CBS, corticobasal 
syndrome; FTD, frontotemporal dementia; FUS, fused in sarcoma; IBMPFD, inclusion body myositis with 
early-onset Paget disease and frontotemporal dementia; NA, not available; TDP, Tar DNA-binding protein; 
UPS, ubiquitin proteasome system.
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The pathological features of MAPT mutations are neuronal loss and gliosis accompanying 
with neuronal inclusions of ptau protein in cortical and subcortical gray and white 
matter.80 The pathological diagnosis of MAPT mutations includes Pick disease, PSP, 
CBD and GGT.90 In general, mutations causing a relative increase of 4R tau isoform by 
alternate splicing of exon 10 are associated with neuronal and glial p-tau inclusions 
resembling the pathology of sporadic PSP and CBD, whereas mutations outside this 
splicing region are associated with Pick bodies containing predominantly 3R or NFT 
containing both 3R and 4R tau isoforms.80
GRN
Progranulin (PGRN) is a growth factor that is involved in various processes including 
wound healing, cell proliferation, tumor growth, neuroinflammation, neuronal survival 
and neurite outgrowth.96 GRN mutation was identified as the second gene which can cause 
FTD.85, 86 Pathogenic mutations in GRN resulted in null alleles, leading to reduced function 
of progranulin (haploinsufficiency). To date, over 70 loss of function GRN mutations have 
been found, representing 5-20% of familial FTD and 1-5% of sporadic FTD cases.17, 97 The 
majority of pathogenic mutations are protein-truncating including nonsense, splice-
site and frameshift mutations, but partial deletions and a complete deletion of GRN 
have also been described.98 Additionally, several missense variants in GRN have been 
reported, however, the pathogenicity of many of these variants are unclear except for 
p.A9D.6 Although the exact pathomechanism how GRN mutations cause FTD is unknown, 
accumulating evidence suggested that PGRN deficiency results in lysosomal dysfunction.96 
Patients with GRN mutations have a highly heterogeneous clinical phenotype, with 
bvFTD as the most common phenotype followed by PNFA.97 Hallucinations and 
delusions have been frequently reported with a frequency up to 25%.99, 100 Clinical 
signs of MND are rarely reported.101 Furthermore, extrapyramidal signs fulfilling the 
diagnosis of CBS have also been observed among GRN mutation carriers.100, 102, 103 GRN 
carriers had a wide range of age at onset, ranging from 35 to 89 years.92, 100, 102 The 
penetrance of mutation carriers is estimated to be 90% at age of 70,97 and the median 
disease duration is 7.0 years.101
The neuropathology of GRN carriers is characterized by many DN accompanied with 
crescentic and oval NCI, most abundant in layer two of the neocortex, consistent with 
FTLD-TDP type A.80 Furthermore, a moderate number of lentiform NII are present. Also, 
DN, NCI and NII are frequently found in the striatum, and variable numbers of NCI are 
found in the dentate gyrus, most of them with a granular morphology.
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C9orf72
In 2011, a pathogenic GGGGCC (G4C2) hexanucleotide repeat expansion in the non-
coding region of C9orf72 has been identified as the most common genetic cause for FTD 
and/or amyotrophic lateral sclerosis (ALS),87, 88 explaining 21% of familial FTD and 6% 
for sporadic FTD in North American and European populations.104, 105 Higher frequency 
has been reported in ALS cohorts with an average of 37% for familial cases and 5% for 
sporadic cases.105 C9orf72 repeats expansion has an autosomal dominant inheritance 
mode, and anticipation in the family has rarely been reported.106 The minimal repeat 
size associated with FTD and/or ALS is not fully clear, but the cut-off is usually set on 
30. Variable repeat size varying from 2-20 repeats in healthy individuals to a larger 
repeat size of a few hundred to several thousands in patients with FTD and/or ALS has 
frequently been observed.107, 108 Furthermore, tissue-specific variation in repeat size 
with a large repeat lengths in brain tissue but shorter in blood, has also been found, 
indicating somatic mosaicism.109 
The underlying disease mechanism of C9orf72 repeats expansion causing FTD and ALS 
is not fully known. Three possible disease mechanism have been suggested: 1) loss of 
function, 2) gain of function through RNA toxicity, and (3) toxicity of dipeptide repeat 
proteins (DPRs) translated from unconventional repeat- associated non-ATG (RAN) 
translation of G4C2 repeats.
110 
Clinically, C9orf72 expansions carriers also had a wide range in age at onset from 27 
to 83 years, and the disease duration ranged from 1 to 22 years.105, 108 BvFTD, ALS or 
combination of FTD-ALS are the most common clinical presentation of mutation carriers, 
and less frequently semantic dementia and non-fluent variant.108, 111 Furthermore, 
initial amnestic symptoms presenting with prominent memory impairment may occur, 
and may fulfill with the clinical diagnosis of AD.1, 108 Psychotic symptoms including 
hallucinations and/or delusions have commonly been reported in C9orf72 expansion 
carriers compared to non-carriers,112, 113 and could be misdiagnosed with psychiatric 
disorders such as schizophrenia or bipolar disorders.114 
Neuropathologically, FTLD-TDP type B is linked to C9orf72 expansions carriers.80 
However, a combination of TDP type A and type B, characterized by moderate to 
numerous NCI in deeper cortical layers with a high proportion of granular NCI, and 
occasionally accompanied with abundant threads and dots, has been found in subsets 
of C9orf72 expansions carriers.81 Furthermore, six different forms of neuronal inclusions 
containing DPR proteins, produced from RAN translation of the G4C2 repeats, have also 
been observed in the brain tissue of C9orf72 expansions carriers.115, 116 
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Rare genetic causes of FTLD
CHMP2B
The first splice site mutation in Charged multivesicular body protein 2B (CHMP2B) was 
identified in a large Danish autosomal dominant FTD family with linkage to chromosome 
3.117 This gene encodes for a component of the Endosomal Sorting Complex Required 
for Transport III, which is involved in protein degradation through endosome-lysosome 
pathway and autophagy.118 The contribution of CHMP2B mutations to FTD is small, 
representing less than 1%. 
Clinically, bvFTD is the common phenotype of CHMP2B mutations carriers.119 
Extrapyramidal symptoms might occur in the advanced stage of the disease process, 
and ALS has occasionally been reported.120, 121
Neuropathologically, abundant NCI that are ubiquitin-IR, but negative for TDP-43 and 
FUS, has been found in dentate granular layer of the hippocampus and the adjacent 
neocortex.122, 123 This pathology is consistent with FTLD-UPS.80
TARDBP
TAR DNA binding protein (TARDBP) encodes for TDP-43, and is involved in the regulation 
of transcriptional activity of messenger RNA splicing, exon skipping and microRNA 
biogenesis.124 In FTLD and/or ALS, TDP-43 is a major component of ubiquitin positive, 
but tau negative inclusions.82 Mutations in TARDBP was initially reported as causative 
gene for ALS representing approximately 3% of ALS cases,125 but other studies have 
reported association with FTD with a mutation frequency close to 1%.126-129 Most 
pathogenic TARDBP mutations are clustered in exon 6, in the conserved C-terminal 
glycine-rich domain.125, 127 
The clinical presentation includes bvFTD and/or ALS, and initial language impair-
ment fulfilling the clinical diagnosis SD or extrapyramidal signs have also been 
reported.128, 130, 131 Only a few studies reported neuropathological findings of TARDBP 
mutation carriers, showing a mild to moderate number of TDP43-IR DN and NCI in 
the neocortical and predominantly subcortical regions, with occasionally neuronal 
intranuclear inclusions.127, 132
VCP
Valosin-containing protein (VCP), also known as p97, is a member of ATPase Associated 
with diverse cellular Activities protein family, and is involved in multiple cellular 
processes including protein degradation via ubiquitin proteasome system, cell 
division, DNA repair.133-136 The first reported VCP mutations was identified in families 
with inclusion body myopathy with Paget’s disease of the bone and frontotemporal 
dementia (IBMPFD).137 IBMPFD is characterized by proximal and distal muscle 
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weakness resembling a limb-girdle dystrophy syndrome, Paget disease of bone and 
frontotemporal dementia.138 To date, more than 15 mutations have been identified in 
VCP, mainly in CDC48 and D1 domains.17 The frequency of VCP mutations is around 
1-3% in FTD and FTD-ALS cohorts.139, 140
Large variation in phenotype has been observed among mutation carriers, even 
for patients within the same family.138, 141, 142 About 90% of the patients presented 
with muscle weakness, 42% with Paget disease of the bone, and 30% with FTD.143 
ALS occurred in up to 10% of the mutation carriers. Due to the large variation in 
phenotype, the term multisystem proteinopathy (MSP) has been introduced to describe 
a combination of two or more phenotypes including IBM, Paget disease of the bone 
or ALS/FTD.144 In the affected tissue, RNA binding protein (e.g. TDP-43, hnRNPA1, and 
hnRNPA2B1) or protein involved in ubiquitin-dependent autophagy proteins (e.g. p62/
SQSTM1, VCP, optineurin, and ubiquilin-2) could be found.
The neuropathology is consistent with FTLD-TDP type D characterized by abundant 
TDP-IR NII and DN.80 NCI are sporadically found in the neocortex.
SQSTM1
Sequestome 1 (SQSTM1), encoding for p62, is a multifunctional protein with multiple 
domains involved in cell survival and cell death.145 It has also been reported that 
SQSTM1 has an important role in targeting ubiquitinated proteins for degradation by 
autophagy or by proteasome pathways. Protein aggregates containing p62 is a hallmark 
of various neurodegenerative diseases, and has been suggested to be caused by an 
impaired autophagy through lysosomal dysfunction. Mutation in SQSTM1 had been 
initially reported as genetic cause of Paget disease of bone, but several studies have 
reported SQSTM1 mutations in patients with FTD and/or ALS considering SQSTM1 as 
a genetic cause for MSP.146-150 It explains 2 to 3% of FTD cases, and 3.8% of the familial 
FTD cases.148, 149 BvFTD is the main presenting phenotype,148, 149 although atypical 
initial presentation such as apraxia of speech and memory impairment has also been 
reported.151, 152 Neuropathological findings consistent with FTLD-TDP type A or type B 
has been reported in a SQSTM1 mutation carriers.153
New FTLD genes in next-generation sequencing era
CHCHD10
Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) is involved 
in mitochondrial cristae morphology and mitochondrial DNA stability.154 Mutation 
in CHCHD10 (p.Ser59Leu) has initially been identified in a family with various clinical 
phenotypes including FTD-like syndrome, MND, cerebellar ataxia and mitochondrial 
myopathy. The frequency of CHCHD10 mutation in FTD and ALS among European 
General introduction and scope of the thesis | 21 
1
cohorts varies from 0.7 to 3.5%.155-158 A higher frequency up to 7.7% is observed in 
Chinese patients with FTD.159 Although distinct rare variants in CHCHD10 have been 
reported in patients with FTD and/or ALS, some variants have also been found in non-
demented controls raising the question whether these variants were pathogenic or 
not fully penetrant.155, 158, 160
hnRNPA1 and hnRNPA2B1
A third genetic cause of MSP are mutations in heterogeneous nuclear ribonucleoproteins 
A1 (hnRNPA1) and heterogeneous nuclear ribonucleoproteins A2B1 (hnRNPA2B1), which 
segregated in two families with MSP.161 These two genes encode for RNA binding 
proteins, and are involved in nucleic acid processing such as splicing regulation.162 The 
identified mutations were mainly clustered in prion like domain which is involved in the 
biogenesis of various membraneless organelles. Mutations in hnRNPA1 and hnRNPA2B1 
are assumed to be a rare genetic cause for FTD and/or ALS as various studies had failed 
to identify any mutations in these genes.161, 163-166
TBK1 and OPTN
The association of loss of function mutations in TANK-binding kinase 1 (TBK1) with 
sporadic ALS cases was discovered in a large case-control exome sequencing study.167 
An independent study confirmed this association with familial ALS cases and FTLD-ALS 
cases, and has evidenced by co-segregation of loss of function (LoF) TBK1 mutations in 
a large ALS-FTD family.168 Several other studies have replicated the association of LoF 
TBK1 mutations with FTD and/or ALS,169-172 but it remained unclear for missense variants 
due to absence of co-segregation with disease and borderline genetic association. 
TBK1 LoF mutations result in 50% loss of TBK1 levels suggesting haploinsufficiency as a 
possible disease mechanism.168, 171 In addition to LoF variants, missense variants located 
close to CCD2 domain of TBK1 has frequently been observed in ALS-FTD phenotype, 
and has been hypothesized to affect the binding with optineurin (OPTN), a gene that 
linked to ALS and FTD.168, 170 The frequency of LoF mutation in TBK1 in FTD and FTD-
ALS is estimated to be 1.1-1.8%,169, 170, 172 and a higher frequency of up to 10% among 
FTD-ALS cases.170, 173 Clinical presentation includes behavioral changes, frequently co-
occur with ALS symptoms, but early memory impairment has also been reported.174 
Neuropathological findings consistent with FTLD-TDP type A or type B have been 
reported in TBK1 mutation carriers.169, 171, 174, 175
OPTN is involved autophagy, and is regulated by TBK1 through phosphorylation.176 The 
contribution of OPTN mutations is small in FTD,177, 178 and only a few studies reported 
compound heterozygous variants in OPTN as a cause of FTLD-TDP type A or FTD-
ALS.171, 177 Interestingly, one FTLD-TDP case carried a deletion in OPTN and nonsense 
mutation in TBK1, suggesting a possibly interaction of these genes in the cause of 
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FTD.171 This report underlined the contribution of oligogenic genes involving in the 
disease phenotype.
Genes with unclear significance in FTLD  
A few genes that are associated with ALS, have also been implicated to cause FTD. 
Two of these genes are ubiquilin-2 (UBQLN2) and FUS, which have been reported to 
be involved in the pathogenesis of ALS and FTD.179, 180
Mutations in UBQLN2, an ubiquitin-like protein, have been identified in X-linked 
dominant ALS and ALS-FTD cases,179 but its contribution to FTD is unclear. Only a few 
studies have reported variants in UBQLN2 in pure FTD phenotype, but all outside the 
frequently mutated PXX repeat domain without supporting co-segregation in families 
or functional experiments.181-183 
Mutations in FUS have been identified as genetic cause of ALS,184, 185 with a mutation 
frequency of 5% in familial ALS and 1% in sporadic ALS.125 Most of the mutations are 
located in the C-terminal, predominantly in familial cases, although mutations in 
the N-terminal have also been reported. The contribution of FUS mutations FTLD is 
uncertain, as only a few studies have reported FUS mutations without neuropathological 
support.180, 186, 187 FUS is localized in the nucleus and is involved in RNA binding, splicing 
and nucleo-cytosolica RNA transport, which is similar to TDP43.125 It is important to note 
that FUS pathology could be found in both ALS and FTLD, but FUS mutations have only 
been observed in exclusively ALS-FUS but not in FTLD-FUS.79, 184, 185, 188 On the contrary, 
TAF-15 and transportin 1 (TRN1) positivity are found in the neuronal inclusions of FTLD-
FUS patients, but not in ALS-FUS patients.189 Additionally, FTLD-FUS proteins has been 
shown to be hypomethylated compared to ALS-FUS proteins.190 These distinct features 
underlined a distinct disease mechanism between FTLD-FUS and ALS-FUS.
Genetic Risk factor
In addition to monogenic cause of FTD, several studies have reported genetic risk factor 
for FTD including variants in transmembrane protein 106B (TMEM106B), Ras-related 
protein Rab-38/cathepsin C (CTSC/RAB38), TREM2 and known FTD genes (MAPT and 
GRN).191-194 Of those, TMEM106B is the most replicated risk factor in FTD, particularly 
among GRN carriers.193-199 The modifying effect of one SNP (rs1990622) in TMEM106B has 
been consistently replicated in GRN mutations carriers,195, 196, 198 in which minor C allele 
of rs1990622 conferred a lower risk, whereas the more common T allele is associated 
with an increased risk of FTD. Interestingly, a lower median age at onset of 13 years has 
been reported for carriers of homozygous T allele of rs1990622 compared to carriers 
of heterozygous and homozygous C allele.195 
General introduction and scope of the thesis | 23 
1
The function of TMEM106B and its relation with GRN is not fully known. Several studies 
indicated that TMEM106B is a lysosomal protein involved in lysosomal size, function and 
lysosomal stress response.200-203 The functional impact of TMEM106B on GRN has been 
supported by the finding of lower plasma GRN levels in GRN carriers and non-demented 
controls carrying the risk allele compared to protective allele.195, 196 Furthermore, more 
than 2.5 times higher expression of TMEM106B in the frontal cortex in FTLD-TDP cases 
compared to unaffected controls.194 In addition to its modifying effect of GRN mutation 
carriers, a protective effect of TMEMB106B has also been found in FTD and FTD-ALS 
patients with C9orf72 expansions carriers.204, 205
Scope of this thesis
Genetic factors play a key role in the etiology of AD and FTLD. Both risk modifying 
common variants and highly penetrant rare variants could contribute to the 
development of AD and FTD. Recent development in next generation sequencing 
enabled us to further investigate the contribution of rare variants in these diseases. The 
distinct genetic, clinical and pathological features underlined the presence of different 
pathomechanisms. The study of genetic factors gives us more insights in the disease 
process, which is essential for the development of disease modifying drugs.
The aim of this study is to describe the contribution of rare variants in AD and FTLD 
using whole exome sequencing, and expands the mutation spectrum of these diseases. 
Furthermore, we aimed to describe the clinical and pathological features of these 
mutations carriers. The thesis is divided in two major parts:
2. Genetics of Alzheimer’s disease
Chapter 2.1 describes the clinical and pathological features of patients with PSEN1 
and PSEN2 mutations including two novel mutations. In Chapter 2.2, we describe rare 
variations in EIF2AK3 gene in Dutch patients with AD and their pathological features. 
3. Genetics of frontotemporal lobar generation
In chapter 3.1, we report two novel and one known VCP mutations in three patients with 
pure FTD as phenotype. Chapter 3.2 describes the finding of a rare variant in TUBA4A 
segregating in a family with FTD. In chapter 3.3, we report clinical and pathological 
findings of a large family with FTD and parkinsonism caused by mutation in PRKAR1B 
gene. In chapter 3.4, we estimate the contribution of PRKAR1B gene in an early-onset 
dementia cohort.
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Mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor 
protein (APP) are major genetic causes of early-onset Alzheimer’s disease 
(EOAD). Clinical heterogeneity is frequently observed in patients with PSEN1 
and PSEN2 mutations. Using whole exome sequencing, we screened a Dutch 
cohort of 68 patients with EOAD for rare variants in Mendelian Alzheimer’s 
disease, frontotemporal dementia and prion disease genes. We identified 
three PSEN1 and two PSEN2. Three variants, one in PSEN1 (p.H21Profs*2) and 
both PSEN2 (p.A415S and p.M174I) were novel, and absent in control exomes. 
These novel variants can be classified as probable pathogenic, except for 
PSEN1 (p.H21Profs*2), in which the pathogenicity is uncertain. The initial 
clinical symptoms between mutation carriers varied from behavioral problems 
to memory impairment. Our findings extend the mutation spectrum of EOAD, 
and underline the clinical heterogeneity among PSEN1 and PSEN2 mutation 
carriers. Screening for AD-causing genes is indicated in presenile dementia 
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2.1
Introduction
Early-onset Alzheimer’s disease (EOAD) accounts for 1-2% of all Alzheimer’s disease 
(AD) cases. It can be caused by mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) 
and amyloid precursor protein (APP) in an autosomal dominant inheritance pattern.1-3 
To date, more than 280 mutations have been found in PSEN1, PSEN2 and APP (www.
molgen.ua.ac.be/ADMutations).4 
Presenilin 1 and presenilin 2 proteins are both key components of gamma secretases, 
which process APP by cleaving into Amyloid beta (Aβ) fragments.5 Mutation in these 
genes impairs the proteolytic activity of gamma secretases, resulting in a disbalance 
of Aβ40 and Aβ42.6 Considerable heterogeneity is found in the clinical presentation 
of PSEN1 and PSEN2 mutation carriers, including initial behavioral, language and 
dysexecutive problems, myoclonus, seizures, spasticity and hallucinations.7, 8 The age 
at onset among mutation carriers also varies greatly, ranging from 23 to 71 years, even 
in families with the same mutation.9 Neuropathologically, PSEN1 mutation carriers 
often have more neuronal loss in the frontotemporal cortex than sporadic AD cases.10 
Furthermore, more neocortical senile plaques and higher Aβ42/Aβ40 plaque ratios are 
observed in PSEN1 and PSEN2 mutation carriers compared to sporadic AD.
In this study, we assessed the contribution of rare variants in Mendelian AD (PSEN1, 
PSEN2 and APP), frontotemporal dementia (FTD) (MAPT, GRN, TARDBP, VCP, CHMP2B, 
FUS and TBK1) and prion disease genes (PRNP) in a Dutch cohort of 68 patients with 
EOAD using whole exome sequencing (WES). We found three novel and two reported 
variants in PSEN1 and PSEN2. We describe the clinical and available pathological features 
of the PSEN1 and PSEN2 variant carriers.
Methods 
Subjects
Patients were included either by referral to the Erasmus Medical Center department 
of neurology (Rotterdam, the Netherlands) or by visits to (nursing) homes. Patients 
underwent a clinical examination, neuropsychological assessment, neuroimaging and, 
if indicated, a lumbar puncture. The diagnosis probable AD was established according 
to the National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for 
AD.11 EOAD was defined as an age at onset of ≤ 65 years. Family history was defined as 
positive if the patient had at least one first degree relative with dementia. Cerebrospinal 
fluid profile (CSF) consistent with AD was defined as amyloid beta 42 <550 pg/mL, 
Tau >375 pg/mL, and pTau>53 pg/ml or a tau/Aβ42 >0.52.12 We selected 68 patients 
with EOAD for WES based on their initial clinical diagnosis of probable AD and/or CSF 
42 | Chapter 2.1
profile consistent with AD, as mentioned above. CSF was present in 41 patients, and 
pathological diagnosis of AD was found in four patients. 
The study was approved by the Medical Ethical Committee of the Erasmus Medical 
Center, and written informed consent was obtained from all participants or their legal 
representatives.
Genetic analysis
DNA from all samples was prepared with the Illumina TruSeq Paired-End Library 
Preparation Kit, and 100 base pair paired-end reads were acquired by sequencing the 
libraries on a HiSeq 2000. Exomes were captured using Nimblegen Seqcap EZ Exome 
Capture Kit v2. All data were generated at the Human Genomics Facility (HuGeF; www.
glimdna.org) at Erasmus Medical Center Rotterdam. Sequencing reads were aligned 
to the hg19 human genome assembly using BWA-MEM (version 0.7.3a),13 followed by 
duplicate marking and sorting alignments by Picard Tools (version 1.9).13 Subsequently, 
Genome Analysis Tool Kit (GATK) (version 3.3) was used to perform indel realignment, base 
quality score recalibration, and variant calling.14 Subsequently, we used Variant Quality 
Score Recalibration from GATK to filter out low-quality variants using thresholds of 90 for 
Single nucleotide variants (SNV) and 50 for indels. All individuals in the WES data were 
checked for sex concordance using Plink.15 Variants were annotated using ANNOVAR.16  
We focused on missense, nonsense, splicing and frameshift variants in Mendelian 
AD (PSEN1, PSEN2 and APP), frontotemporal dementia (FTD) (MAPT, GRN, TARDBP, 
VCP, CHMP2B, FUS and TBK1) and prion disease genes (PRNP) as described in previous 
studies.17, 18 Any identified variants with a minor allele frequency ≥0.1% in the Genome 
aggregation database (gnomAD), Healthy EXomes (HEX), Genome of the Netherlands, 
and in-house WES data from the Rotterdam Study, were filtered out.19-22 Subsequently, 
we interpreted the identified variants using the Alzheimer Disease & Frontotemporal 
Dementia Mutation Database (www.molgen.ua.ac.be/admutations/)4 and AlzForum 
(www.alzforum.org/mutations) databases, and a literature search. Combined Annota-
tion Dependent Depletion score (CADD) was used to predict the pathogenicity of 
the variants.23 Variants in PSEN1 and PSEN2 were further classified according to the 
algorithm described by Guerreiro et al.24 All identified variants were confirmed by 
Sanger sequencing. Screening of chromosome 9 open reading frame (C9orf72) repeat 
expansions was performed on selected cases with upper and/or lower motor neuron 
signs or a family history positive for motor neuron sign. 
Histology and immunohistochemistry
The Netherlands Brain Bank performed brain autopsy according to their Legal and 
Ethical Code of Conduct. Tissue blocks taken from all cortical areas, hippocampus, 
amygdala, basal ganglia, substantia nigra, pons, medulla oblongata, cerebellum, and 
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cervical spinal cord, were embedded in paraffin blocks and subjected to routine staining 
with hematoxylin and eosin, periodic acid-Schiff reaction, and silver staining. The slides 
were also immunochemically stained with Anti-β-Amyloid, 1-42 (Biolegend, 12F4, 
dilution 1:400), Anti-β-Amyloid, 1-40 (Biolegend, 11A50-B10, dilution 1:400), α-synuclein 
(Novocastra, NCL-ASYN; dilution 1:10000) and AT8 (Thermo Fisher Scientific, MN1020; 
dilution 1:200). Braak stage was ascertained according to the revised National Institute 
on Aging-Alzheimer’s Association guidelines.25
Results
The mean age at onset in our cohort of 68 EOAD cases was 57.7 years (range 51-65). A 
positive family history was found in 39 cases (57%). 
Mutation screening
After filtering, we found five rare variants, three in PSEN1 and two in PSEN2 (Table 1). Two 
variants in PSEN1 were previously described in EOAD cases (p.A79V and p.P264L).26-28 
One single PSEN1 (p.H21Profs*2) (Figure 1) and both PSEN2 (p.A415S and p.M174I) 
were novel. No rare variants were found in APP gene. All variants, except one in PSEN1 
(p.A79V), were unknown in gnomAD, HEX, GoNL and exome data from the Rotterdam 
Study. No rare variants in SORL1, TREM2 or ABCA7 have been found in the five PSEN 
carriers. The main clinical features of the PSEN1 and PSEN2 mutations carriers are 
summarized in Table 2.
Figure 1. Electropherogram of PSEN1 p.H21Profs*2 variant.

























































































































































































































































































































































































































































































































































































































































































































































































































































































46 | Chapter 2.1
Novel PSEN1 mutation p.H21Profs*2
PSEN1 p.H21Profs*2 is located in exon 3 which codes for the N-terminal domain. The 
female carrier, aged 60, presented with progressive memory impairment, followed 
by problems in orientation, housekeeping, verbal expression, and loss of initiative. 
Neurological examination one year after onset showed a Mini Mental State examination 
(MMSE) of 23/30, mild bradyphrenia, and left-sided cogwheel sign during risperidone 
medication prescribed for nightmares. Neuropsychological assessment showed deficits 
in multiple domains including memory, executive functions, and visual perception, 
however several tests were prematurely ended due to poor performance. MRI showed 
global brain atrophy and extensive white matter lesions in the parieto-occipital region. 
During follow up, the patient was treated with acetylcholinesterase inhibitors until death, 
aged 65. Family history revealed a mother with dementia with an age at onset of 60.
Novel PSEN2 mutation p.M174I
The p.M174I variant in the PSEN2 gene was identified in a female patient who developed 
memory problems at the age of 53. This variant is located in the hydrophilic loop 
domain of the presenilin 2 protein. The patient developed progressive anomia and 
memory impairment within the first three years. She had a depressed mood and was 
apathetic. Neurological examination (two years after onset) showed an MMSE score of 
18/30, short-term memory impairment, dyscalculia, bradyphrenia, and apraxia. Over 
time, the patient developed behavioral changes, including aggression, restlessness, 
obsessive thinking, blunted emotions, and binge eating. MRI showed generalized 
cerebral atrophy most prominent of the frontal lobes; CSF was not available. The clinical 
diagnosis was either presenile AD with frontal presentation or a behavioral variant of 
frontotemporal dementia (bvFTD). After admission to a nursing home, she developed 
hallucinations, seizures, spasticity and mutism. She died from pneumonia aged 64. The 
patient’s mother had been diagnosed with AD at the age of 75.  
Neuropathological examination of p.M174I PSEN2 carrier revealed severe neuronal loss and 
gliosis of the frontal, temporal and parietal cortices, cornu ammonis (CA) region 1 of the 
hippocampus and to a lesser extent in the other CA regions, subiculum and occipital cortex. 
Abundant AT8-positive threads and tangles accompanied by many Aβ-positive senile 
plaques of variable size and morphology were found in the neocortex, predominantly in 
the frontal cortex, and to a lesser extent in parietal and temporal cortices and CA1 of the 
hippocampus (Figure 2A-E). Classical, predominantly Aβ42-positive plaques with a dense 
core were seen in 5-10% of the plaques. Only a small number of plaques were stained Aβ40-
positive (Figure 2B and C). The severe involvement of the frontal, temporal and parietal 
cortices is consistent with advanced stage AD, Braak stage 6, A3B3C3.25 Furthermore, many 
α-synuclein positive Lewy bodies (LB) were seen (Figure 2F), especially in the amygdala 
and parahippocampal cortex, and a few in the substantia nigra and brainstem.
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Novel PSEN2 mutation p.A415S
The PSEN2 (p.A415S) variant, located in the transmembrane IX domain, was identified 
in a female patient aged 59 who presented with memory impairment and gait 
disturbance. She developed difficulties in verbal expression with problems in word 
finding, hallucinations and myoclonus. Her grandmother, aunt and uncle also had 
dementia, all with onset age > 65. Neurological examination revealed an MMSE of 
17/30, hyperreflexia in the arms and legs, and a spastic gait. Neuropsychological 
assessment showed impairment in memory, language, perceptuospatial skills, and 
praxis. MRI showed global cerebral and cerebellar atrophy. Her CSF was compatible 
with an AD profile with decreased amyloid beta (203 pg/ml), increased phospho-tau (95 
pg/ml) and total tau (551 pg/ml). Cognitive functions including verbal expression and 
motor functioning deteriorated over the following three years, and she was admitted 
to a nursing home. At a later stage, aged 65, she became mutistic and wheelchair 
bound.
Previous reported PSEN1 mutations p.A79V and p.P264L
The patient with PSEN1 p.A79V mutation presented with cognitive impairment, 
delusions, hallucinations and parkinsonism suggestive for probable dementia with 
Lewy bodies (DLB) when aged 64.29 Family history revealed five siblings and a father 
who had AD before the age of 65. Three of the affected siblings also suffered from 
hallucinations. DNA was only available in one sister with AD and onset-age 74 who 
also carried the PSEN1 p.A79V mutation. 
The second mutation, PSEN1 p.P264L, was found in a patient who presented with gait 
disturbance aged 56. Memory impairment, behavioral changes and impairment in 
word comprehension and word finding were also observed early in the disease process. 
The clinical diagnosis was suspected bvFTD or a frontal variant of AD with primary 
lateral sclerosis. The patient’s grandmother, mother and one sister also had dementia. 
Screening on C9orf72 was negative. 
Discussion
We identified one novel frameshift deletion in PSEN1 (p.H21Profs*2) and two novel 
missense in PSEN2 (p.A415S and p.M174I) using WES in a Dutch cohort with EOAD. These 
novel variants were not present in the public sequencing database and population-
match exomes. Additionally, we found two known PSEN1 variants (p.A79V and p.P264L), 
reported as pathogenic in previous studies.31 The PSEN1 and PSEN2 variant carriers 
had variable clinical presentation including memory impairment, behavioral changes, 
pyramidal and extrapyramidal symptoms. 
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The first novel variant, PSEN1 p.H21Profs*2, is a frameshift mutation resulting in a 
premature stop codon in the sequences of exon 3, and as a consequence, a truncated 
protein. Frameshift deletions in PSEN1 and PSEN2 were reported as a possible genetic 
cause of EOAD, however, the pathogenicity is debatable.7, 18, 30 Variable phenotypes of 
the frameshift deletion mutation carriers including AD, mild cognitive impairment, 
frontotemporal dementia and amyotrophic lateral sclerosis have been reported. 
Segregation or functional studies supporting the pathogenicity of these mutations are 
scarce. One study reported a reduced presenilin 2 protein expression in the lymphoblast 
cells of a PSEN2 (p.G359Lfs*74) mutation carrier compared to control, but a reduced 
presenilin 2 protein expression was also found in a mutation carrier with autopsy 
confirmed frontotemporal lobar degeneration.18 We classified the pathogenicity of our 
novel variant as a variant of uncertain significance, as we were unable to investigate the 
functional effect due to the lack of additional blood or brain tissue from the patient.
The second novel variant, PSEN2 p.M174I, was classified as probable pathogenic 
according to the algorithm proposed by Guerreiro et al.24 based on reported mutation 
in the same codon (p.M174V) and the altered Aβ level at neuropathology. However, 
conflicting results about the pathogenicity of p.M174V have been reported.24, 31-33 
Although the pathogenicity of PSEN2 p.M174V is unclear, our case carried a different 
PSEN2 variant with a high CADD score of 20.8, which is unknown in gnomAD. 
Furthermore, Our case’s high number of neocortical senile plaques with a higher Aβ42/
Aβ40 ratio are consistent with the reported pathological features of PSEN1 and PSEN2 
mutations carriers;10 therefore, this variant may be causative for AD.
The third novel variant, PSEN2 p.A415S, was classified as probable pathogenic based 
on: 1) conserved residues in PSEN1 A431; 2) previously reported mutations in the same 
codon (A431E and A431V);34, 35 3) CSF profile with low amyloid beta and high phospo- 
and total tau indicative for AD. Furthermore, the damaging effect of this variant was 
also supported by a high CADD score of 33.
The atypical AD symptoms of the mutation carriers in our study have been frequently 
reported in PSEN1 carriers.8 Up to 16% of PSEN1 carriers had an atypical presentation, 
and about 8% of PSEN1 mutations carriers presented with behavioral changes at onset. 
Similar to previous reports, the PSEN1 p.P264L carrier in our study also had symptoms 
consistent with spastic paraparesis.36 Spastic paraparesis is present in 25% of PSEN1 
cases, and is frequently associated with mutations beyond codon 200.8, 37
Additionally, three of the five carriers in our study had delusions or hallucinations 
during the disease course. In one (PSEN1 p.A79V) carrier, the clinical diagnosis was 
suspect for DLB29 or AD due to the presence of hallucinations and parkinsonism 
together with memory impairments. Interestingly, three siblings of this carrier also had 
hallucinations, but prominent cognitive impairment made the clinical diagnosis of AD 
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more likely. The association of PSEN1 p.A79V with DLB as phenotype has been reported 
previously.38 Notably, DLB phenotype has also been reported in a patient with PSEN2 
p.A85V mutation, which is homolog to PSEN1 p.A79V.39 Neuropathological examination 
of the PSEN2 p.A85V carrier showed abundant neocortical LB as well as AD pathology, 
suggesting a link between this mutation and LB pathology. Up to 96% of LB pathology 
has been reported in familial AD with PSEN1 mutations, while lower percentages have 
been reported in AD with PSEN2 mutation (64%) and sporadic AD (60.7%).40, 41 However, 
this difference in LB pathology between these groups has not been confirmed in other 
studies.42, 43 Unfortunately, no brain tissue of the PSEN1 p.A79V carrier was present to 
examine the presence of LB pathology. Another possibility for the DLB phenotype in our 
case may be the presence of another gene mutation for DLB. Recent studies identified 
the genetic association of variants in the glucocerebrosidase (GBA) gene with DLB.44-46 
In our cases, screening of GBA did not identify any rare variants in this gene (data not 
shown). Nevertheless, the presence of unidentified genetic factor(s) contributing to 
the DLB phenotype cannot be ruled out.
We used exome sequencing to screen for mutations in known dementia genes. Although 
we were able to identify small deletion and missense mutations using this method, 
large deletion such as DeltaE9 in PSEN1,47 C9orf72 repeat expansions, and copy number 
variations variants can be missed, and thus we may underestimate the frequency of the 
mutations. However, these mutations in PSEN1 and PSEN2 are rare, and the observed 
frequency of PSEN variants in 7% of our cohort of 68 EOAD is in line with those reported 
earlier by Brouwers et al.48 Another limitation is that the follow-up time in most patients 
was limited to a few years, and we cannot rule out that additional symptoms may have 
developed later during their disease course. Lastly, DNA was only available from a sister 
with AD of the p.A79V mutation carrier; we were unable to include other family members 
of the other mutation carriers. Therefore, segregation analysis could not be performed 
for these mutation carriers.
Our study provides further insights into the genetics of AD by identifying three novel 
mutations in PSEN1 and PSEN2, and highlights the clinical heterogeneity of the presenilin 
mutation carriers. Although overlapping clinical diagnosis with FTD or DLB was found 
in some patients, we were unable to identify other probable pathogenic dementia-
causing genes besides PSEN1 and PSEN2. Genetic screening of AD causative genes 
is valuable in patients with clinically suspected EOAD with atypical clinical features, 
particularly in familial cases.
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Next generation sequencing has contributed to our understanding of the 
genetics of Alzheimer’s disease (AD), and has explained a substantial part 
of the missing heritability of familial AD. We sequenced 19 exomes from 8 
Dutch families with a high AD burden, and identified EIF2AK3, encoding for 
protein kinase RNA-like endoplasmic reticulum kinase (PERK), as a candidate 
gene. Gene based burden analysis in a Dutch AD exome cohort containing 
547 cases and 1070 controls showed a significant association of EIF2AK3 
with AD (OR 1.84 [95% CI 1.07-3.17], p-value 0.03), mainly driven by the 
variant p.R240H. Genotyping of this variant in an additional cohort from the 
Rotterdam study showed a trend towards association with AD (p-value 0.1). 
Immunohistochemical staining with pPERK and peIF2α of three EIF2AK3 
AD carriers showed an increase in hippocampal neuronal cells expressing 
these proteins compared to non-demented controls, but no difference was 
observed compared to AD non-carriers. This study suggests that rare variants 
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia, characterized by 
progressive decline in memory and other cognitive functions.1 Genetic factors are 
strongly linked to AD, and in about 5% of cases an autosomal dominant mode of 
inheritance has been reported.2 In autosomal dominant forms of early-onset AD, 
mutations in β-amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 
(PSEN2) have been found to be causative genes;3-7 this accounts for approximately 13% 
of early-onset AD.8 In late-onset AD, the ε4 allele of apolipoprotein E gene have been 
found to be the most common risk factor.9
Neuropathologically, the aggregation of misfolded proteins is a major hallmark of many 
neurodegenerative disorders.10 The accumulation of extracellular amyloid plaques and 
intracellular neurofibrillary tangles are the hallmarks of AD.11 Previous studies suggest 
that disrupted protein homeostasis in the endoplasmic reticulum (ER) and activation 
of unfolded protein response (UPR) may be major drivers in AD pathogenesis.10, 12 The 
UPR is induced by three transmembrane proteins in the ER: protein kinase RNA-like 
endoplasmic reticulum kinase (PERK), Inositol Regulating Enzyme 1 (IRE1) and Activating 
Transcription Factor 6 (ATF6). Activation of UPR lead to transient suppression of protein 
synthesis and increased expression of genes aimed to restore the homeostasis of the 
ER.10 Pharmacological and genetic manipulation of the UPR pathways in animal studies, 
in particularly the PERK pathway, has been reported to inhibit neurodegeneration.13
Advances in next generation sequencing technology have contributed substantially to 
our understanding of the genetics of AD. In recent years, studies using whole exome 
sequencing (WES) and whole genome sequencing reported the association of rare 
variants in PLD3, ABCA7, TREM2 and SORL1 with an increased risk in AD.14-18 Furthermore, 
a large exome micro-array study identified rare coding variants in PLCG2, ABI3 and 
TREM2, explaining a small part of missing heritability in AD.19 These studies indicate 
the existence of other rare variants related to the heritability of AD. 
In this paper, we performed WES in eight Dutch AD families with probable autosomal 
dominant inheritance, and identified Eukaryotic Translation Initiation Factor 2 Alpha 
Kinase 3 (EIF2AK3), encoding for PERK, as a candidate AD risk gene in two of these 
families. Together with previous reports on an increased activation of PERK in AD brain 
and the involvement of PERK in memory and learning,20 these findings suggest the 
possible role of EIF2AK3 in the pathogenesis of AD.
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Materials and Methods
Subjects
Our discovery dataset included 19 AD patients from eight Dutch families with a high 
AD burden. Each family had at least two patients with AD suggestive of an autosomal 
dominant inheritance pattern, except one family with an uncertain mode of inheritance 
due to the early death of both parents. The mean age at disease onset in the families 
varied from 62.5 to 71.3 years (Table 1). Non-demented first and second-degree family 
members of each family were also included if available. Using WES, all patients were 
screened negative for mutations in PSEN1, PSEN2 and APP; APP copy number mutations 
were also excluded. For WES, we included DNA samples of at least two patients with 
AD from each family. Non-demented family members with a minimum age of 65 were 
used to test for segregation in their respective family.














NLAD 1 5 8 3 70.4 (60-89) 69.1 (65-77) 46.2 0.2/0.5/0.3
NLAD 2 2 2 2 62.5 (52-73) 69.0 (68-70) 50.0 0/0.25/0.75
NLAD 3 5 2 3 71.3 (68-77) 78.5 (71-86) 71.4 0/0/1
NLAD 4 5 1 2 62.8 (59-65) 66.7 (61-72) 57.1 0/0.12/0.88
NLAD 5 2 0 2 66.0 (NA) NA 0.0 0/0.75/0.25
NLAD 6 3 1 3 67.7 (64-70) 69.0 (NA) 75.0 0/0.67/0.33
NLAD 7 2 3 2 71.0 (66-76) 73.3 (69-78) 20.0 0/0/1
NLAD 8 2 4 2 64.5 (59-70) 71.4 (70-73) 50.0 0/1/0
Number of patients and controls included from each family. Cases are the total number of included patients 
with Alzheimer’s disease and patients with mild cognitive impairment. Controls contains the total number 
of included individuals without subjective of objective memory impairment during the last visit. Age at 
onset is the mean age of first disease onset of all included cases, and the age at last visits is the mean age 
of all included controls. Age at onset and age at last visits in years. AD, Alzheimer’s disease; WES, individuals 
selected for whole exome sequencing; NA, not available.
Patients and family members were recruited after referral to the department of 
Neurology in the Erasmus Medical Center, or after visiting (nursing) homes. Diagnosis 
of probable AD was confirmed in all patients according to the National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association criteria for AD.21
To replicate the association of our candidate gene with AD, we used exome data 
available from 547 AD cases and 1070 controls from three different sites (the Rotterdam 
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Study, Amsterdam Dementia Cohort (ADC-VUmc) and Alzheimer Centrum Erasmus MC 
(AC-EMC)) included from a Dutch AD exome dataset, previously described by Holstege 
et al.18 We then genotyped our candidate variant in 1055 AD cases and 6162 controls 
from the Rotterdam study;22 any individuals from the Rotterdam Study included in the 
exome data were excluded for genotyping.
Our study has been approved by the Medical Ethical Committee of Erasmus Medical 
Center, and written informed consent was obtained from all participants or their legal 
representatives.
Whole exome sequencing analysis
Exomes of 19 AD patients from the discovery set, the Rotterdam Study cohort, and 
the AC-EMC cohort were captured using Nimblegen Seqcap EZ Exome Capture Kit v2. 
Exomes from the ADC-VUmc cohort were captured using the Nimblegen SeqCap EZ 
Exome capture kit v3. All data were generated at the Human Genomics Facility (HuGeF; 
www.glimdna.org) at Erasmus MC Rotterdam, the Netherlands. DNA from each sample 
was prepared with the Illumina TruSeq Paired-End Library Preparation Kit, and 100 
base-pair paired end reads were acquired by sequencing the libraries on a HiSeq 2000. 
For the Dutch exome dataset, we used the overlapping regions between capture kits 
during calling of the data. Sequencing reads were aligned to the hg19 human genome 
assembly using BWA-MEM (version 0.7.3a)23, and Picard Tools (version 1.9)24 were used 
to mark duplicates and to sort the alignments. Subsequently, Genome Analysis Toolkit 
(GATK) (version 3.3) was used to perform indel realignment and base quality score 
recalibration.25 Haplotype Caller from GATK was used to create gVCF files, and to call 
variants from these gVCF files. For the exome data from the eight families (discovery 
set), we used hard filters according to GATK best practices to filter out low quality 
variants. For the exome data from the three Dutch cohorts, we used Variant Quality 
Score Recalibration (VQSR) with >99% sensitivity to filter out low-quality variants. 
Subsequently, Plink was used to calculate Principle component (PC), and outliers on 
the first two PCs were removed.26 Related individuals with identity by decent value 
> 0.1 were also removed from the analysis set. All individuals in the WES data were 
checked for sex concordance using Plink.26 Variants from all datasets were annotated 
using ANNOVAR.27 
In our discovery set, we used a family based analysis to identify candidate genes 
from the eight families. Each family was analyzed separately to identify the candidate 
variants in their respective family. We focused on shared variants among the affected 
family members which resulted in an amino acid change. Subsequently, variants with 
a frequency of 0.5% or lower in 1000 genomes, NHLBI Exome Sequencing Project (ESP), 
Exome Aggregation Consortium (ExAC), Genome of the Netherlands, and in-house 
WES data from the Rotterdam Study were selected (Supplementary Table 1).28-32 If 
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the same variant or different variants in the same gene were identified in at least two 
families, these variants were selected as candidates for follow up and tested with Sanger 
sequencing for segregation in their respective families.
Sanger sequencing
We used Primer 3 33 to design primers for candidate variants. PCR amplification was 
performed using Qiagen Taq DNA polymerase (Qiagen, CA, USA). Direct sequencing 
of PCR products was performed using Big Dye Terminator chemistry ver. 3.1 (Applied 
Biosystems), and run on an ABI3130 genetic analyzer and an ABI3730xl genetic analyzer 
(Applied Biosystems, CA, USA). The sequences were analyzed with Sequencher software, 
version 4.5 (Genecodes, VA, USA) and Seqscape version 2.6 (Applied Biosystems, CA, 
USA).
Genotyping of rs147458427 variant in EIF2AK3
The variant rs147458427 (p.R240H) was genotyped using TaqMan SNP Genotyping 
Assays and genotypes of rs147458427 were determined using TaqMan Allelic 
discrimination. Signals were read with the Taqman 7900HT (Applied Biosystems Inc.) and 
analyzed using the Sequence Detection System 2.4 software (Applied Biosystems Inc.). 
To evaluate genotyping accuracy, all heterozygous calls were typed twice to confirm 
genotypes. Single variant association effects for AD association were calculated using 
R (version 3.2.3) “seqMeta” tool v.1.6.0 adjusting for gender. APOE status was added as 
covariate in the secondary analysis.
Statistical analysis of the candidate genes in the Dutch exome dataset
Single variant association effect for AD association was calculated using R (version 
3.2.3) “seqMeta” tool v.1.6.0 adjusting for gender. Burden test was calculated for our top 
candidate gene in the family-based analysis using burdenMeta function in “seqMeta” 
tool v.1.6.0. Only variants with minor allele frequency (MAF) ≤ 1% in ExAC was included 
in the burden test, adjusting for gender. In the secondary analysis, we performed these 
analyses on our top candidate gene, adjusting for gender and APOE status.
Histology and immunohistochemistry
The Netherlands Brain Bank performed brain autopsy according to their Legal and 
Ethical Code of Conduct. Tissue blocks of three EIF2AK3 carriers (two from family 
NLAD 1 and one from family NLAD 4) were taken from all cortical areas, hippocampus, 
amygdala, basal ganglia, substantia nigra, pons, medulla oblongata, cerebellum, 
and cervical spinal cord. They were embedded in paraffin blocks and subjected to 
routine staining with haematoxylin and eosin, periodic acid-Schiff reaction and silver 
staining. Immunohistochemistry was performed with antibodies directed against 
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phosphorylated pancreatic endoplasmic reticulum kinase (pPERK) (sc-32577, Santa 
Cruz biotechnology, CA, 1:12800) and phosphorylated eukaryotic initiation factor-2α 
(peIF2α) (SAB4504388, Sigma-Aldrich, St. Louis, MO, 1:100). We performed staining 
of pPERK and peIF2α on the frontal, temporal and hippocampal regions of our three 
pathological-confirmed AD EIF2AK3 carriers, three AD non-carriers, and three non-
demented controls. Immunohistochemical staining of the neurons with pPERK and 
peIF2α were scored with a semi-quantitative method using a modified version of 
the scale developed by Stutzbach et al and Hoozemans et al: Negative (-): no cells 
stained, rare (+): 1–3 cells stained, ++: 4–20 cells stained or up to 10 percent of cells 
stained, +++: 20+ cells stained or 11 to 30 percent of cells stained, ++++: high density 
of stained cells (> 30 percent) in almost every field of the section.34,35 In the frontal and 
temporal regions, the average number of positive stained cells per field were counted 
in nine different fields of the cortical layer at 20x magnification. In the hippocampus, 
we used a different scoring method as this region is often severely affected in AD with 
extensive neuronal loss. We counted the total number of neurons with a nucleus, as well 
as the number of these neurons containing pPERK or peIF2α staining to calculate the 
percentage of stained neurons. We focused on Cornu Ammonis 1 (CA1) and subiculum, 
as these contain the largest number of positive stained cells, and calculated the average 
percentage of stained cells per field in three different fields of CA1 and subiculum, each 
at 40x magnification. 
We used Mann-Whitney U test to examine the difference between AD EIF2AK3 carriers 
and non-carriers. All tests are two-sided significant, and a p-value below 0.05 was 
assumed as being statistically significant.
Immunoblot analysis
Post-mortem fresh-frozen brain tissue of frontal cortex from three carriers of EIF2AK3 
mutations (III:15 and III:18 from family NLAD 1 and III:7 from family NLAD 4, Supplemen-
tary Figure 1) and three AD cases were extracted from the frontal cortex with buffers of 
increasing strength.36 Briefly, grey matter was extracted at 5 ml/g (volume/weight) with 
low salt buffer (10mM Tris, pH 7.5, 5mM EDTA, 1mM DTT, 10% sucrose, and a cocktail of 
protease inhibitors), high salt-Triton buffer (low salt + 1% TritonTM X-100 + 0.5M NaCl), 
myelin floatation buffer (30% sucrose in low salt + 0.5M NaCl), and sarkosyl (SARK) 
buffer (1% N-lauroylsarcosine in low salt + 0.5M NaCl). The SARK insoluble material was 
extracted in 0.25 ml/g urea buffer (7M urea, 2M thiourea, 4% 3-[(3- cholamidopropyl) 
dimethylammonio]-1-propanesulphonate (CHAPS), 30mM Tris, pH 8.5). Proteins were 
resolved by 7.5% SDS-PAGE and transferred to PVDF membranes (Millipore). Following 
transfer, membranes were blocked with Tris buffered saline containing 3% powdered 
milk and probed with the antibody p-PERK (sc-32577, Santa Cruz). Primary antibodies 
were detected with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG 
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(Jackson ImmunoResearch), and signals were visualized by a chemiluminescent reaction 
(Millipore) and the Chemiluminescence Imager Stella 3200 (Raytest).
Results
Family based exome analysis of the discovery set
In our discovery analysis of 19 AD patients from eight families, we found an average 
of 91 (range 26-136) candidate variants per family after filtering (Supplementary table 
1). Combining the candidate variants of the eight families, we found 101 variants in 
36 candidate genes, with some genes showing many variants shared among families 
(Supplementary Table 2). We excluded the MUC genes as potential candidate as these 
are reported as frequent hitters in many WES datasets.37 We selected the gene EIF2AK3, 
encoding for pancreatic endoplasmic reticulum kinase (PERK) as top candidate gene,7 
based on its involvement in memory and learning, and on its neurodegenerative role 
in AD and other neurodegenerative diseases,12, 38 
The first EIF2AK3 variant, p.R240H (rs147458427), was heterozygous in four affected 
individuals (including one with mild cognitive impairment) of family NLAD 1, and 
in one non-demented, 72-year old cousin of the proband (Supplementary Figure 1). 
This variant had a CADD score of 31 and a frequency of 8.00x10-04 in ExAC. The second 
EIF2AK3 variant, p.N286S (rs150474217), had a low CADD score of 0.002 and a frequency 
of 3.00x10-05 in ExAC, and was confirmed in four patients with AD from family NLAD 4 
and in one non-demented, 72-year old individual at last visit. One sibling with memory 
complaints and a normal Mini mental state examination score, did not carry the variant. 
Two of three patients with AD in family NLAD 4 carried homozygous APOE ε4; the 
third patient was heterozygous for APOE ε4. All patients were diagnosed with early 
onset AD. 
Sanger sequencing on the remaining variants in the 32 candidate genes shared among 
the eight families (MUC genes excluded) confirmed variants in 15 genes (Supplementary 
table 2). Segregation analysis of the variants in these 15 genes in their respective family 
did not show perfect segregation for most variants; the segregation in some variants 
could not be tested due to limited samples from related individuals.
Evaluation of EIF2AK3 variants in Dutch cohorts
To determine the genetic association of EIF2AK3 in AD, we performed gene-based 
burden analysis of EIF2AK3 variants on the Dutch AD WES dataset. We detected 23 
EIF2AK3 variants in this dataset (Figure 1 and Supplementary Table 3), of which 19 had 
an allele frequency <1% in ExAC; 17 of these rare variants were missense mutations. 
Burden test of all variants in EIF2AK3 with MAF <1% in ExAC showed an increased risk 
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for AD (OR=1.84; 95%CI 1.07-3.17, p=0.03). Single variant analysis showed more carriers 
of variant p.R240H in cases (OR=4.22; 95%CI 1.06-16.80, p=0.04), but the nominal 
significant did not sustain the Bonferroni correction (Supplementary Table 3). We then 
performed a second analysis with APOE as additional covariate showing the frequency 
of EIF2AK3-carriers with at least one copy APOE ε4 is 62% (16/26). The single variant 
analysis of p.R240H (OR=4.47, p=0.04) and the burden analysis (OR=1.9, p=0.025) were 
similar to the analysis without APOE as covariate. 
As the variant p.R240H showed a suggestive signal with a high CADD score, we 
genotyped this variant in an independent cohort from the Rotterdam study containing 
1055 cases and 6162 controls. We found an increased frequency in AD cases compared to 
controls (OR=3.03; 95%CI 0.78-11.48, p=0.10), and an association with AD after adjusting 
for APOE as additional covariate (OR=2.57; 95%CI 0.69-9.51, p=0.16), however, in both 
cases the results were not statistically significant.
Figure 1. Schematic representation of EIF2AK3 gene and relative position of the EIF2AK3 variants found 
in the present study. The gene EIF2AK3 contains 1116 amino acids and is composed of a signal peptide, a 
regulatory domain and a catalytic domain. Variants highlighted in red are found in the family based analysis.
Immunohistochemistry and immunoblot analysis
In our EIF2AK3 carriers, many neurons with positive staining for pPERK and peIF2α 
were seen in the hippocampus, as well as a low to moderate number of positively 
stained neurons in the frontal and temporal cortex (Table 2). The activated pPERK and 
peIF2α staining in neurons were punctate shaped and were located in the cytoplasm, 
as reported in previous studies (Figure 2A-F).34, 35 One carrier (III:18) from family 1 had 
severe neuronal loss in the CA regions and subiculum. Overall, the staining of peIF2α 
was more prominent than pPERK (Figure 2A,2D). All elderly non-demented controls 
showed a low to moderate degree of pPERK staining in the hippocampus. EIF2AK3 
carriers had significantly more positive staining than non-demented controls in the 
hippocampus (p=0.04) and temporal region (p=0.03). For peIF2α, a trend for more 
positive staining was only observed in the hippocampus of EIF2AK3 carriers compared 
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to non-demented controls (p=0.07). We found no difference in all examined regions 
when comparing EIF2AK3 carriers with AD non-EIF2AK3 carriers; all EIF2AK3 carriers had 
Braak stages 6 with extensive tau pathology in the hippocampus, frontal, temporal 
and parietal cortices. 
Figure 2. Immunohistochemical staining of pPERK and peIF2α in the AD cases with EIF2AK3 mutations. 
Activated pPERK and peIF2α was found in the hippocampus and temporal regions (A-F). High numbers of 
pPERK stained cells were observed in the cornu ammonis (A) and subiculum (B) of the hippocampus, and 
lesser numbers were found in the temporal cortex (C). Abundant neurons with peIF2α staining were also 
found in the hippocampus (D), and a moderate number of stained cells were found in the frontal cortex 
(E). Cytoplasmic peIF2α staining is punctate shaped (F), and is similar to the pPERK staining (B). Scale bars 
have been added to the figures.
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We used western blot analysis with a series of buffers with increasing strength to 
solubilize proteins to investigate biochemical alteration of pPERK. One band of 
approximately 140 kDa in low salt, representing pPERK, was found in both EIF2AK3 
mutation carriers and AD cases. We found no differences in banding and solubility 
of pPERK between carriers of EIF2AK3 and AD non-EIF2AK3 carriers (Supplementary 
Figure 2).
Discussion
This is the first study to investigate the role of rare variants in EIF2AK3 in patients with 
AD. We performed whole exome sequencing in eight Dutch families with a high burden 
of AD, and identified EIF2AK3 as a candidate gene in two families. Subsequently, gene 
based analysis in an independent Dutch WES cohort showed suggestive association 
of EIF2AK3 with AD. These effects seemed to be mainly driven by variant p.R240H. 
Although pPERK and peIF2α staining was more prominent in EIF2AK3 carriers than in 
controls, it was similar to AD non-EIF2AK3 carriers. 
We identified two distinct variants in EIF2AK3 segregating with AD in two different 
families, although unaffected carriers found in each family suggested incomplete 
penetrance; however, they may still develop AD at an older age. The association of an 
EIF2AK3 variant with AD has been reported previously, wherein one SNP (rs7571971) 
in EIF2AK3 was associated with AD in APOE ε4 carriers, but not independent of APOE,39 
however, to date, no studies have examined the association of rare variants in EIF2AK3 
with the risk of AD. The gene burden test of EIF2AK3 in our Dutch AD exome dataset 
supported this association of rare variants with AD (p=0.03), in which it was mainly driven 
by the variant p.R240H with a CADD score of 31, but we were unable to confirm the 
association between p.R240H and AD in an additional cohort from the Rotterdam study, 
although there was a trend towards association with AD. A possible explanation for the 
lack of significance is the relatively small sample size for this rare variant. Notably, the 
high frequency of APOE ε4 carriers among the EIF2AK3 carriers in the two families and in 
the Dutch AD exome dataset further support an association of EIF2AK3 variant with AD 
in APOE ε4 carriers as indicated by Liu et al,39 although similar results were found for the 
association tests with and without APOE as covariate. Studies with larger sample sizes are 
needed to examine the effects of rare variants in EIF2AK3 on the risk of developing AD.
The potential significance of EIF2AK3 variants in our families also lies in the fact that 
PERK is a transmembrane protein involved in learning, memory and unfolded protein 
response (UPR).20, 40 Our hypothesis was that variants in EIF2AK3 may enhance PERK 
signaling, resulting in increased phosphorylation of tau by glycogen synthase kinase 
3β (GSK3β) and amyloidogenesis (by BACE1). Previous studies have indicated that 
PERK-eIF2α signaling is involved in the modulating of tau phosphorylation and APP 
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processing in AD,35, 40, 41 but that it is also correlated with the level of tau pathology in 
Progressive Supranuclear Palsy and AD.34, 35 pPERK immunoreactivity also colocalized 
with GSK3β in neuronal cells, which is involved in tau phosphorylation.35, 41 Treatment 
with a PERK-inhibitor (GSK2606414) in transgenic mice with frontotemporal lobar 
degeneration and overexpression of p.P301L mutation resulted in reduced GSK3β-
levels and tau phosphorylation compared to transgenic mice without PERK inhibitor 
treatment.42 Moreover, PSEN1 (5XFAD) mutated mice with PERK haploinsufficiency had 
lower levels of Beta-secretase 1 (BACE1) than those with normal PERK levels, resulting 
in lower amyloid-beta peptides levels and plaque burden, as well as fewer memory 
deficits and cholinergic neurodegeneration.40 Reduced synaptic plasticity and spatial 
memory deficits were found in APP/PS1 AD model mice with PERK happloinsufficiency.43 
Although these studies supported a role of PERK signaling in the pathogenesis of AD, 
functional experiments are needed to confirm the effect of EIF2AK3 variants. 
The increase of PERK-eIF2α signaling in the EIF2AK3 carriers is supported by the more 
positive staining of pPERK and peIF2α compared to non-demented controls, indicating 
an increased activation of UPR. This increased UPR has also been observed in AD and 
PSP patients in previous studies.34, 44 However, we did not find any differences in pPERK 
and peIF2α staining between EIF2AK3 carriers and AD non-EIF2AK3 carriers, suggesting 
EIF2AK3 mutation carriers might not induce more UPR activation than other AD patients. 
A possible explanation is that EIF2AK3 mutation carriers may trigger UPR activation 
early in the disease process, without the ability to observe this at the end stage AD. 
The main limitation of our study is the family-based analysis used to identify the 
candidate genes; we only selected genes containing rare variants in at least two families 
for follow-up. We cannot rule out the possibility that other possible candidates in the 
families were missed. However, this method has previously been successfully used by 
Cruchaga et al, resulting in the identification of the genetic association of PLD3 with 
AD.14 Furthermore, EIF2AK3 was the only gene in our candidate list involved in the 
pathogenesis of AD. Another limitation is the limited available samples of related cases 
and (old) non-demented controls in some families to analyze segregation; some non-
demented controls may still develop dementia at older age. Finally, the frequency of 
APOE ε4 is high in some families, and APOE ε4 segregates with the disease in some of 
them. This is also true for family 4, in which variant p.N285S was found; four patients 
and one individual with memory complaints carried at least one copy of APOE ε4. 
However, all four patients carrying p.N285S and APOE ε4 had early onset AD, indicating 
a possible additional effect of genetic variation in EIF2AK3 on the risk of AD among 
APOE ε4 carriers, as indicated in a previous study.39 Future analyses in larger case-control 
studies are necessary to confirm this association.
In conclusion, our study showed that rare variants in EIF2AK3 may be associated with an 
increased risk of AD based on segregation among the patients with AD in two families 
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and a gene-based analysis in the Dutch WES cohort. Immunohistochemistry confirmed 
more activation of UPR, characterized by increased pPERK and peIF2α in AD patients 
compared to non-demented controls, but not between EIF2AK3 carriers and AD non-
carriers. Further studies are needed to investigate the full contribution of rare variants 
in EIF2AK3 in the development of AD.
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Supplementary Figure 1. Pedigrees of families with EIF2AK3 variants. The upper pedigree shows the family 
(NLAD 1) of patients with Alzheimer’s disease (AD) with EIF2AK3 p.R240H variant, and the lower pedigree 
the family (NLAD 4) with the EIF2AK3 p.N285S variant. Filled symbols are affected individuals, and a quarter-
filled symbols are individuals with subjective memory complaints. Symbols with a diagonal line represent 
deceased individuals. The proband is indicated with triangle. Numbers in the symbols indicate the number 
of individuals. The individuals III:14, III:15 and III:18 from NLAD 1 and individuals III:3 and III:4 from NLAD 4 
were selected for whole exome sequencing. Plus sign indicates that the individual carry the variant, and 
minus sign indicates that the variant is absent. APOE status is available for subset of the included individuals. 
AAO, age at onset; AAD: Age at death; AV, Age at last visit; P, Pathological confirmed AD.
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Supplementary Figure 2. Immunoblot analysis of PERK in EIF2AK3 carriers and AD non-EIF2AK3 carriers. 
Proteins were extracted from the frontal cortex of EIF2AK3 carriers and non-EIF2AK3 carriers with Alzheimer’s 
disease. Antibody against pPERK showed a band of ~140 kDa in low salt (LS), which is indicated with the 
arrow. We found no differences in solubility of pPERK between EIF2AK3 carriers and non-EIF2AK3 carriers. 
Also, no difference in banding pattern was seen between EIF2AK3 carriers and non-EIF2AK3 carriers. Low 
salt (LS), TritonTM X-100 (TX), sarkosyl (SA) and urea (UR).
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3CHAPTER 3
Genetic heterogeneity in 
frontotemporal lobar degeneration
3.1CHAPTER 3.1
Three VCP mutations in patients 
with frontotemporal dementia
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Valosin-containing protein (VCP) is involved in multiple cellular activities. 
Mutations in VCP lead to heterogeneous clinical presentations including 
inclusion body myopathy with Paget’s disease of the bone, frontotemporal 
dementia and amyotrophic lateral sclerosis, even in patients carrying the same 
mutation. We screened a cohort of 48 patients with familial frontotemporal 
dementia (FTD) negative for MAPT, GRN and C9orf72 mutations for other 
known FTD genes by using whole exome sequencing. In addition, we carried 
out targeted sequencing of a cohort of 37 patients with frontotemporal 
lobar degeneration with transactive response DNA-binding protein 43 
(TDP-43) subtype from the Netherlands Brain bank. Two novel (p.Thr262Ser 
and p.Arg159Ser) and one reported (p.Met158Val) VCP mutations in three 
patients with a clinical diagnosis of FTD were identified, and were absence 
in population-match controls. All three patients presented with behavioral 
changes, with additional semantic deficits in one. No signs of Paget or 
muscle disease were observed. Pathological examination of the patient with 
VCP p.Arg159Ser mutation showed numerous TDP-43 immunoreactive (IR) 
neuronal intranuclear inclusions (NII) and dystrophic neurites (DN), while 
a lower number of NII and DN were observed in the patient with the VCP 
p.Thr262Ser mutation. Pathological findings of both patients were consistent 
with FTLD-TDP subtype D. Furthermore, only rare VCP-IR NII was observed in 
both cases. Our study expands the clinical heterogeneity of VCP mutations 
carriers, and indicates that other additional factors, such as genetic modifiers, 
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Introduction
Valosin-containing protein (VCP), also known as p97, is a member of ATPase Associated 
with diverse cellular Activities protein family.1, 2 VCP is composed of an N-terminal 
domain (CDC48) involved in ubiquitin binding, two D1-and D2 domains that bind and 
hydrolyze ATP, and a flexible C-terminal region.1, 3 These structures can be assembled 
into a homohexamer.3, 4 VCP is involved in multiple cellular processes including 
protein degradation via ubiquitin proteasome system,5 cell division, nuclear envelope 
formation,6 endoplasmic reticulum associated protein degradation (ERAD),7 aggresome 
formation,8 Golgi apparatus assembly, autophagy, mitophagy, endosomal trafficking, 
cell cycle, and DNA repair.9 
The classical phenotype of mutations in VCP is inclusion body myopathy with Paget’s 
disease of the bone and frontotemporal dementia (IBMPFD) with an autosomal 
dominant inheritance.10 IBMPFD is characterized by proximal and distal muscle 
weakness resembling a limb-girdle dystrophy syndrome, Paget disease of bone and 
frontotemporal dementia (FTD).11 Currently, different mutations in domains linker 1, D1 
and predominantly CDC48 are reported to this multisystem disease.12 The phenotype 
of these mutations can be variable, even within the same family: patients could solely 
present with myopathy, FTD or amyotrophic lateral sclerosis (ALS).12-15 Myopathy is the 
most common presenting features of this disease, and is found in about 91% of the 
patients, while an FTD phenotype was observed in approximately 30% of patients with 
VCP mutations.16 Pathologically, transactive response DNA binding protein of 43 kDa 
(TDP-43) and p62 immunoreactive (IR) short dystrophic neurites (DN) with neuronal 
intranuclear inclusions (NII), classified as FTLD-TDP type D, are characteristic for VCP 
mutations.17, 18 
In this study, we sequenced a cohort of 48 patients using whole exome sequencing 
(WES) and analyzed 37 pathological confirmed FTLD-TDP cases using targeted 
sequencing, leading to the identification of three mutations in VCP (including two 
novel) in three unrelated Dutch patients presenting with FTD. Here, we here describe 
the clinical and available pathological characteristics of these mutation carriers. 
Methods
Subjects
The Dutch FTD cohort included patients with a clinical diagnosis of FTD, ascertained 
as part of an on-going genetic-epidemiological study in the Netherlands since 1994.19 
Detailed clinical information of the patients was obtained by interviewing relatives 
and reviewing medical records from hospitals or nursing homes. Patients underwent 
a neurological examination and neuropsychological assessment when possible. 
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Neuroimaging including computed tomography (CT), magnetic resonance imaging 
(MRI) and single-photo emission computed tomography (SPECT) was also reviewed 
when available. The diagnosis of behavioural variant of FTD (bvFTD) was established 
according to the international consensus criteria by Rascovsky,20 and ALS was diagnosed 
when patients met El Escorial criteria.21 Pathological diagnosis of frontotemporal lobar 
degeneration (FTLD) is confirmed by the pathologist of the Netherlands Brain Bank.
In the Dutch FTD cohort, we selected all patients with FTD and with a positive family 
history for dementia or ALS, but without mutations in MAPT, GRN and repeat expansion 
in c9orf72 (n=48). The mean age at onset was 59.0 ± 9.4 years (range 36.2-73.9), and 
the mean age at death was 67.3 ± 9.9 years (range 42.5-82.7). Pathological diagnosis of 
FTLD was confirmed in 13 patients (FTLD-TDP in 12 and 1 FTLD-Tau), and no autopsy 
was performed in the remaining 35 patients. Additionally, a cohort of 37 patients 
with FTLD-TDP without mutations in GRN and repeat expansion in c9orf72 from the 
Netherlands Brain Bank was selected for targeted sequencing (data of family history 
were incomplete). The mean age at onset of the latter cohort was 59.9 ± 7.4 years (range 
45.2-80.5). The mean age at death was 68.3 ± 6.4 (range 54.5-87.4).
DNA was obtained from blood in patients selected for WES and was extracted from 
cerebellar brain tissue of patients selected for targeted sequencing. The study is 
approved by the Medical Ethical Committee of the Erasmus Medical Centre and the 
Netherlands Brain Bank, and informed consent is obtained from all participants.
Genetic and bioinformatic analysis
Whole exome sequencing was performed using Nimblegen v2 Seqcap EZ Exome Kit 
(Roche) for exome capturing. DNA was prepared with the Illumina TruSeq Paired-End 
Library Preparation Kit according to manufacturer’s instructions, and sequenced on a 
HiSeq 2000 (Illumina, San Diego, CA). The data was generated at the Human Genomics 
Facility (HuGeF; www.glimdna.org) at Erasmus MC according to an in-house pipeline.
Targeted sequencing was performed using customized exon capture kit. A list of known 
neurodegenerative disease genes was captured using custom-designed targeted 
panel created by SureDesign (Agilent Technologies, Santa Clara, CA). DNA library was 
prepared by NEBNext Ultra DNA Library Prep Kit for Illumina according to manufacturer’s 
instructions, and paired-end sequencing was performed using Illumina HiSeq 4000 
(Illumina, San Diego, CA). Sequences were processed in-house using Mayo Clinic’s DNA 
analysis pipeline Genome GPS v4.0. 
Alignment of the sequencing reads to the human reference genome GRCh37 was 
performed using Burrows-Wheeler Aligner.22 After alignment, duplicate reads were 
marked and removed using Picard (v1.119).23 HaplotypeCaller from Genome Analysis 
Toolkit (GATK) was used for variant calling, and quality control using variant quality score 
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recalibration and hard filters according to GATK best practice. Functional annotations 
of variant sites were performed using ANNOVAR.24 Combined Annotation Dependent 
Depletion (CADD) score (v1.3) was used to predict the pathogenicity of the variants.25 
In both sequencing data, we focused on disease-causing genes in AD and FTD (APP, 
PSEN1, PSEN2, MAPT, GRN, TARDBP, VCP, SQSTM1, CHMP2B, CHCHD10, FUS, CSF1R, TREM2, 
UBQLN2, SOD1, OPTN and TBK1). Non-synonymous or protein truncating variants 
(including nonsense or frameshift INDELS) with minor allele frequency of <0.01% 
from the genome Aggregation Database (gnomAD) were retained.26 Additionally, 
we used the sequencing data from Genome of the Netherlands (GoNL) and exome 
data of non-demented individuals from the Rotterdam study (n=2101) to filter out 
polymorphism.27, 28 
All candidate variants were validated by Sanger sequencing, and sequenced on an 
ABI3730xl genetic analyzer (Applied Biosystems, CA, USA). 
Histology and immunohistochemistry
Brain autopsy was performed in the p.Thr262Ser and p.Arg159Ser VCP mutation carriers 
by the Netherlands Brain Bank. Immunohistochemical staining was performed using 
the following antibodies: Hyperphosphorylated tau (AT8, 1:40, Innogenetics), amyloid-β 
protein (1:100, DAKO), p62 (1:200, BD Biosciences Pharmingen), phospho (p) TDP-43 
(1:100, Biotech) and VCP (ab11433-50; 1:500, Abcam). The pathological diagnosis of 
FTLD was made by neuropathologist (A.J.M.R.). TDP-43 pathology was classified in 
subtypes according to the algorithm described by Mackenzie et al.18
Results
Genetic analysis
In the WES cohort, we found three rare nonsynonymous variants after filtering: two in 
VCP (p.Thr262Ser and p.Met158Val), and one in TARDBP (p.Ile383Val). In the targeted 
sequencing data, we found one additional variant in VCP (p.Arg159Ser) and one variant 
in APP (p.G119R). Sanger sequencing confirmed all variants. The variant in APP gene 
was most likely not pathogenic due to its location (exon 4). The variant in TARDBP 
had been reported previously.29 All three variants in VCP were unknown in gnomAD, 
GoNL and exome data from the Rotterdam Study, and two of these (p.Thr262Ser and 
p.Arg159Ser) have not been reported previously (Table 1).
Clinical features of VCP mutations carriers
Patient 1 (p.Met158Val) - At 41 years old, this patient presented with reduced empathy, 
loss of interest in grooming, reduced verbal output, and increased aggressiveness. 




















































































































































































































































































































































































































































































































Three VCP mutations in patients with frontotemporal dementia | 93 
3.1
Prominent difficulties with finding words and naming objects were noticed early in the 
disease process. He was also obsessive in collecting and disassembling devices, and 
was ticking on couches. Neurological examination one year after disease onset showed 
word finding problems and short-term memory impairment. Fasciculations or muscle 
weakness were absent. Routine blood tests showed a normal calcium, phosphate and 
alkaline phosphatase. Neuropsychological assessment revealed lack of disease insight, 
semantic deficits, executive dysfunction, and to a lesser extent impairment of memory 
and visual constructive function. MRI showed cortical atrophy and moderate bilateral 
temporal atrophy. The clinical diagnosis was bvFTD with pronounced semantic deficits. 
Patient died at the age of 46. No autopsy was performed. Family history showed no 
dementia in his both parents at age of 64, but dementia with behavioral changes in 
his grandfather on father’s side at the age of 55 (1A), and dementia in his 79 year-old 
grandmother. Both grandparents on mother’s side developed dementia at old age.
Patient 2 (p.Arg159Ser) – At 56 years old, this female patient developed personality 
changes and lost interest in her hobbies. She became egoistic and aggressive towards 
her husband, and she had transiently suicidal thoughts. There were no memory 
complaints and her orientation was normal. Her spontaneous speech diminished, 
and finally she became mute. CT-scan at 59 years old showed enlarged ventricles with 
cortical atrophy. The patient died at the age of 62 due to cachexia. Brain autopsy was 
performed. Family history revealed that her mother developed dementia at the age 
of 58 years (Fig. 1B).
Patient 3 (p.Thr262Ser) – At age 60, this female patient presented with reduced empathy, 
childish behavior, withdrawal from social contact and loss of interest in grooming (Table 
1). She spent money on charities and gambling, and was drinking excessive amounts of 
alcohol. She developed memory problems and became disoriented. She also lost her 
skills in playing violin at professional level. Apathy, wandering and reduced verbal output 
were observed at the age of 64 years. She was admitted in the hospital with epileptic 
seizures, which was treated with anti-epileptics. Neurological examination five years 
after disease onset revealed reduced verbal output with echolalia. Signs of myopathy 
or bone disease, muscle weakness or fasciculations were absent. At neuropsychological 
testing, she had impairment in fluency, executive tasks and semantic paraphasias. 
Routine blood and cerebrospinal fluid examination revealed no abnormalities, with 
normal alkaline phosphatase and phosphate. CT scan showed atrophy of the frontal 
lobes and SPECT showed frontal hypoperfusion. The clinical diagnosis bvFTD was 
established. In the end stage of her disease, epileptic seizures increased in frequency, 
and she died at the age of 67. Brain autopsy was performed. Family history revealed 
that her mother presented with hyperorality, roaming and disorientation suggestive 
for the clinical diagnosis of bvFTD; she died at 62 years of age (Fig. 1C).
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Neuropathological findings of p.Arg159Ser and p.Thr262Ser carriers
Macroscopically, prominent frontal atrophy was observed in both cases. Histological 
examination showed neuronal loss with gliosis in upper three neocortical layers, cornu 
amonnis (CA) 1, subiculum and parahippocampus, and in the insula and thalamus. 
Staining with pTDP-43 and p62 antibodies showed moderate to numerous NII and 
Figure 1. Pedigree of the VCP mutation carriers. Pedigrees show family members of p.Met158Val mutation 
carrier (A), the p.Arg159Ser mutation carrier (B), and the p.Thr262Ser mutation carrier (C). Symbols with a 
diagonal line represent deceased individuals. The proband is indicated with the triangle. Numbers in the 
symbols indicate the number of individuals. Half-filled symbols represent individuals with Frontotemporal 
dementia and a quarter-filled symbols represent individuals with uncharacterized dementia. AAO, Age at 
onset; AAD, Age at death.
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short DN in all layers of the frontal and temporal cortex, and to a lesser extent in the 
parietal cortex (2A-2E), but none were detected in the dentate gyrus, CA regions of the 
hippocampus and occipital cortex. Abundant DN and NII were found in the neocortex 
of p.Arg159Ser case (2C and 2D), while much lesser DN and NII were observed in 
p.Thr262Ser (2A and 2B). Overall, round or lentiform-shaped NII of variable size and 
DN were found in the upper cortical layers, and less frequently in the deeper layers. 
A few TDP-43-IR neuronal cytoplasmic inclusions (NCI) were also found in the cortical 
regions of both cases, and were sporadically found in the medulla oblongata and 
spinal cord of p.Thr262Ser case. Both cases can be classified as FTLD-TDP type D.18 VCP 
immunostaining revealed low numbers of NII scattered in the upper layer of the cortical 
regions (Figure 2F), but no NCI were found. Amyloid-β immunostaining showed a few 
senile plaques and sporadically neuritic plaques in p.Arg159Ser carrier corresponding 
with Thal 2, Braak 2 and Consortium to Establish a Registry for AD (CERAD) 0.30 In 
p.Thr262Ser carrier, only a few hyperphosphorylated tau depositions without plaques 
were observed corresponding with Braak 1.
Figure 2. Immunohistochemistry of the brains from two VCP mutations carriers. Lentiform neuronal 
intranuclear inclusions (NII) positive for transactive response DNA binding protein of 43 kDa (TDP-43) 
immunohistochemical staining were observed in frontal cortex of p.Thr262Ser mutation carrier (A). Some 
rare TDP-43 positive NII were also found in the brainstem of this case (B). In contrast, numerous TDP-43 
immunoreactive NII and dystrophic neurites (DN) were observed in all layers of the frontal (C) and temporal 
cortices (D) of p.Arg159Ser mutation carrier. The NII were also immunoreactive for p62 (E). Staining of VCP 
revealed rare NII (F). The arrows indicate the pathological findings. Scale bar is 20 μm.
Discussion
In this study, we identified two novel and one reported mutation in the VCP gene in 
patients with bvFTD, and we provided neuropathological features of the two novel 
mutations (p.Thr262Ser and p.Arg159Ser) carriers. The initial clinical presentation of 
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behavioral problems (including semantic deficits in one) without any signs of motor 
neuron disease or myopathy indicated the clinical diagnosis of bvFTD. Neuropathological 
findings in two patients showed numerous TDP43-IR NII and short DN compatible with 
FTLD-TDP type D and rare VCP-IR NII. 
The pathogenicity of the three VCP mutations is supported by the fact that mutations 
at the same codon have been reported previously (Table 1).13, 17, 31 Furthermore, the 
mutations in the present study are not present in population-matched controls, and 
were identified in the CDC48 and D1 domain, wherein most of the pathogenic VCP 
mutations have been reported.12 The mutation p.Met158Val has previously been 
identified in a patient with sporadic ALS,13 but it has not been reported in FTD before. 
The pathogenicity of this mutation is supported by increased translocation of TDP-43 
from the nucleus to cytoplasm compared to those transfected with wild-type VCP in 
transfected SH-SY5Y cells and HEK293T cells.13 Mutations in codon 159 and 262 have 
been reported in patients with variable phenotypes including, FTD, ALS, IBMPFD.17, 31-33 
The pathological findings of FTLD-TDP type D in our mutations carriers is consistent 
with previously reported findings of VCP mutation carriers.17, 31 
The clinical presentation of pure FTD without any signs of Paget disease of the bone 
or myopathy in all three patients is in contrast to the classical phenotype of IBMPFD 
associated with mutations in VCP.10 Distinct phenotypes including pure FTD or ALS 
have been described in other mutations at the same codons,13, 31, 32 suggesting that 
additional genetic or environmental factors may determine the clinical phenotype. 
Another possibility might be a preclinical state of IBM or Paget disease, however, 
normal values of alkaline phosphatase in two patients made Paget disease unlikely. 
Furthermore, no muscle weakness or fasciculations were reported in neurological 
examinations ruling out IBM or ALS. The variation in age at onset and the unaffected 
parents of the proband in pedigree A also supported the presence of possible genetic 
modifiers in VCP mutations carriers.
The presence of VCP-IR NII in both cases indicated the involvement of mutant VCP in 
protein degradation. The neuropathological findings of numerous TDP43-IR NII and DN 
in both cases were similar to previously reported VCP mutations at the same codons.17, 
31 However, the distribution and the severity of the neuronal inclusions and DN differed 
between the two cases, with a lower number of NII and DN in the p.Thr262Ser carrier. 
These differences were unlikely to be related to the disease duration as the disease 
duration was shorter in the p.Arg159Ser carrier. A possible explanation is that the 
different location of the mutations may explain the extent of the pathology. More 
studies are needed to elucidate the disease mechanism of VCP mutations.
The frequency of 3.5% of VCP mutations could not be compared to other studies, as we 
screened a highly biased cohort of those patients without any other known mutations. 
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Our findings indicated that it is worthwhile to screen for VCP mutations, especially 
after excluding the most common mutations for FTD. In our Dutch FTD cohort, the 
frequency of VCP mutations was 4.2% in those with a positive family history. A limitation 
of the present study is that clinical information of the latest stages of the disease is 
unavailable. Patients were deceased many years ago, and were not followed until dead. 
At last, co-segregation analysis in families could not be performed due to the lack of 
DNA samples from relatives. 
In conclusion, we report three VCP mutations, of which two novel mutations, in three 
Dutch patients with bvFTD. Pathological findings and previously reported mutations 
at the same codon support the pathogenicity of these mutations. Our findings expand 
the genetic and clinical spectrum of VCP mutations, and further underline the clinical 
heterogeneity. Future studies are warranted to investigate the involvement of genetic 
modifiers in the disease process of VCP carriers.
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Pathological accumulation of intermediate filaments can be observed in 
neurodegenerative disorders, such as Alzheimer’s disease, frontotemporal 
dementia and Parkinson’s disease, and is also characteristic for neuronal 
intermediate filament inclusion disease. Intermediate filaments type IV 
include three neurofilament proteins (light, medium and heavy molecular 
weight neurofilament subunits) and α-internexin. The phosphorylation of 
intermediate filament proteins contributes to axonal growth, and is regulated 
by protein kinase A. Here we describe a family with a novel late-onset 
neurodegenerative disorder presenting with dementia and/or parkinsonism 
in 12 affected individuals. The disorder is characterized by a unique 
neuropathological phenotype displaying abundant neuronal inclusions by 
hematoxylin and eosin staining throughout the brain with immunoreactivity 
for intermediate filaments. Combining linkage analysis, exome sequencing 
and proteomics analysis, we identified a heterozygous c. 149 T>G (p.Leu50Arg) 
missense mutation in the gene encoding the Protein kinase A type I-beta 
regulatory subunit (PRKAR1B). The pathogenicity of the mutation is supported 
by segregation in the family, absence in variant databases, and the specific 
accumulation of PRKAR1B in the inclusions in our cases associated with a 
specific biochemical pattern of PRKAR1B. Screening of PRKAR1B in 138 patients 
with Parkinson’s disease and 56 patients with frontotemporal dementia did 
not identify additional novel pathogenic mutations.
Our findings link a pathogenic PRKAR1B mutation to a novel hereditary 
neuro degenerative disorder and suggest an altered protein kinase A function 
through a reduced binding of the regulatory subunit to the A-kinase anchoring 
protein and the catalytic subunit of protein kinase A, which might result in 
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Introduction
Neurofilament proteins assembling into neuron-specific intermediate filaments (IF) type 
IV, are major constituents of the axonal cytoskeleton. Neurofilaments undergo significant 
changes in their subunit composition during development and in adult neurons, and 
play an essential role in axonal growth, axonal transport and signalling pathways.1 In 
the CNS, the major neuronal IF can be distinguished into three neurofilaments proteins: 
NF-L (light), NF-M (medium) and NF-H (heavy), and α-internexin, each composed of 
an N-terminal head domain, an α-helix-rich central rod domain, and a C-terminal tail 
domain.2 Phosphorylation of the Lys-Ser-Pro repeats sites at the C-tail of NF-H and NF-M 
and at sites at the N-terminal domain, was proven to be essential for neurofilament-
specific function.3 The cyclic AMP-dependent protein kinase A (PKA) plays a major 
role in phosphorylation of neurofilaments,4 and hyperphosphorylation of Lys-Ser-Pro 
repeats sites causes disrupted neurofilament axonal transport, prevents turnover of 
neurofilaments by ubiquitin proteasome system, and results in the accumulation of 
neurofilaments.4-7  
PKA is an heterotetramer, consisting of two regulatory and two catalytic subunits, which 
is inactive in the absence of cyclic AMP.8 Binding of cyclic AMP to regulatory subunits 
unleashes the catalytic subunit, thereby enabling PKA signalling. The regulatory 
subunits also provide binding sites for A-kinase anchoring protein (AKAP), a scaffold 
protein for targeting PKA signalling.9, 10 Mutation in these regulatory subunits are shown 
to alter the PKA function.11, 12
Several neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, 
motor neuron disease, and frontotemporal dementia (FTD) show aggregation of 
neurofilaments in association with disease-specific accumulation of tau, α-synuclein 
or transactive response DNA-binding protein 43 (TDP-43), respectively.5 Neuronal 
intermediate filament inclusion disease (NIFID), a rare neurodegenerative disorder, 
shows NF and fused in sarcoma (FUS) protein-positive inclusions, which are negative 
for tau, TDP-43 and α-synuclein.13-18 NIFID is a non-familial disorder,16, 19, 20 and neither 
pathogenic variants in any of the genes coding for IFs and FUS, nor biochemical 
modifications of IF were found.15, 21, 22
Furthermore, neurofilaments inclusions are found in patients with Charcot-Marie-Tooth 
disease type 2E and in transgenic mice with a mutation at the major phosphorylation 
site (Ser55Asp) of NEFL gene.23-25 Also, a transgenic mouse model overexpressing 
α-internexin, induces the formation of cerebellar torpedoes, and abnormal accumulation 
of neuronal IF.26 
In this paper, we report a novel familial neurodegenerative disorder with a highly 
specific neuropathological phenotype consisting of abundant α-internexin-positive, but 
118 | Chapter 3.3
FUS-negative neuronal inclusions. By means of genome-wide linkage analysis, exome 
sequencing and proteomics of neuronal inclusions, we have identified a pathogenic 
mutation in the gene coding for the type I-beta regulatory subunit of protein kinase 




We studied a three generation-large family with twelve affected patients presenting 
with dementia and/or extrapyramidal syndrome (Fig. 1 and Table 1). Medical information 
was limited in the five deceased affected members (II:1, III:1, III:12, III:13, III:14). One 
clinically unaffected patient, III:9, who died from myeloid leukemia at 57 years old, has 
been described with α-synuclein negative Lewy bodies previously.27 The proband (III:4) 
from this family was evaluated for motor and mental complaints at the age of 56 years. 
The age at onset of the affected individuals varied between 45 and 64 years, the mean 
disease duration was 14.8 years, but varied from 5 to 25 years. 












II:1 45 70 25 - + + NA
III:1 NA NA NA NA - + NA
III:2a 50 67 17 - + _ NA
III:3 50 75 25 - + NA Frontal
III:4a 56 61 5 - + + Generalised
III:5 - - - 65 - - NA
III:6 60 - - 67 + + Generalised
III:7 <57 63 NA - + NA NA
III:8 <60 62 NA - + NA NA
III:9a - 57 - - - - NA
III:10 63 71 8 - + + Generalised
III:11 - - - 80 - - NA
III:12 <65 67 NA - + NA NA
III:13 64 73 9 - + NA Generalised
III:14 NA 74 NA - + NA NA
Range 45-64 61-75 5-25
+ or – indicate the presence or absence of the phenotype or information; NA, not available.
a Autopsy confirmed cases.
PRKAR1B in neurodegenerative disease | 119 
3.3
Figure 1. Pedigree of the family with PRKAR1B mutation. Filled symbols represent affected individuals 
by behavioural symptoms, dementia and or parkinsonism, and empty symbols represent unaffected 
individuals. Symbols with a diagonal line represent deceased individuals. Pathology is denoted by P, and 
the proband is indicated by an arrow. Numbers in symbols indicates the number of individuals. Sex of 
the pedigree members are obscured to protect privacy. * = individuals included in linkage analysis; + = 
individuals included in exome sequencing.
DNA was extracted from peripheral blood samples of patients III:2, III:3, III:4, III:5, III:6, 
III:10, III:11, and from the spleen of patient III:9. The study was approved by the Medical 
Ethical Committee of the Erasmus Medical Center Rotterdam, and all family members 
participating in the study or their legal representatives have given informed consent. 
A series of 138 unrelated patients with Parkinson’s disease and an autosomal dominant 
pattern of inheritance were also studied. The clinical diagnosis of Parkinson’s disease 
was established according to widely used criteria.28 The patients originated from Italy 
(n=114), Brazil (n=14), Portugal (n=9) and The Netherlands (n=1). The average onset age 
of Parkinson’s disease symptoms was 53.5 ± 11.7 years (range 20-75), and the average 
disease duration was 8.5 ± 7.1 years (range 1-36). In these patients the entire PRKAR1B 
coding region (10 exons) and exon-intron boundaries were sequenced by Sanger 
protocols in order to find possible pathogenic variants. Primers and PCR protocols are 
reported in the Supplementary Table 1. PRKAR1B variants were also analyzed in exome 
sequenced cohorts of familial FTD (n=51) and FTD-FUS (n=5). The average onset age 
of symptoms was 58.4 ± 8.6 years (range 36-73) in familial FTD and 33.7 ± 2.4 (range 
30-36) in FTD-FUS. The average disease duration was 66.8 ± 8.8 (range 43-83) in familial 
FTD and 43.1 ± 3.7 (range 39-46) in FTD-FUS.
Genomic analysis
CSV files containing SNP call data from HumanCytoSNP-12v2.1(Illumina) arrays of 
five related patients, see Fig. 1, were adapted by GenomeStudio (Illumina) for linkage 
analyses using Allegro29 implemented in easyLINKAGE Plus.30 SNPs with a call rate 
lower than 95% were excluded from the calculations. Mendelian inheritance check 
was performed for all family members, with the program PedCheck.31 SNPs showing 
Mendelian inconsistencies were excluded from the calculation. Individuals who were 
encoded by the pedigree information file were used for allele frequencies computation. 
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Two separate multipoint linkage analyses were performed (affected only) on genotypes 
from five affected individuals using Allegro with a SNP spacing of 0.2 cM and one of 
0.5 cM. LOD scores in sets of 100 markers were calculated assuming the disease to be 
an autosomal dominant disorder with a gene frequency of 0.0001 in the population. 
Regions showing a LOD score > 1.5 in both models were used as candidate regions 
(Supplementary Fig. 1). As borders, flanking SNP markers were used. Additionally, 
genome wide copy number analysis in genotyped individuals was performed using 
signal intensity files generated with GenomeStudio 2011, V2011.1 (Illumina, San Diego, 
CA) in Nexus Copy Number, Discovery Edition, ver. 5.1 (BioDiscovery, El Segundo, CA).
Three individuals (III:2, III:3 and III:4) were selected for exome sequencing (Fig. 1). 
Whole exome capture and sequencing were performed by LGC Genomics GmbH 
(Berlin, Germany). Exomes were captured by Agilent’s SureSelect AllExon Kit, and were 
sequenced with 100 base pair reads on the Illumina HiSeq2000 platform, according 
to the manufacturer’s protocol. Reads were mapped to the human reference genome 
sequence (assembly GRCh37/hg19) using the Burrows-Wheeler Alignment Tool.32 The 
identified variants per individual were called by using Genome analysis Tool Kit (GATK) 
and annotated by ANNOVAR.33, 34 GATK was also used for base quality recalibration, 
local sequence realignment and variant filtering to minimize base calling and mapping 
errors. Variants with quality score < 30, quality over depth < 5, strand bias > -0.10 and 
depth < 20 were filtered out. Additionally, Indels with strandbias > -1.0 instead of -0.10 
were filtered out. We used the dbSNP129 (http://www.ncbi.nlm.nih.gov/projects/SNP/), 
the 1000 genome project (www.1000genomes.org/) and the National Heart Lung 
Blood Institute Exome Variant Server (https://evs.gs.washington.edu/EVS/) to filter out 
polymorphisms. The predicted functional effects of the novel sequence variants were 
assessed by Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), Sorting Intolerant 
from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.html), PROVEAN (http://
provean.jcvi.org/seq_submit.php) and Mutation Taster (www.mutationtaster.org). The 
conservation of amino acid across different species was identified by MUCLES.35
Histology and immunohistochemistry
The Netherlands Brain Bank performed brain autopsy (III:2 and III:4) within four hours 
of death according to their Legal and Ethical Code of Conduct of the Netherlands Brain 
Bank. Tissue blocks were taken from all cortical areas, hippocampus, amygdala, basal 
ganglia, substantia nigra, pons, medulla oblongata, cerebellum, and cervical spinal 
cord, and were embedded in paraffin blocks and subjected to routine staining with 
haematoxylin and eosin, periodic acid-Schiff reaction and silver staining. Brain autopsy 
and routine staining of the third case (III:9) was described by van Duinen (van Duinen 
et al., 1999), and several regions were obtained for immunohistochemistry.
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Immunohistochemistry was performed with antibodies directed against: hyperphos-
phorylated tau (AT-8, Innogenetics, Ghent, Belgium; 1:400); β-amyloid protein (DAKO, 
Glostrup, Denmark; 1:100, following formic acid pre-treatment); α-synuclein (Zymed 
Laboratories, San Francisco, California, USA; undiluted, following formic acid pre-
treatment); poly-ubiquitin-binding protein p62 (BD Biosciences Pharmingen, San 
Diego, CA, USA; 1:200, following pressure cooking); TDP-43 (ProteinTech Group, 
Chicago, IL, USA; 1:100, following pressure cooking); neuroserpin (Abcam; 1:100); SMI-
31 (Sternberger, Lutherville, MA; 1:5000); SMI-32 (Sternberger; 1:7000) α–internexin 
(Invitrogen, Camarillo, CA, USA, 1:100, following pressure-cooking); FUS (ProteinTech; 
1:25–1:200 with initial overnight incubation at room temperature, following pressure 
cooking), and PRKAR1B (2x anti-PRKAR1B, Abcam ab38225; 1:50 and Santa Cruz 
Biotechnology SC-907, Inc; 1:125). Specificity of PRKAR1B antibody is described in 
other studies.36, 37 Primary antibodies were incubated overnight at 4°C followed with 
BrightVision horseradish peroxidase-linked secondary antibody (Immunologic). The 
immunoreactivity was visualized by freshly prepared Liquid DAB Substrate Chromogen 
solution (DAKO). Slides were counterstained with Mayer’s haematoxylin and mounted 
in Entellan.
Double immunofluorescence staining
For double staining, autofluorescence of brain tissue was quenched by treatment with 
0.1% Sudan Black B (Sigma-Aldrich) in 70% ethanol. Secondary antibodies were Cy3-
conjugated anti-mouse (Jackson ImmunoResearch; 1:100) and Alexa 488-conjugated 
anti-rabbit secondary antibody (Invitrogen; 1:100). Slides were mounted in Mowiol and 
analysed by confocal microscope (Leica). 
Electron-microsocopy
Minute pieces of frontal cortex were fixed in 4% glutaraldehyde in 0.1 M phosphate (pH 
7.2), postfixed in 1% osmiumtetroxide and embedded in Epon. Semithin sections (1 μ) 
were stained with toluidine blue. Areas of interest were selected for ultrathin sectioning 
(50-60 nm). Contrast was enhanced by staining with lead citrate.
Quantitative proteomics
Approximately 1000 positive inclusions were excised by laser capture microdissection 
(Carl Zeiss Microscopy, Göttingen, Germany) from each of the two brains (III:2 and III:4). 
In addition, tissues from the same brain areas of two healthy control brains without 
inclusions were collected in the same manner. Tissues were lysed in 25 µL SDS sample 
buffer, separated by 10% SDS PAGE, and stained with colloidal Coomassie Blue. Each 
gel lane was cut into two gel pieces of equal size, destained, and incubated with trypsin 
(1 µg, Promega) for 16 hrs at 37°C. 
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Peptides were separated on a 200 mm reversed phase nano-column (100 µm ID packed 
with 3 µm Alltima C18 particle from Alltech) using an Eksigent NanoLC ultra system 
(AB-Sciex). The acetonitrile concentration in 0.1% acetic acid was increased linearly from 
4.5% to 38% in 40 min, and to 80% in 1 min. The flow rate was 400 nL/min. The eluted 
peptides were electro-sprayed into the LTQ-Orbitrap discovery (Thermo Electron). The 
mass spectrometer was operated in a data-dependent mode, in which one MS full scan 
(m/z range from 330 to 2000) was followed by MS/MS scans on five most abundant ions. 
The exclusion window was 25 sec. The mass spectrometric data was searched against 
the IPI human database (ipi human v3.87) with MaxQuant software (version 1.3.0.5). 
The search parameters were MS tolerance, 20 ppm; MSMS tolerance, 0.5 Da; enzyme, 
trypsin with maximum missed cleavages of 2.
Sequential biochemical fractionation and immunoblot analysis
Post-mortem frozen brain tissue from two cases (III:2 and III:4), two frontotemporal 
lobar degeneration (FTLD) TDP cases and two Alzheimer’s disease cases, were dissected, 
weighted, and sequentially extracted with buffers of increasing strength as previously 
described.38 Briefly, grey matter was extracted at 5 mL/g (volume/weight) with low salt 
buffer (10 mM Tris, pH 7.5, 5 mM EDTA, 1 mM DTT, 10% sucrose, and a cocktail of protease 
inhibitors), high salt-Triton buffer (LS + 1% Triton X-100 + 0.5M NaCl), myelin floatation 
buffer (30% sucrose in LS + 0.5M NaCl), and sarkosyl (SARK) buffer (1% N-Lauroyl-
sarcosine in LS + 0.5 M NaCl). The SARK insoluble material was extracted in 0.25 mL/g 
urea buffer (7M urea, 2M thiourea, 4% 3-[(3-Cholamidopropyl) dimethylammonio]-1-
propanesulfonate (CHAPS), 30 mM Tris, pH 8.5). Proteins were resolved by 7.5 % SDS-
PAGE and transferred to PVDF membranes (Millipore). 
Following transfer, membranes were blocked with Tris buffered saline containing 
3% powdered milk and probed with the mouse monoclonal antibody PKA [RI] raised 
against the C-terminal portion (aa 225-381) of the type I regulatory subunit (610166, 
Becton Dickinson Laboratories), the polyclonal antibody PKA Iβ reg (sc-907 (c-19), 
Santa Cruz) and a mouse monoclonal anti-α-internexin (32-3600, Invitrogen). Primary 
antibodies were detected with horseradish peroxidase-conjugated anti-mouse or 
anti-rabbit IgG (Jackson ImmunoResearch Europe, UK), and signals were visualized by 
a chemiluminescent reaction (Millipore) and the Chemiluminescence Imager Stella 
3200 (Raytest, Switzerland).
For dephosphorylation experiments, urea fractions were dialyzed against RIPA buffer 
and treated with 400 units lambda phosphatase (New England Biolabs, Ipswich, UK) 
for 30 min at 30°C.
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Results
Clinical and pathological features 
Behavioural changes (self-neglect, delusions), with apathy and anxiousness, and 
memory problems with disorientation, followed by stiffness, shuffling gait, and frequent 
falls without tremor were the presenting symptoms in most of the patients (Table 1). 
Impaired attention and concentration, and deficits in memory, language, executive 
and visuo-constructional functions were found in two neuropsychologically evaluated 
patients (III:4 and III:6). MMSE and FAB of the proband were respectively 20 and 6, 
and 18 and 8 for patient III:6. These two patients showed mild to moderate rigidity, 
bradykinesia, postural instability, small-stepped gait and normal ocular movements, 
and no cerebellar and motor neuron disease signs at neurological examination on the 
first evaluation. Unified Parkinson’s Disease Rating Scale of the proband showed 6 points 
in part I, 13 points in part II, 16 points in part III, Hoens and Yahr grade four and Schwab 
and England ADL scale of 40%. EMG in the proband revealed no evidence for motor 
neuron disease, myopathy or polyneuropathy. Generalized cerebral atrophy was seen 
on MRI or CT of the brain in four patients (III:4, III:6, III:10, III:13), and more prominent 
frontal atrophy in proband (III:4) (Supplementary Fig. 2). Dopaminergic medication 
in two patients had only a modest effect. Moreover, [18F] fluorodeoxyglucose PET 
showed frontal hypometabolism in the proband (Supplementary Fig. 2), but a normal 
FP-CIT scan and normal CSF profile which is incompatible with Parkinson’s disease and 
Alzheimer’s disease. Brain autopsy was performed in three patients (III:2, III:4 and III:9). 
Macroscopic examination showed mild cerebral atrophy (III:2, III:4, III:9), slightly more 
pronounced in the frontoparietal cortex in two. An irregular tumor, defined as glio-
blastoma multiforme in the right temporal lobe was found in the brain of III:4 (absent 
on MRI one year earlier). 
The neocortex showed normal cytoarchitecture in all three brains, with moderate 
neuron loss in the substantia nigra in two, and severe loss of Purkinje cells in one case. 
Abundant eosinophilic, periodic acid-Schiff reaction negative, neuronal cytoplasmatic 
inclusions (NCI) with a glossy weakly stained core were observed in all neocortical 
regions in layers 3 - 6, hippocampus, substantia nigra, brainstem and spinal cord. Low 
to moderate number of inclusions were seen in the caudate nucleus, putamen, pallidum 
and the cerebellum (III:2), and in the dentate gyrus of patient III:9. These inclusions 
stained strongly with p62 and α-internexin antibodies (Fig. 2A-2C), and less intense 
with neurofilament antibodies, such as, SMI 31 and SMI 32. Larger inclusions showed 
a target-like picture with a halo and a weakly stained core, whereas smaller inclusions 
had a more homogeneous intense staining. Immunohistochemistry was negative for 
FUS, α-synuclein, AT-8, β-amyloid, neuroserpin, and TDP-43. No intranuclear inclusions 
were seen.
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Genomic and proteomic analysis
Two multipoint linkage analyses of 5 affected patients revealed six regions with LOD 
score > 1.5 (Supplementary Table 2). No overlapping copy number variant was detected 
in affected genotyped individuals. Exome sequencing produced approximately 6.4 
Gigabases of reads per sample. The average coverage of targeted region was 57x, 
with 74%, 72%, and 74% covered at least 20x, respectively (Supplementary Table 3). 
This resulted into a calling of about 48.000 allelic variants per individual after quality 
filtering using GATK (Supplementary Fig. 3). We examined the exome data on known 
FTD and PD genes, but no pathogenic variants in known FTD genes (PGRN, MAPT, 
c9orf72, CHMP2B, VCP and FUS) and PD genes (LRRK2, PARK2, PARK7, PINK1, SNCA, VPS35, 
ATP13A2, FBXO7, PANK2 and PLA2G6) were found.  
Figure 2. Distribution of neuronal cytoplasmatic inclusions found in familial neurofilamentopathy due to 
the mutation in the PRKAR1B gene. Strong immunoreactivity of neuronal cytoplasmatic inclusions (NCI) 
with antibodies against α-internexin (A) and p62 (B) in the dentate gyrus of the hippocampus (HC) is seen 
in patient III:2. Granular cells of the dentate gyrus show diffuse weak nuclear staining without cytoplas-
matic inclusions with FUS antibody (C). PRKAR1B-positive NCI with various sizes are abundant in the HC (D) 
and frontal region (E). A central unstained core surrounded by a strongly immunoreactive halo is found for 
larger inclusions in different cortices. Many inclusions are also found in the granular layer of the cerebellum 
(F). The same finding of PRKAR1B-positive NCI is seen in the HC (G) of the second patient (III:4). Substantia 
nigra show moderate neuron loss and positive immunoreactivity for PRKAR1B (H). These inclusions are also 
seen in lower motor neurons of the spinal cord (I). Scale Bar: A and B = 20 µ; C-I = 50 µm.
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We performed the genetic analysis in two steps. First, we filtered the exome sequencing 
data combining with linkage analysis to reduce the number of variants. An analysis of 
non-synonymous, splice-sites, stop and frameshift variants (SNPs and indels) in the six 
regions with LOD score > 1.5 showed seven variants shared by the three patients and 
not annotated by dbSNP129 and having an allele frequency < 1% in 1000 Genomes 
Project and Exome Variant Server. 
Second, we combined proteomics data with the candidate variants found by genetic 
analysis to identify the causative gene. A total of 1000 inclusions were excised by means 
of microlaser dissection from fresh-frozen brain samples of patients III:2 and III:4, and 
corresponding inclusion-free tissue of the same size was obtained from two control 
brains. The dissection was repeated once from one of the patient samples to obtain a 
total of 3 replicates. Mass spectrometry of the inclusion bodies was sufficiently sensitive to 
identify proteins present, but not sufficient to detect protein modifications. Quantitative 
proteomics analysis revealed six proteins (Polyubiquitin-C, α-internexin, neurofilament 
light polypeptide, cAMP-dependent protein kinase regulatory subunit type I-beta, 
neurofilament medium polypeptide and Heat shock cognate 71 kDa protein) that were 
present consistently and solely in the inclusion samples (Supplementary Table 4).  
Combining proteomics analysis with the candidate variants from exome sequencing 
resulted in one single variant, the novel missense heterozygous variant in PRKAR1B 
on chromosome 7p22 (exon 2: c. 149T>G; p.Leu50Arg; RefSeq NM_002735.2), which is 
conserved and predicted as pathogenic by four different in silico methods that predict 
functional effects of sequence variations (Fig. 3 and Supplementary Table 5). No novel 
Figure 3. Schematic representation of the PRKAR1B genomic structure and conservation of the muta-
tion.  Electropherogram showing the PRKAR1B mutation at position chr7:750,997 (A>C) in exon 2 (c.T149G; 
p.Leu50Arg) present in the affected individual (III-4) and absent in an unaffected control of the family (A). 
Schematic structure of PRKAR1B (isoform NM_002735.2) and the position of the mutation identified in the 
present study is shown. Exons are represented with blue boxes, untranslated regions in gray boxes (B). 
Alignment of the protein region containing the highly conserved leucine amino acid residue across differ-
ent species is shown (C). The leucine on position 50 (NP_002726.1) is indicated in the red box.
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and pathogenic variants were found in the genes coding for the remaining five proteins 
identified in the proteomics analysis of the inclusion bodies. Sanger sequencing 
confirmed the presence of the p.Leu50Arg variant in the affected individuals III:2, III:3, 
III:4, III:6, III:9 and III:10, and its absence in unaffected family members (III:5 and III:11). 
Sequencing of the PRKAR1B coding region (10 exons) and exon-intron boundaries in 
a cohort of autosomal dominant Parkinson’s disease (n=138) and basophilic inclusion 
body disease (n=2) revealed several silent and intronic polymorphisms, which are all 
annotated in dbSNP, and two non-synonymous rare heterozygous variants, also present 
in dbSNP (Supplementary Table 6). The first, p.Ile40Phe, was detected in six Parkinson’s 
disease probands (MAF 0.013, similar to dbSNP MAF 0.022), and is considered benign 
by most of the prediction programs (Supplementary Table 5). The other, p.Arg232Gln, 
was found in only one Parkinson’s disease proband, and is considered pathogenic by all 
the prediction programs. However, this variant does not co-segregate with Parkinson’s 
disease in the family (one affected sib was not a carrier). This variant is also annotated 
in dbSNP because of just one allele detected in the 1000 Genome project, and is not 
present in the Exome Variant Server. Analysis of whole exome sequencing data in a 
cohort of familial FTD with unknown gene defect (n=51) and FTD-FUS (n=5) did not 
reveal any potential pathogenic rare variants in PRKAR1B (Supplementary Table 6).
Immunohistochemistry and biochemical analysis
Immunohistochemistry with PRKAR1B antibodies revealed intense staining of the 
inclusions in brain of the three cases (Fig. 2). Cytoplasmatic inclusions were exclusively 
seen in neurons and had a variable size. Most inclusions were round and compact 
with strong PRKAR1B immunoreactivity, and some neurons showed a more granular 
cytoplasmatic staining (Fig. 2D-I). Round inclusions were seen in the dentate granule 
cells (Fig. 2D), Cornu Ammonis 1–4, subiculum and entorhinal cortex, and in all layers 
of the neocortex (Fig. 2E) of the two patients (III:2 and III:4). Many inclusions were also 
observed in the hippocampus (Fig. 2G), substantia nigra (Fig. 2H), brainstem and spinal 
cord (Fig. 2I), whereas lower number of inclusions are found in the caudate nucleus, 
putamen and pallidum. The dentate nucleus and granular layer of the cerebellum 
showed many cytoplasmatic inclusions in patient III:2 (Fig. 2F), but only some in the 
same region of patient III:4. Available slices of three brain regions (pons and two 
neocortex) of patient III:9 also showed abundant PRKAR1B positive inclusions. Overall, 
more inclusions are found in patient III:2 than in similar regions of the other two cases. 
Large inclusions showed a faint core with strongly stained halo. The PRKAR1B antibody 
labelled the inclusions more intensely than p62 and α-internexin. No glial cytoplasmatic 
inclusions were seen in the cerebral white matter. 
Double-labelling immunofluorescence with α-internexin and PRKAR1B antibodies 
showed that nearly all α-internexin positive inclusions were also PRKAR1B-positive 
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(Fig. 4A-C). Less than five percent of the inclusions, predominantly those with a smaller 
size, labelled either for α-internexin or PRKAR1B. Double labelling also showed the 
spatial relationship of these two proteins within the inclusions; PRKAR1B antibody 
often labelled the core, whereas α-internexin labelled a halo at the outer side of the 
inclusions (Fig. 4D-F). 
Figure 4. Double-label immunofluorescence for PRKAR1B (green) and α-internexin (red) in familial neu-
rofilamentopathy due to PRKAR1B mutation. Immunofluorescence of the inclusions with PRKAR1B (A) 
and α-internexin [INA] (B). Some inclusions label homogeneous staining with co-localization of INA and 
PRKAR1B (C). Merged images clearly show that both markers label distinct components of inclusions with 
a central core labelling for PRKAR1B antibody (D) surrounded by a halo labelling for INA (E, F). Scale bar: 
A and B = 5 µm; D-F = 10 µm. (G and H) Ultrastructural examination of inclusions demonstrates dense ag-
gregates of filaments of 11-16 nm surrounded by granule coated fibrils and cellular organelles, G=9000x 
and H=22500x enlarged.
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Ultrastructurally, the core within the body consisted of electron-dense material, and 
fibrils were found in areas with remnants of vesicles and mitochondria (Fig. 4G and H). 
The body is composed of dense aggregates of filaments (densely packed fibrils with 
often a radiating aspect at the edges), while the paler halo consisted of bundles of both 
circularly and longitudinally arranged filaments. 
Neurofibrillary tangles or plaques in Alzheimer’s disease (n=4), Lewy bodies in Parkinson’s 
disease (n=10) and Lewy body dementia (n=5), glial inclusions in multiple system 
atrophy (n=4), TDP-43-positive inclusions in FTLD (n=4), Pick bodies, Neurofibrillary 
tangles or pretangles in FTLD with MAPT gene mutations as well as healthy controls 
(n=4), did not show any staining with the PRKAR1B antibody, demonstrating the 
specificity of PRKAR1B accumulation in our cases (Data not shown). 
To characterize potential biochemical alterations of PRKAR1B, proteins were sequentially 
extracted from temporal cortex from two cases (III:2 and III:4) as well as neurological 
controls with a series of buffers with an increasing ability to solubilise proteins and 
analyzed by immunoblot using an antibody that recognizes both isoforms of the type 
I regulatory subunits of PKA (BD Laboratories).
Two bands at the expected molecular weights of PRKAR1A and PRKAR1B (~48 and 
50kDa) were consistently present in the sarkosyl fractions in PRKAR1B mutation cases 
and FTLD and Alzheimer’s disease. However, a strikingly different biochemical profile 
was seen in the urea fractions (fraction enriched for highly insoluble proteins) for the two 
PRKAR1B mutation cases compared to controls (Fig. 5A). Whereas controls showed only 
minimal reactivity in the urea fraction, a massive enrichment for PRKAR1B was observed 
in the two cases accompanied by the presence of additional bands of lower and higher 
molecular weight as well as a high relative molecular mass (Mr) smear. Similar results 
were observed with a second antibody raised against PRKAR1B (Santa Cruz, data not 
shown). Since the appearance of higher migrating bands is suggestive for abnormal 
posttranslational modifications such as hyperphosphorylation, we investigated the 
phosphorylation state of PRKAR1B by treating dialyzed urea fractions with lambda 
protein phosphatase. However, this did not reveal any obvious changes in the banding 
pattern (Supplementary Fig. 4). No biochemical alterations with respect to changes in 
solubility or appearance of additional bands were observed for α-internexin between 
our PRKAR1B mutation cases and controls (Fig. 5B).
In silico prediction of the PRKAR1B mutation on PRKAR1B protein structure
PRKAR1B codes for the R1β-subunit of cyclic AMP-dependent protein kinase A, which is 
a tetramer in its inactive form composed of two catalytic and two regulatory subunits 
(Fig. 6A and B).39 Binding of cyclic AMP to the regulatory subunits unleashes the catalytic 
subunits, thereby allowing phosphorylation of PKA substrates. The regulatory subunits 
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dimerize via their N-terminal dimerization/docking (D/D) domains. In the inactive PKA 
tetramer, the D/D domains of the R1β isoform form an integral part of the holoenzyme; 
while the cyclic AMP binding domains and the linker region tightly interact with one 
catalytic subunit additional trans interactions with the catalytic subunit in the other 
heterodimer (Fig. 6B). The leucine at position 50 of the PRKAR1B protein is located on 
the dimer interface formed by the N-terminal D/D domains of the regulatory subunits 
(Fig. 6A). The leucine side chain forms a hydrophobic core together with several other 
conserved hydrophobic residues to create this dimer interface (Fig. 6B). A change of 
leucine to arginine at this position creates a steric hindrance, because due to its larger 
size the arginine side chain will not fit within the hydrophobic core. Furthermore, the 
positive charge on the arginine side chain will potentially introduce unfavourable 
electrostatic interactions with its symmetry-related arginine across the dimer interface. 
In one scenario, the dimerization interface may still be formed but with local structural 
Figure 5. Biochemical analysis of PRKAR1B and α-internexin. (A) Proteins were sequentially extracted from 
temporal grey matter from two cases (III:2 and III:4) with the PRKAR1B mutation and neurological controls 
(Alzheimer’s disease [AD] and frontotemporal lobar degeneration with TDP-43 inclusions [FTLD-TDP]). Low 
salt- (LS), Triton X-100- (TX), sarkosyl- (SA) and urea- (UR) fraction were separated by SDS-PAGE and im-
munoblotted with anti-PKA RI antibody (BD Laboratories). Cases and controls showed bands in the sar-
kosyl fraction corresponding to PRKAR1A (~48 kDa) and PRKAR1B (~50kDa). Note the dramatic increase of 
highly-insoluble PRKAR1B in the UR fraction in cases compared to controls accompanied by appearance of 
additional bands of ~45kDa and ~55 kDa and a high molecular mass smear. (B) The same protein fractions 
were analyzed by α–internexin immunoblot revealing no obvious changes with respect to changes in solu-
bility or appearance of additional bands between cases and controls.
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rearrangements resulting in an altered conformation. Due to the intimate connections 
between the D/D domains and the catalytic subunits, these local rearrangements may 
be propagated throughout the holoenzyme and affect the cyclic AMP-induced response 
and thus activation of the kinase.39 Furthermore, the D/D dimerization interface creates 
Figure 6. The L50R mutation is located on the interface between the docking/dimerization domains of 
the protein kinase A regulatory subunit β. (A) Organization of the PKA protein subunits. The regulatory 
subunits contain an N-terminal dimerization/docking (D/D) domain, followed by a linker region and two 
cAMP binding domains (CNBA and CNBB). The catalytic subunit contains an N-terminal myristylation site 
for membrane anchoring (blue circle), N-and C-terminal lobes and tails with phosphorylation sites (green 
circles). The p.Leu50Arg mutation maps to the D/D domain of the regulatory subunit. (B) Overall struc-
ture of the PKA tetrameric holoenzyme containing two catalytic and two regulatory subunits. The catalytic 
subunits C (white) and C’ (pink) are shown in space filling representation, with ATP bound to subunit C 
represented in black sticks. The secondary structure elements of the regulatory subunits are shown in cyan 
(subunit R1β=PRKAR1B) and in purple (symmetry-related subunit R1β’) with the leucine on the interface 
between the D/D domains in red space filling representation. The holoenzyme is shown in two different 
orientations. (C) The importance of the D/D-dimer interface formation for binding to A-kinase anchoring 
proteins is shown by the structure of the D/D domain of the homologous PRKAR1α subunit in complex 
with a peptide from Dual-specific AKAP2. Secondary structures are shown in cyan and purple (regulatory 
subunit D/D domains) and white (Dual-specific AKAP2). Side chains of Leu 50 at the D/D interface are indi-
cated in red stick representation surrounded by transparent spheres. Figure is created using Pymol (deLano 
Scientific).
PRKAR1B in neurodegenerative disease | 131 
3.3
the docking site for AKAPs (Fig. 6C),40 and local rearrangements may affect AKAP binding 
and thereby PKA signalling and targeting PKA to a specific subcellular location.10, 40 
In another scenario the arginine completely prevents formation of the dimerization 
interface between the D/D domains. This would affect correct holoenzyme formation 
and thereby PKA activation. In addition, the unassembled D/D domain interfaces 
would expose large hydrophobic areas which are prone to aggregation resulting in 
insoluble protein.
Discussion
This study describes a novel hereditary neurodegenerative disorder associated with 
a mutation (c.149T>G; p.Leu50Arg; RefSeq NM_002735.2, NP_002726.1) in the gene 
coding for the Type I-beta regulatory subunit of the PKA with an unique neuropatho-
logical phenotype with PRKAR1B accumulation into abundant neuronal inclusions. 
The mutation is predicted to prevent or alter dimerization between the D/D domains 
within the PKA holoenzyme, thereby exposing hydrophobic protein regions that may 
result in aggregation, or reducing the binding of the regulatory subunits to both the 
catalytic subunits of PKA, and to AKAP. The frequency of this mutation appears to be 
rare, as the mutation is absence in dbSNP and Exome Variant Server. Moreover, no 
pathogenic mutation in PRKAR1B could be identified in a cohort of familial Parkinson’s 
disease or frontotemporal dementia.
The present disorder has a rather unspecific phenotype consisting of dementia and 
parkinsonism with poor response to levodopa, normal FP-CIT scan, and normal CSF 
biomarkers, which have ruled out Parkinson’s disease and Alzheimer’s disease. The 
neuropsychological profile with impairment of multiple cognitive domains and clinical 
symptoms are consistent with the involvement of all cortical and subcortical regions of 
the brain. Cerebellar and motor neuron signs were lacking at neurological examination 
despite the widespread inclusions in cerebellum and spinal cord; however, we cannot 
exclude that the patients may develop such signs in the last stage of the disease 
during their stay in a nursing home. Its hereditary occurrence has initially not been 
recognized,27 but distinguishes it from the mostly sporadic NIFID. Furthermore, the 
absence of immunoreactivity with α-synuclein and FUS antibodies distinguishes this 
disorder from Parkinson’s disease and NIFID. The co-occurrence with cancers (myeloid 
leukemia and glioblastoma) in two out five patients is quite remarkable. PKA stimulates 
the expression of the NR4 receptor, and NR4 is involved in several malignancies, such 
as glioblastoma and myeloid leukemia.41 It might be worth screening for potential 
variants in PRKAR1B in cohorts of patients with these malignancies and to see whether 
the mutation alters the expression of NR4 receptor. However, this is beyond the scope 
of this research.
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The present approach of combining genome-wide linkage analysis, exome sequencing 
and proteomic analysis of neuronal inclusions allowed us to identify a heterozygous 
p.Leu50Arg variant in PRKAR1B in five affected family members, consistent with an 
autosomal dominant mode of inheritance. The highly specific pattern of PRKAR1B 
accumulation in inclusions in the three autopsy-proven cases together with the 
dramatic enrichment of PRKAR1B in highly insoluble protein fractions with appearance 
of abnormal Mr species, the negative PRKAR1B immunoreactivity in any other 
neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, Lewy body 
dementia, multiple system atrophy, Pick’s disease, and FTLD-TDP-43) and the absence of 
the mutation in variant databases, strongly argues for a causative role of this mutation 
in this family.
The pathophysiological mechanism how this mutation leads to neurodegenerative 
disease remains to be investigated by establishing cell culture and animal models. 
Our first hypothesis is that the mutation leads to impaired dimerization between the 
regulatory R1β subunits and catalytic subunits within the PKA holoenzyme. Structural 
changes within the holoenzyme may liberate the catalytic subunits which could 
be vulnerable to degradation, resulting in reduced PKA activity. This hypothesis is 
supported by loss of PKA catalytic subunit and PKA activity shown in PKA regulatory 
knockout mice.11 However, catalytic subunits unleashed by mutation-induced structural 
changes may also lead to increased PKA activity, as has been found in the p.Ser9Asn 
mutation of PRKAR1A.12 PRKAR1B knock-out mice have impaired long-term potentiation 
and long-term depression in the mossy fibers – Cornu Ammonis 3 region of the 
hippocampus and visual cortex.42-44
A second pathophysiological mechanism is that the Leu50Arg mutation on the subunit 
interface of the D/D-domain can induce structural changes to the docking site for AKAP 
which is located across this interface, and abolish the binding between AKAP and the 
regulatory subunit.39, 40 An important function of AKAP is to target the holoenzyme in 
close proximity to the dedicated substrates by binding to the D/D-domain,39 which is 
important for creating the microenvironment for PKA signaling. It is likely that impaired 
binding to AKAP causes subcellular dislocalization of the complex, thereby disturbing 
PKA signaling on the dedicated substrates.
The Leu50Arg PRKAR1B mutation and subsequent change in PKA function probably 
leads to an imbalance of the phosphorylation status of N-terminal head and C-terminal 
tail domain of neurofilaments. PKA is responsible for transient phosphorylation of 
specific sites on the N-terminal head domain of neurofilaments.7 Phosphorylation levels 
of N- and C-terminal are related to each other, and are essential for axonal transport.5, 7 
Therefore, the imbalance of phosphorylation would explain the additional accumulation 
of α-internexin and other neurofilaments in the cell soma in the present cases. 
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The aggregate formation of PRKAR1B, its biochemical enrichment and additional 
bands in urea fractions can be the result of posttranslational modifications such as 
(hyper)phosphorylation. While our dephosphorylation experiments are not indicative 
for abnormal phosphorylation, more sophisticated biochemical analyses are needed 
to further address this. In addition, the high Mr smear in the immunoblot might be 
explained by poly-ubiquitination of PRKAR1B protein in the proteosomal degradation.45 
The aggregation of PRKAR1B might entrap other proteins like IFs just as a secondary 
phenomenon, like we see in inclusions characteristic for other neurodegenerative 
diseases.1 
Although we have not seen obvious changes and presence of abnormal Mr α-internexin 
protein species in our cases by immunoblot, the analysis of phosphorylation alterations 
of IFs requires further investigation by more sensitive means such as mass spectrometry. 
Future studies to explore the phosphorylation of IF in model systems carrying the 
Leu50Arg mutation are required to address this. Finally, the unique pathological 
phenotype of the present disorder is supported by the distinct pattern of PKA type I 
regulatory bands on Western blots of brain tissue. To find out the reason of the different 
pattern between cases and controls, more sophisticated proteomic analysis would be 
required in the future. 
In conclusion, we provide evidence that a mutation in PRKAR1B is associated with a 
new type of a familial neurodegenerative disease with dementia and parkinsonism 
characterized by specific and abundant accumulation of PRKAR1B into neuronal 
inclusions. Our findings link altered regulation of PKA by mutant PRKAR1B to human 
late-onset neurodegeneration.
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Supplementary figures and tables
Supplementary figure 1. Plots of the LOD scores using Allegro. Two separate multipoint linkage analyses 
were performed (affected only) on genotypes from five affected individuals using Allegro with a SNP 
spacing of 0.2 cM (A) and one of 0.5 cM (B). Regions with LOD scores >1.5 (blue line) in both models were 
used as candidate regions (blue arrows).
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Supplementary figure 2. Neuroimaging findings from the proband (III:4). Axial images using FLAIR 
sequence showed symmetrical cortical atrophy and enlarged ventricles. Thinning of the mesencephalon 
(A) and atrophy of the caudate nucleus were observed (B). Imaging of the brain metabolic activity using 
[18F] fluorodeoxyglucose and PET showed symmetrical frontal hypometabolism (C and D). Metabolic 
deficient is also seen at the thalamus (C).
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Supplementary figure 3. Bioinformatic analysis of exome sequencing.
Supplementary figure 2. Biochemical analysis of phosphorylation state of PRKAR1B. (A) Dialyzed urea 
fractions from two cases with PRKAR1B mutation were either not treated (-) or treated (+) with lambda 
protein phosphatase (λ-PP), separated by SDS-PAGE and analyzed by immunoblot with anti-PKARI antibody 
(BD Laboratories). No obvious changes were observed in the banding pattern after dephosphorylation. (B) 
To control for de-phosphorylation activity of the used enzyme and conditions, a urea fraction from a FTLD-
TDP cases was used and analyzed by immunoblot with a phosphorylation-specific TDP-43 antibody (clone 
1D3). Note the lack of immunoreactivity after λ-PP treatment.
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Supplementary Table 1. PCR primers and protocol for the amplification and sequencing of PRKAR1B 
fragments
Oligonamea Sequence Size
prkar1b-ex2F GGGCCGTCACGTTTAACACC 465 bp
prkar1b-ex2R ACCACGGGACAGAGGGAAGG
prkar1b-ex2SF GAGCCTGAAGGGCTGTGAGC 183 bp
prkar1b-ex2SR AGGACACGTGCGAAGGGAAG
prkar1b-ex3F AAGTGGGGATGATGGGGATG 557 bp
prkar1b-ex3R CTGAGACCCCCAGGAGGATG
prkar1b-ex4F TAACAGCAGGCTGAGGGTGGA 350 bp
prkar1b-ex4R CCGGAGAAGGCAGCTGTGAT




prkar1b-ex7F CTCTGCCCACAAGCGAAAGG 460 bp
prkar1b-ex7R CCTCCACCCCTTTCCACTCC
prkar1b-ex8F AGCTCCCTGCCCTTCATGG 529 bp
prkar1b-ex8R TCCATAATACCAACAACACTCAACTGC
prkar1b-ex9F TGTCTTGGACTGTGGCTGTGG 381 bp
prkar1b-ex9R GGGCAGGAGGAATCTCAGTGG
prkar1b-ex10F ACGTGGTGTCGGCAGTGG 396 bp
prkar1b-ex10R TTGGGGGAACAGGACTGAGC
prkar1b-ex11F CAGGACAATGGCTAGCTGAACG 504 bp
prkar1b-ex11R GGCCCACACCTCACACAGC
a primers used for PCR amplification and Sanger sequencing reactions.
PCR protocol
The amplification reactions were performed in a total volume of 20 μl, containing 1x FastStart Taq DNA 
Polymerase buffer, 200 μM of each dNTP, 10 μM forward primer, 10 μM reverse primer, 0.5 unit FastStart Taq 
DNA Polymerase (Roche Diagnostics) and 20 ng genomic DNA. PRKAR1B_2F/R was amplified with addition 
of 1XGC-melt (Roche Diagnostics). PRKAR1B-ex2SF and PRKAR1B-ex2SR were used to validate the variant 
in sample III:9 isolated from DNA extracted from the spleen.
The PCR conditions were as follows: initial denaturation, 7 min 30 sec at 96ºC, followed by 9 cycles of: 30 
sec denaturation at 960C; 30 sec annealing (1st cycle at 700C, with 10C/cycle decrease); 1 min extension at 
720C. Then, 25 cycles of: 30 sec denaturation at 960C; 30 sec annealing at 600C; 1 min extension at 720C. 
Final extension: 5 min at 720C. The PCR reactions were purified using 5 units ExoI (Fermentas) and 1 unit Fast 
AP (Fermentas), 45’ 37oC, 15’ 800C. Direct sequencing was performed using Big Dye Terminator chemistry 
ver. 3.1 (Applied Biosystems) as recommended by the manufacturer. Dye terminators were removed using 
SephadexG50 (GE Healthcare) and loaded on an ABI 3130XL Genetic Analyzer (Applied Biosystems). For 
sequence analysis the software packages Sequence Analysis version 5.3 (Applid Biosystems) and Seqscape 
version 2.6 (Applied Biosystems) were used.
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Supplementary Table 2. Candidate regions from linkage analysis
UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly







Supplementary Table 3. Exome sequencing statistic per sample
III: 2 III:3 III:4 Average
Total reads 6776289400 6615714400 6449885600 6613963133
Total aligned reads 3975374358 3684889797 3408320419 3689528191
% aligned 58.66594715 55.6990459 52.84311429 55,736
% of 1X 95.7 96.2 96.1 96
% of 5X 89.7 90.2 90.8 90,23
% of 10X 83.3 84.1 85.4 84,27
% of 20X 71.7 74.2 73.9 73,24
Coverage 61.38 56.89 52.62 56,96
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PolyPhen-2 HumDiva Probably Damaging Probably Damaging Benign






PROVEAN Deleterious Deleterious Neutral
MUTATION TASTER Disease causing Disease causing Disease causing
a Preferred model for evaluating rare alleles, dense mapping of regions identified by GWAS and analysis of 
natural selection.
b Preferred model for the evaluation of Mendelian disease-causing variants, which requires distinguishing 
mutations with drastic effects from the remaining human variation, including abundant mildly deleterious 
alleles.
c The substitution is predicted to be damaging if the score is ≤ 0.05, and tolerated if the score is > 0.05.
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Exon 11 rs28488947 c.1065C>T p.Phe355= 0,0000 0,0070 0,0470 A=154/G=12778
Exon 11 rs11545042 c.1014T>C p.Thr338= 0,1786 0,0620 0,1730 G=1852/A=11016
Exon 11 rs370829885  c.1008G>A p.Ala336= 0,0714 0,0000 - T=11/C=12851
Exon 11 rs28626752 c.984A>G p.Ala328 0,0000 0,0070 0,0520 C=220/T=12678
intron 10 rs28585978 c.974-8A>C 0,0000 0,0070 0,0510 G=130/T=12716
Exon 10 rs78260651 c.903C>T p.Ser301= 0,0000 0,0040 0,0010 A=21/G=12561
Intron 9 rs71518309 c.892-18G>C 0,4196 0,4750 0,3950 G=7290/C=5128
Intron 9 rs118004775 c.892-39G>A 0,0804 0,0000 0,0720 T=863/C=11311
Intron 9 rs62431411 c.891+38A>G 0,4554 0,3010 0,3910 C=5499/T=7499
Intron 9 rs62431412 c.891+24C>T 0,5000 0,3010 0,3910 A=5498/G=7500
Exon 9 rs3211362 c.846T>C p.Ile282= 0,5000 0,3040 0,4010 G=5629/A=7369
Exon 9 rs77809618 c.810G>A p.Ala270= 0,0000 0,0040 0,0010 T=12/C=12986
Intron 7 rs9330368 c.709-16A>C 0,5000 0,3480 0,2810 G=8773/T=4225
Exon 7 rs200069843 c.695G>A p.Arg232Gln 0,0000 0,0040 0,0010 -
Exon 7 rs76061469 c.642C>T p.Thr214= 0,0000 0,0110 0,0010 A=22/G=12976
Intron 4 rs117395529 c.440+34G>A 0,0179 0,0000 0,0270 T=71/C=12935
Intron 4 rs142693952 c.440+25G>A 0,0000 0,0250 0,0080 T=172/C=12834
Exon 2 rs61732492 c.118A>G p.Ile40Phe 0,0000 0,0220 0,0130 C=258/T=12748
a References for annotation of variants: GenBank n. NM_002735.2 and NP_002726.1.
b SNP reference number in dbSNP137.
c Minor allele frequency in frontotemporal dementia (FTD) and Parkinson’s disease (PD).
d Minor allele frequency in dbSNP.
e Minor allele frequency in Exome variant Server.
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Letter to the Editor
Reply: PRKAR1B mutations are a rare cause of fused in sarcoma negative neuronal 
intermediate filament inclusion disease
Tsz Hang Wong,  Annemieke J.M.H. Verkerk, Annemieke J. Rozemuller, Rob Willemsen, 
Manuela Neumann, Vincenzo Bonifati, John van Swieten
We thank Dr. Pottier and colleagues for their interest in our recent study, reporting the 
identification of a novel mutation in the PRKAR1B gene in a family with FUS-negative 
NIFID cases.1 Mutations in this gene seems to be rare in most neurodegenerative 
disorder as no additional pathogenic mutations have been found so far in patients 
with Parkinson’s disease, frontotemporal dementia (FTD) and Alzheimer’s disease.1,2
In the Letter, Dr. Pottier and colleagues reported the absence of mutations in PRKAR1B 
gene in small series of three pathologically confirmed NIFID cases who were FUS 
negative. This observation in NIFID cases with strong accumulation of neurofilament 
proteins is especially important, as the protein kinase A (PKA) holoenzyme has an strong 
effect on phosphorylation of neurofilament proteins. Therefore, we agree with their 
suggestion that genetic screening in the PRKAR1B pathway may identify new genetic 
defects in the etiology of FUS-negative NIFID. Finally, screening in PRKAR1B gene is still 
indicated in patients with frontotemporal dementia and parkinsonism, especially in 
those with positive family history. 
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Genetic factors are important in all forms of dementia, especially in early onset 
dementia. The frequency of major gene defects in dementia has not been 
investigated in the Netherlands. Furthermore, whether the recently in a FTD 
family identified PRKAR1B gene is associated with an Alzheimer’s disease (AD) 
like phenotype, has not been studied. With this study, we aimed to investigate 
the mutation frequency of the major AD and FTD genes and the PRKAR1B 
gene in a well-defined Dutch cohort of patients with early onset dementia. 
Mutation analysis of the genes PSEN1, APP, MAPT, GRN, C9orf72 and PRKAR1B 
was performed on DNA of 229 patients with the clinical diagnosis AD and 74 
patients with the clinical diagnosis FTD below the age of 70 years. PSEN1 and 
APP mutations were found in, respectively 3.5 and 0.4% of AD patients, and 
none in FTD patients. C9orf72 repeat expansions were present in 0.4% of AD 
and in 9.9% of FTD patients, whereas MAPT and GRN mutations both were 
present in 0.4% in AD patients, and in 1.4% resp. 2.7% in FTD patients. We did 
not find any pathogenic mutations in the PRKAR1B gene. PSEN1 mutations are 
the most common genetic cause in Dutch AD patients, whereas MAPT and GRN 
mutations were found in less than 5 percent. C9orf72 repeat expansions were 
the most common genetic defect in FTD patients. No pathogenic PRKAR1B 
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Introduction
Dementia is a major health problem with a world-wide prevalence of 44 million in 
2013, estimated to increase to 135 million in 2050.1 Only a minority of the patients 
with dementia have an early onset, with a prevalence of dementia of 1–10 in 10,000 in 
persons aged 45–65 years.2 Early onset dementia is usually defined as dementia with 
an onset before the age of 65 years, with Alzheimer’s disease (AD) and frontotemporal 
dementia (FTD) as most common subtypes.2,3
Genetic factors play an important role in all types of dementia, especially in early onset 
dementia. An autosomal dominant family history is found in 10–20% of the patients 
with early onset dementia and can be explained by mutations in the presenilin 1 and 
2 (PSEN1 and PSEN2) and amyloid-beta-protein precursor (APP) genes in up to 50% of 
the early onset AD families, and in the microtubule-associated-protein-tau (MAPT) gene, 
(pro) granulin (GRN) gene and C9orf72 gene in most FTD families.4 The frequency of 
the latter gene defects in Dutch FTD patients has been reported in previous studies,5,6 
which also showed a wide variation in the clinical presentation in mutation carriers, 
including an AD-like presentation. In contrast, mutation screening has not been carried 
out in Dutch early onset AD patients so far.
Recently, a mutation in the PRKAR1B gene has been identified in a Dutch family with 
an autosomal dominant FTD-like presentation. Mutations in this gene are probably a 
rare cause of FTD, as no pathogenic variants were found in other patients with familial 
FTD7. Its phenotype encompasses behavioural and cognitive changes with mild 
parkinsonism. However, no pathogenic mutations were found in a cohort of familial 
Parkinson patients.7 Whether mutations in the PRKAR1B gene may result in an AD-like 
phenotype, as is the case for GRN and some specific MAPT mutations, has not been 
studied.
With this study, we aimed to estimate the mutation frequency of the most common 
autosomal dominant AD and FTD genes in Dutch early onset AD and FTD patients, and 
to investigate whether mutations in the newly identified PRKAR1B gene are a frequent 
cause of early onset AD.
Patients and methods
Subjects
We included all patients with a clinical diagnosis FTD (n=74) or AD (n=229) below 
the age of 70 years from the memory clinic-based Amsterdam Dementia Cohort who 
visited the Alzheimer centre of the VU University Medical Centre in Amsterdam between 
October 2000 and November 2008 of whom DNA was available for research purposes. 
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All patients were evaluated following a standard protocol including neurological 
examination, neuropsychological testing, biochemical analysis of blood, neuroimaging, 
and EEG. The clinical diagnosis was made by consensus in a multidisciplinary team. 
The diagnosis “possible” or “probable” AD was made according to the NINCDS-ADRDA 
criteria,8 FTD according to the criteria of Neary et al.9 In all subjects with possible or 
probable AD, cerebrospinal fluid (CSF) was collected for scientific purposes, however, 
the CSF results were not included in the clinical decision making. Our laboratory applies 
reference values of Aβ1-42 ≤ 550 pg/ml and t-tau > 375 pg/ml.
10 The age at onset was 
defined as the age at which the first symptom, compatible with cognitive decline or 
with the diagnosis FTD, was observed by the spouse or a close relative. Family history 
was obtained from the medical records and considered positive in case of at least one 
1st degree with dementia or, in FTD patients, with dementia or amyotrophic lateral 
sclerosis (ALS). Autosomal dominant inheritance was defined as the occurrence of at 
least three affected persons in at least two generations of one family. The characteristics 
of the patients can be found in Table 1. Of the patients with FTD, 68 were also included 
in our previous study on the mutation frequency of C9orf72 repeat expansions.6
Table 1. Characteristics of the patients
FTD patients (n=74) AD patients (n=229)
Male (percentage) 45 (60.8) 104 (45.4)
Mean age at diagnosis, years (range) 61.2 (46–69) 61.0 (35–69)
Mean disease duration at diagnosis (range) 3.9 (0–18) 3.5 (0–13)
Mean age at death, years (range)* 63.2 (46–71) 63.9 (39–74)
Positive family history (percentage)** 28 (37.8) 80 (34.9)
* Information on age at death available of 24 FTD and 47 AD patients.
** Positive family history in case of at least one first degree relative with dementia or, in FTD patients, with 
ALS.
Genetic analysis
Genomic DNA was extracted from peripheral-blood leukocytes according to standard 
procedures. All exons and exon–intron boundaries of the genes PSEN1, MAPT, GRN 
and PRKAR1B and exons 16 and 17 of the APP gene were amplified from genomic DNA 
(conditions and primer sequences available upon request). Direct sequencing was 
performed using BigDye terminator chemistry (Applied Biosystems, Foster City, CA), 
and sequencing products were processed on an Applied Biosystems 3730 automated 
DNA sequencer and analysed using SeqScape software version 2.7 (Applied Biosystems). 
Nucleotides are numbered according to Genbank accession numbers NM_007318 
(PSEN1), NM_201414 (APP), NM_005910 (MAPT), NM_002087 (GRN) and NM_002735 
(PRKAR1B) with A of initiator ATG numbered as +1.
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In 181 AD patients, analysis of the PRKAR1B gene was performed on exome sequencing 
data. Whole exome capture and sequencing were performed by Human Genomics 
Facility at Rotterdam. Exomes were captured by Nimblegen seqcap EZ human exome 
v3, and were sequenced with 2 × 100 paired-end sequencing on the Illumina HiSeq 2000 
platform, according to the manufacturer’s protocol. Reads were mapped to the human 
reference genome sequence (UCSC hg19) using the Burrows-Wheeler Alignment Tool.11 
Duplicate read removal, local sequence realignment and variant filtering to minimize 
base calling and mapping errors were performed by Samtools,12 Picard (http://picard.
sourceforge.net) and Genome analysis Tool Kit (GATK).13 The identified variants per 
individual were called using GATK and annotated by ANNOVAR.14 Variants with quality 
score < 50, quality over depth < 5.0, Strand bias > 0.75 and depth < 5.0 were filtered 
out. The average read depth for the PRKAR1B gene was 402×, with a range of 11 
(exon 2) to 832. Variants in the PRKAR1B were examined on their frequency in dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP, build 138), the 1,000 genome project 
(www.1000genomes.org), the National Heart Lung Blood Institute Exome Variant 
Server (EVS) (https://evs.gs.washington.edu/EVS) and the Genome of the Netherlands 
(GoNL) (http://www.nlgenome.nl). Predicted functional effects of all protein-coding 
PRKAR1B were assessed by Polyphen-2 (http://genetics.bwh.harvard.edu/pph2), 
Sorting Intolerant from Tolerant (SIFT) (http://sift.jcvi.org/www/SIFT_enst_submit.
html), PROVEAN (http://provean.jcvi.org/seq_submit.php) and Mutation Taster (www.
mutationtaster.org). Splice site prediction was performed by Alamut 2.0 (Interactive 
Biosoftware). Possible pathogenic variants were confirmed by Sanger sequencing.
Patients were screened for APP gene deletions and duplications using the multiplex 
ligation-dependent probe amplification (MLPA) method and SALSA kit P170 APP 
probes mix according to the manufacturer’s instructions (MRC-Holland b.v.) Results 
were analyzed using GeneMarker Software (version 1.75, SofGenetics, LLC). Dosage 
ratio values of ≤ 0.7 and ≥ 1.3 were used as boundaries for deletions and duplications, 
respectively. At least one negative control was used, no positive controls were available.
The hexanucleotide repeat expansion in the C9orf72 gene was determined by repeat-
primed polymerase chain reaction as described previously.6,15 A cut-off value of 30 
repeats was used to define expanded repeats.16 The C9orf72 analysis was successful in 
218 AD and 72 FTD patients.
Statistical analysis
Means and percentages were calculated with SPSS, version 20.0 (Chicago, Ill., USA).
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Results
No pathogenic PRKAR1B mutations were identified in AD or FTD patients. Nonetheless, 
several variants were found, mainly synonymous variants (Table 2). In two AD patients, 
a non-synonymous variant of unknown significance was found. The variants p.Thr85Asn 
and p.Ala139Thr are predicted to be benign by at least 3 out of 4 software programs. 
The variant c.708+6T>C, possibly affecting a splice site, was found in one AD patient. 
This variant is a known SNP with a prevalence of 0.6% in the Dutch population and 
predicted to be benign by 4 out of 5 splice site prediction algorithms, and therefore, 
unlikely to be pathogenic. 
Mutations in the PSEN1 gene were found in 8 out of the 229 patients with AD (3.5%), and 
a duplication of the APP gene, a MAPT mutation, a GRN mutation and a C9orf72 repeat 
expansion were each identified in one AD patient (0.4%). All mutations found in AD 
patients have been described previously and are considered to be pathogenic (www.
molgen.vib-ua.be/ADMutations). The mutations and a description of the presenting 
phenotype of the patients can be found in Table 3. The overall mutation frequency in 
AD patients was 11% in familial and 2% in sporadic cases. The parents of the sporadic 
patients with PSEN1 mutations died at an age older than 64  years. Information on 
the current age or age of death of the parents of the patient with the C9orf72 repeat 
expansion is lacking. The CSF analysis in the patients with an AD-like clinical presentation 
and a MAPT mutation or C9orf72 repeat expansion showed a normal amyloid-beta and 
increased tau level, while increased tau and decreased amyloid-beta levels were found 
in the patient with the AD-like presentation and the GRN mutation. 
Analysis of 74 FTD patients showed one MAPT mutation (1.4%), two GRN mutations 
(2.7%), seven C9orf72 hexanucleotide repeat expansions (9.9%) and no mutations in 
the genes PSEN1 and APP. A description of the presenting phenotype of the patients 
with mutations can be found in Table 4. The p.Asn296Asp mutation in the exon 10 of 
MAPT gene is likely to be pathogenic as several other pathogenic mutations have been 
reported involving this amino acid, although this mutation has not been reported earlier. 
Both mutations in GRN gene have been described before as pathogenic mutations 
(www.molgen.vib-ua.be/ADMutations). All FTD patients with mutations had a positive 
family history for dementia or ALS, the mutation frequency in familial cases was, 
therefore 36%, and zero in sporadic cases.
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Discussion
The main finding of our study is that we found no evidence for pathogenic PRKAR1B 
mutations in a large cohort of patients with early onset dementia. We found an overall 
mutation frequency of 5% in AD patients, with PSEN1 being the most commonly 
mutated gene and a low frequency of mutations in other genes. In FTD patients, the 
mutation frequency was 14%, mostly consisting of hexanucleotide repeat expansions in 
the C9orf72 gene. We identified MAPT and GRN gene mutations and a repeat expansion 
in the C9orf72 gene in three patients with clinically AD.
The negative results of the PRKAR1B analysis suggest that mutations in this gene are 
rare in early onset dementia patients. Although it is likely that mutations in this gene are 
not associated with an AD-like phenotype, this needs to be studied in a larger cohort.
The observed mutation frequency of common genes in both early onset AD and FTD 
patients is relatively low compared to other studies.4 Most of our FTD patients were 
previously included in a Dutch study, in which a total mutation frequency of 26.3% was 
found in FTD patients.6 However, this latter cohort was enriched by a large proportion 
of patients with an autosomal dominant family 
history, referred to our collaborating centre with special expertise in hereditary FTD. 
The frequency of C9orf72 repeat expansions is comparable between the past and 
present study.
The age at onset and phenotype of the patients with mutations are in most cases in 
concordance with previously described associated phenotypes. Interestingly, mutations 
were found in three AD patients with a negative family history. Furthermore, one of 
the patients with the PSEN1 mutation p.Arg269His had his first manifestations at the 
age of 66 years, a late onset according to the most commonly used definition. This 
mutation was previously found in several families and is most often associated with 
early onset AD.17-19 In one family, however, the mean age at onset was above 65 years.20 
These findings suggest that a late onset of AD and a negative family history do not by 
definition exclude an identifiable genetic cause.
Interestingly, 13% (3/13) of the mutations in patients with the clinical diagnosis of AD 
were found in a FTD gene. An Alzheimer-like phenotype has been previously described 
in patients with the mutation p.Arg406Trp in the MAPT gene (www.molgen.vib-ua.
be/ADMutations), and this specific case has been described before.21 A phenotype 
with predominant memory loss resembling AD is frequently seen in GRN mutations.22 
Although low CSF amyloid-beta levels have been described in GRN mutation carriers,23 
a low amyloid-beta and high tau level in the CSF in this patient strongly suggests a 
concomitant AD. Furthermore, the clinical diagnosis frontal variant of AD in the patient 
with a C9orf72 repeat expansion could retrospectively be considered as a misdiagnosis 
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by the presence of a normal CSF amyloid-beta and increased tau level. This is further 
supported by frontal, temporal and cerebellar atrophy on MRI compatible with FTD, 
especially a C9orf72 repeat expansion.
One of the strengths of our study is the well-defined large cohort of early onset dementia 
patients. The extensive investigations performed on patients with dementia are likely 
to have resulted in a correct diagnosis in most patients, especially if the CSF results had 
been included in the clinical decision making. This is confirmed by the low frequency of 
mutations in the FTD genes in EOAD patients with an AD CSF profile, and no mutations 
in the AD genes in FTD patients.
One major limitation of our study is that we performed genetic analysis of common 
genes associated with AD and FTD only. As the frequency of mutations in other genes, 
like PSEN2, CHMP2B, VCP and TDP-43, is very low, we did not expect to find any mutations 
in these genes. Furthermore, the sensitivity and specificity of the method used for 
the analysis of the C9orf72 repeat expansion differs by performing laboratory.24 Since 
unreliable results of the C9orf72 analysis were not included in the outcome, the actual 
mutation frequency may be slightly higher than reported. Also, since the depth of the 
exome sequencing was quite low for some exons of the PRKAR1B gene, it is possible 
that mutations in this gene have been missed.
In conclusion, no pathogenic PRKAR1B mutations were found in our Dutch cohort 
of early onset AD and FTD patients. Furthermore, mutations in AD patients are quite 
rare, but are occasionally also found in patients with a late onset dementia or lacking 
a positive family history. Therefore, patients and relatives with questions about the 
heritability of the dementia should be referred to a clinical geneticist for counselling 
independently of age at onset and family history. Also, mutations in genes associated 
with FTD may cause an AD-like phenotype. In FTD patients, we only found mutations 
in patients with a positive family history for dementia and/or ALS. However, previous 
studies have shown that especially repeat expansions in the C9orf72 gene may be 
present in sporadic cases.6,16 Therefore, also all FTD patients with questions about a 
genetic cause should be offered genetic counselling.
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During the last decade, major advances have been made in the genetics of Alzheimer’s 
disease (AD) and frontotemporal lobar degeneration (FTLD) by the introduction of 
next generation sequencing (NGS) which allowed us to study rare genetic variants 
with large effect size on disease risk. Whole exome sequencing (WES) has also been 
proven to be a cost-effective approach to identify underlying genetic causes in 
neurodegenerative diseases, in particularly in Mendelian form of disease. Patients with 
previously unspecified dementia have been given a definite diagnosis. Several new 
genetic defects in known or novel genes have been found, and have also resulted in 
further classification of neurodegenerative diseases. To date, no cure is available for 
AD and FTLD. The confirmation of a specific genetic form of dementia is important 
for future drugs trials, especially for starting therapy in early stage of disease process. 
The advantages of WES compared to traditional Sanger sequencing has led to a rapid 
implementation in clinical diagnostic process. However, WES could result in many 
genetic variants with uncertain significance (VUS) to disease or incidental genetic 
findings. This have raised questions on how to characterize these findings and how to 
inform patients and families about these findings.
This thesis aimed to study the contribution of rare genetic variations in AD and FTLD 
using WES, and to describe corresponding clinical and pathological features of these 
mutations carriers. The main findings reported in this thesis will be outlined and 
discussed in relation to other studies. At last, we will provide recommendations for 
genetic variations identified by WES, and will discuss the future direction for genetic 
research in AD and FTLD and the clinical implementation of NGS.
Genetic heterogeneity in Alzheimer’s disease
AD is a genetically complex disease with a highly heritable component.1 The genetics of 
AD is heterogeneous encompassing highly penetrant autosomal dominant mutations 
usually in early-onset AD (EOAD), and genetic risk factors contributing to risk on late-
onset AD. With the introduction of NGS in genetic research of AD, several new genes 
have been identified involving both EOAD and late-onset AD (LOAD). Rare variants in 
Sortilin-related receptor 1 (SORL1), ATP Binding Cassette Subfamily A Member 7 (ABCA7) 
and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) have been consistently 
replicated to be associated with AD, whereas the contribution of several candidate genes 
in AD such as Phospholipase D3 (PLD3) and Unc-5 netrin receptor C (UNC5C) remained 
uncertain.2 One possible explanation for the lack of association might be phenotypic 
variability among patients with neurodegenerative disease, which challenges clinician 
to define correct clinical diagnosis.
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PSEN1 and PSEN2 in EOAD
In Chapter 2.1 we reported three presenilin 1 (PSEN1) and two presenilin 2 (PSEN2) 
variants identified in a Dutch cohort of 68 EOAD patients using WES. Three variants, one 
in PSEN1 and two in PSEN2, have not been previously reported. These novel variants, 
except one frameshift variant in PSEN1 (p.H21Profs*2), were assigned as probable 
pathogenic according to the algorithm proposed by Guerreiro et al.3 The pathogenicity 
of these three novel variants is also supported by their absence in Exome aggregation 
consortium database and the exome database from the Rotterdam study. However, 
we have classified the variant PSEN1 p.H21Profs*2 as a VUS as clinical significance of 
frameshift mutations in PSEN1 is uncertain, and supporting functional experiments 
and segregation data in the family were absent.4-6 
The highly variable clinical presentation of the PSEN1 and PSEN2 variant carriers in our 
study, including behavioral changes and gait disturbances occasionally accompanied 
with spastic paraparesis or hallucinations, is in line with previous reported studies.5, 7 
Up to 16% of PSEN1 mutation carriers have been reported to have an atypical initial 
clinical presentation,7 which challenges the diagnostic process during lifetime. For this 
reason, WES could be helpful for diagnostic purposes. 
EIF2AK3 associated with AD
In Chapter 2.2, we described eight families with a suggestive autosomal dominant 
mode of inheritance for AD, and absence of PSEN1, PSEN2 and APP gene mutations. Using 
WES, we have identified two distinct rare variants in Eukaryotic Translation Initiation 
Factor 2 Alpha Kinase 3 (EIF2AK3) gene segregating with disease in two AD families. 
EIF2AK3 encodes for protein kinase RNA-like endoplasmic reticulum kinase (PERK), which 
functions as a sensor in the endoplasmic reticulum involved in the activation of the 
unfolded protein response (UPR).8 PERK has been implicated to be involved in learning, 
memory and pathogenesis of AD.9, 10 The association of rare variants in EIF2AK3 with 
AD in our study has also been supported by an enrichment of rare variants in the WES 
data of Dutch individuals with AD compared to healthy non-demented controls. One 
previous study has reported an association of one single nucleotide polymorphism in 
EIF2AK3 with AD in APOE ε4 carriers,11 but no studies have examined the contribution of 
rare variant in EIF2AK3 with AD to our knowledge. Burden test by collapsing all variants 
in EIF2AK3 with MAF < 1% showed an almost two times increased risk of AD. It has to 
be noted that the single p.Arg240His variant was the main driver for this association. 
Although there was a potential risk modifying effect of this variant for AD, we could not 
demonstrate this association in an independent cohort of AD cases and non-demented 
controls, but there was a trend towards association. The lack of significance could be 
due to the relatively small sample size in our study. Future replication studies with larger 
sample sizes are needed to investigate the association of EIF2AK3 with AD.
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Neuropathologically, we observed an increased activation of UPR markers phosphoryl-
ated (p) PERK and phosphorylated eukaryotic initiation factor-2α (peIF2α) among the EI-
F2AK3 carriers compared to non-demented controls suggesting an increased UPR activity. 
However, this increased UPR was similar to non-EIF2AK3 carriers with AD, implicating that 
these EIF2AK3 variations may not induce more UPR activation in the pathomechanism of 
AD. Activated UPR has been reported in patients with AD and progressive supranuclear 
palsy (PSP).12, 13 One possible explanation is that EIF2AK3 variants may activate UPR early 
in the disease process, but do not differ in the end stage of the disease.
The exact mechanism how rare EIF2AK3 variants contribute to AD is unclear. We hypoth-
esized that EIF2AK3 variants may enhance PERK signaling, resulting in increased phos-
phorylation of tau by glycogen synthase kinase 3β (GSK3β) and amyloidogenesis (by 
β-site APP cleaving enzyme 1 (BACE1)). Previous studies have indicated that PERK-eIF2α 
signaling is involved in the modulating of tau phosphorylation and amyloid precursor 
protein (APP) processing in AD.9, 14, 15 Increased PERK-eIF2α signaling is also correlated with 
the level of tau pathology in PSP and AD.13, 14 Interestingly, genetic and pharmacological 
modulation of PERK pathway in mouse model has resulted in amelioration of clinical 
and neuropathological features of AD and related disorders, suggesting this could be a 
potential therapeutic target for the treatment and prevention of neurodegeneration.16 
However, severe pancreatic side effects such as hyperglycemia and pancreatic toxicity 
hinder the translation of PERK signaling modifying medication to be implemented in 
clinical trials. 
Our study further supports the genetic contribution of EIF2AK3 to the pathogenesis 
of AD, and may provide new insights in the pathogenesis of AD, and hopefully in the 
therapeutic interventions for AD patients. Future functional studies are warranted 
to investigate the contribution of rare variants in EIF2AK3 to the development of AD.
Genetic heterogeneity in frontotemporal lobar degeneration
FTLD is characterized by a highly variable clinical presentation, and can be accompanied 
with amyotrophic lateral sclerosis (ALS) as well as atypical parkinsonian disorder includ-
ing corticobasal syndrome (CBS) and PSP.17 At genetic level, FTLD is heterogeneous, 
and has a strong genetic component with positive family history among FTLD patients 
up to 50%.18 Pathologically, neuronal depositions of transactive response DNA-binding 
protein of 43 kDa (TDP43) or tau protein can be found in majority of FTLD cases. FTLD 
and ALS have considerable clinical, genetic and pathological overlap, and can be classi-
fied as FTLD-ALS spectrum disorder with possibly sharing disease mechanism (Nguyen 
2018).19 Since the discovery of C9orf72 repeat expansion as major genetic cause of 
FTLD-ALS spectrum, several new FTLD-ALS causing genes including Tank binding kinase 
1 (TBK1), Coiled-coil-helix-coiled-coil-helix domain-containing protein 10 (CHCHD10) 
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and Tubulin alpha 4A (TUBA4A) have been identified using NGS technologies.20, 21 In 
Chapter 3.1 and 3.2 we demonstrated mutations in two ALS genes (VCP and TUBA4A) 
with pure FTLD phenotype. In Chapter 3.3 and 3.4 we demonstrated a novel gene 
mutation causing a rare form of FTLD, and aimed to estimate the frequency of this 
mutation in a cohort of neurodegenerative diseases.
VCP
In Chapter 3.1 we reported two novel and one earlier reported mutation in valosin-
containing protein (VCP) gene in 85 patients with frontotemporal dementia (FTD), 
identified using WES and targeted sequencing of known causative genes involved in 
neurodegenerative disorders. All patients were negative screened for mutations in 
microtubule associated protein tau (MAPT), progranulin (GRN) and Chromosome 9 open 
reading frame 72 (C9orf72). The pathogenicity of VCP mutations was supported by: 1) 
previously reported mutations in the same codon; 2) absence in healthy control exomes 
and public exome databases;22-26 3) neuropathological findings consistent with FTLD-
transactive response DNA-binding protein (TDP) type D.27 A wide variation in phenotypic 
presentation has been reported among VCP mutation carriers, even within the same 
families.28, 29 In our study, behavioral variant FTD (and additional semantic impairment in 
one) without any signs of motor neuron disease or myopathy was the main phenotype 
of the mutations carriers. This clinical presentation was in contrast with classical VCP 
mutation associated phenotype of inclusion body myopathy with Paget’s disease of the 
bone and FTD,30 albeit VCP mutation carriers with pure FTD or MND has been frequently 
reported.23-26 Similar to previous studies, we have also observed a variable age at onset 
ranging from 41 to 60. This large clinical variability indicates the presence of possible 
genetic modifiers. However, no genetic modifiers have been found in VCP mutations 
carriers so far. Future research including large cohort of VCP mutation carriers with distinct 
phenotype may help us in the search for these (genetic) modifying factors.
TUBA4A
An enrichment of TUBA4A variants has initially been reported in an exome-wide analysis 
of familial ALS patients compared to controls, however, the evidence for its causal role 
in FTD and/or ALS is scarce due to: 1) limited number of replication in other FTD and/or 
ALS cohorts; 2) absence of cosegregation with disease.19, 21 In Chapter 3.2 we reported 
a novel TUBA4A variant cosegregated with disease in a family with FTD phenotype. 
This variant was assumed to be probably pathogenic based on a high Combined 
annotation-dependent depletion (CADD) score, unknown in GnomAD database, and 
cosegregation in five affected individuals. Behavioral variant FTD was the phenotype of 
three patients, and dementia with parkinsonism in one. No symptoms of ALS have been 
noticed. Neuropathologically, a mixed of FTLD-TDP type A and type B characteristics 
has been observed in one carrier.27 
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Although TUBA4A variants have been reported to be a rare genetic cause of ALS,6, 21, 31 its 
genetic contribution in FTD remains unclear. Only one study has reported a frameshift 
mutation in TUBA4A (p.Arg64Glyfs*90) in a patient with clinical FTD phenotype without 
supporting neuropathology.6 We reported for the first time a novel TUBA4A variant 
cosegregating with disease in an extended family with FTD and/ dementia including 
neuropathological features of one carrier, indicating that TUBA4A could be a rare genetic 
cause of FTD. Although the potential involvement of TUBA4A variant in our FTD family 
is supported by cosegregation and in silico prediction tools, we could not rule out that 
other candidate variants identified by WES are possibly related to the disease in this 
family. Functional studies are needed to investigate the potential role of this variant 
in the pathogenesis of FTD.
Novel PRKAR1B gene in frontotemporal lobar degeneration
In Chapter 3.3 we reported a large family with dementia and parkinsonism with unique 
neuropathological features. The clinical phenotype is rather unspecific consisting of 
uncharacterized dementia, FTD and atypical parkinsonian disorder. Neuropathological 
examination of three patients showed mild cerebral atrophy with abundant neuronal cyto-
plasmatic inclusions (NCI) positive stained for p62, neurofilament, and α-internexin, but 
negative for fused in sarcoma (FUS), α-synuclein, and TDP43. This neuropathological phe-
notype is in contrast with neuronal intermediate filament inclusion disease (NIFID), in which 
FUS and α-internexin-IR NCI have been observed.32, 33 By combination of genome-wide 
linkage analysis, WES and proteomic analysis we identified a novel mutation (p.Leu50Arg) 
in protein kinase A type I-beta regulatory subunit (PRKAR1B) gene cosegregating in the 
family. The unique neuropathological phenotype consisting of abundant PRKAR1B-IR NCI 
(which are absence in other neurodegenerative disorders), accompanying with biochemi-
cal alteration on western blot supported the pathogenic effect of this mutation. 
Two possible pathomechanisms of this mutation could be hypothesized: 1) by affecting 
effective dimerization between the dimerization/docking (D/D) domains within the 
protein kinase A (PKA) holoenzyme, and as a consequence exposing hydrophobic 
protein regions that may result in aggregation; 2) by reducing the binding of the 
regulatory subunits to both the catalytic subunits of PKA, and to A anchoring protein 
(AKAP), a protein involved in targeting PKA signalling. In vivo and in vitro studies should 
be done to elucidate the exact effect of PRKAR1B on its substrate.
Our study has evidenced the success of combining NGS with proteomics techniques 
(proteogenomic method) to identify disease-causing gene. Interestingly, a similar 
approach has also been applied in one study resulting in the identification of disease-
associated genes.34 Future studies should favouring the use of combination of different 
omics data in genetic studies. 
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PRKAR1B mutation is assumed to be a rare cause of FTLD as no additional mutations are 
reported to date. Screening for PRKAR1B variants in FUS negative NIFID cases did not 
find any mutation in one study.35 In Chapter 3.4 we aimed to estimate the frequency of 
PRKAR1B in a Dutch cohort of patients with clinical diagnosis FTD (n=74) or AD (n=229) 
below the age of 70. We have identified seven variants in PRKAR1B gene, of which two 
nonsynonymous variants with unknown significance. Although the frequencies of 
both variants were rare (< 1%) in public database such as Exome Variant Server and 
Genome of the Netherlands, these variants were predicted to be benign by most in 
silico prediction tools. Neither neuropathology available nor cosegregation analysis 
supporting the pathogenic nature of these variants were available. 
The identification of PRKAR1B mutation in FTLD extends our understanding of genetic 
and neuropathology of FTLD. The lack of studies reporting PRKAR1B mutation indicates 
that this mutation is a rare cause of FTLD. Large sequencing studies are essential to 
estimate the frequency of PRKAR1B mutation in FTLD and other neurodegenerative 
diseases. Functional studies are warranted to investigate the disease mechanism of 
PRKAR1B mutation and its relation with intermediate filaments. 
The variability in clinical presentation complicates making the correct diagnosis, resulting 
in overlapping diagnosis. We have demonstrated that WES could be a useful tool in the 
diagnostic process.
Recommendations for clinical use of WES
Since the introduction of WES, several novel variants in novel genes as well as known 
disease-causing genes have been identified in AD and FTD.1, 36 The accomplishment of 
WES in the genetic research has also led to a rapid implementation of WES in the clinical 
setting due to its powerful and efficient approach to identify causative mutations. 
Nevertheless, the massive use of WES has also resulted in the identification of a large 
number of variants of unknown significance (VUS). Supporting evidence such as 
segregation studies or functional experiments for the pathogenicity of these variants 
is often absent. The question remains how to interpret these variants. Several studies 
have reported guidelines and standards aiming to assess the clinical relevance of 
genetic variants.37-40 It is important to determine whether the gene function is affected 
by the variant of interest, and whether the phenotype of interest can be caused by 
functional change of the variant. Relevant information determining the relation of a 
variant to disease includes type of variants in a gene that are known to result in disease, 
disease phenotype(s) associated to gene, inheritance patterns of described variants 
for disease, protein domains implicated to pathogenesis of disease and described 
gene-phenotype correlations. Previous studies may provide us valuable information 
regarding functional change of protein affected by gene mutation and relation of 
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a gene to disease. Additionally, prevalence of disease, age at onset and inheritance 
mode of disease could help us further assessing the potential relevance of a variant 
in relation to disease. Variants with high allele frequencies in publically available data 
(i.e. Exome Aggregation Consortium, 1000 Genomes) were assumed to be less likely 
causing rare diseases.41, 42 It is important to keep in mind that publically available data 
of genetic variation also includes presymptomatic individuals with late onset disease, 
asymptomatic individuals with low penetrance disease or individuals with younger 
than typical age at onset, and heterozygous carriers with recessive traits. At last, gene 
expression in various organs and underlying pathophysiology of the disease of interest 
may also help us to determine the potential involvement of a gene to disease.
Various in silico prediction programs have been developed to predict the pathogenicity 
of genetic variants.40 Most prediction tools have been focused on missense variant 
including commonly used tools such as Polyphen-2,43 SIFT,44 MutationTaster.45 Other 
prediction tools including CADD,46 Genesplicer,47 Human Splicing Finder,48 could also 
predict non-coding variants and splice site variants. These prediction tools differ 
have distinct algorithms to predict possible effect of a variant, and each tool has their 
own strengths and weaknesses. Therefore, a combination of multiple tools should be 
considered to prioritize the candidate variants. 
In general, genetic segregation provides a robust support for assessing the pathogenic 
effect of a variant, particularly when it segregates in extended families. However, DNA 
samples of additional family members are often limited or unavailable. In absence 
of genetic segregation, supporting functional experiments of a variant may provide 
evidence for the potential damaging effect of the variant. In vitro assays using cell 
models in particularly induced pluripotent stem cells, and animal models could provide 
insights in the disease mechanism.
Future perspective
Genetic research post-WES era
Although GWAS and WES have substantially been contributed to the identification of 
novel genetic mutations in AD and FTD,49 a substantial part of the genetic contribution 
in these diseases remains unknown, with up to 57.7% of FTLD-TDP patients could not 
be explained by known mutations.50 Due to various technical and analytic issues of 
WES (as described in our introduction), whole genome sequencing (WGS) has been 
suggested to be superior to WES in analyzing coding variants, copy number variants 
or structural variants. Several studies have successfully identified novel mutations in 
AD and FTLD using WGS.50, 51 With decreasing costs, WGS has become more and more 
popular. Beyond mutations in coding regions, mutations in non-coding regions could be 
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involved in the pathophysiology of the disease.52 Non-coding regions such as promotor, 
insulator and enhancers are essential for gene regulation. One could speculate that 
mutations in these regions could have a tremendous effect on gene expression. It can 
be hypothesized that at least some of the missing heritability may be explained by 
mutations in these non-coding regions.
In the genetic analysis of rare variants, large sample sizes in cases and controls are 
essential for increasing success rate to identify rare variants associated with disease. 
Various AD and FTD consortia have been set up to collect large number of cases 
and controls for rare variant analysis, and have successfully identified novel genetic 
association for AD and FTD.50, 53, 54  
Sequencing analysis has usually been carried out on DNA extracted from blood, in 
particularly for clinical analysis of patients with neurodegenerative diseases, whose 
brain tissues were not available. However, mutations can be tissue-specific,55 and the 
presence of genetic differences between cells among one single individual is possible, 
also referred as somatic mosaicism. The detection of these somatic mutations can be 
challenging due to unavailability of affected tissue. One example of somatic mosaicism 
is C9orf72 repeat expansion in which higher repeat lengths have been observed in brain 
tissue than in blood.56 However, normal C9orf72 repeat lengths in blood but expanded 
repeats in brain tissue have not been reported so far. Somatic mosaic mutations in brain 
tissue containing a mixed of mutant cells and normal cells might result in aggregation 
of disease-specific protein locally, and as a subsequent lead to spreading of protein 
aggregates in a prion-like way.55 This hypothesis is particularly of interest for sporadic 
disease without known mutations. Classical Sanger sequencing and arrays are often 
not sensitive enough to detect this low level of mosaic mutations. Recent development 
of NGS allows us to detect low mutation levels using ultra deep sequencing. One study 
has proved that ultra deep sequencing of brain region of AD patients could identify 
mosaic mutations in cells with an allele frequency as low as 1 percent.57 Although 
the pathogenicity of these mosaic mutations is unknown, this study highlighted the 
presence of mosaic mutations in known AD mutations and indicated the possible 
involvement of these mutations in the development of disease.
The integration of NGS, mass spectometry technology and bioinformatic tools enabled 
us to study a disease traits at different levels encompassing genomics, epigenetic 
factors (epigenomics), RNA (transcriptomics), metabolites (metabolomics) and proteins 
(proteomics), and has allowed to investigate the relationship between distinct omics 
data.58 The study of multi-omics data can help us to elucidate the pathomechanism of 
the disease, for example how alteration at genomic or epigenomic level might result in 
changes at metabolomic or proteomics level. This is of particularly interest for complex 
disease such as AD, in which multifactorial factors contribute to development of disease. 
We have demonstrated in chapter 3.3 how combining WES (genomics) and proteomic 
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data could result in the discovery a novel mutation in neurodegeneration. Besides, it 
can also be a major step toward personalize medicine based on these multi-omics data.
Functional studies are still warranted to elucidate the exact disease mechanism. 
Promising methods such as induced pluripotent stem cells and CRISPR technology, 
studying a disease status by introducing the mutation of interest, can provide us 
insights in the disease mechanism how the mutation results in specific phenotype.59 
Clinical implementation
In clinical setting, NGS has been applied to diseases with uncertain diagnosis, treatment 
and surveillance of devastating diseases such as cancer.60 Due to clinical overlap of 
distinct neurodegenerative diseases, WES has increasingly been used for clinical 
diagnosis, even in sporadic cases. However, one should be cautious of classifying 
variants as damaging as this may have disastrous consequences for patients and 
families. Besides, unexpected incidental genetic findings for diseases unrelated to the 
observed phenotype, such as increasing risk for cancer, may result in dilemmas whether 
to report these findings to the patients or not. Nowadays, specific disease panels are 
often requested in clinical setting to avoid this problem. Clinicians should be aware 
of these problems before applying WES. Early communication about these issues to 
patients can avoid misunderstanding.
In cancer diagnostics, tumor tissue has been classified by their genetic changes rather 
than their originating tissue nowadays,60 and this genetic profile of the tumor tissue is 
essential for determining the choice of treatment. Considering the clinical heteroge-
neity of AD and FTLD, genetic testing of patients is valuable to determine the correct 
diagnosis including the underlying pathomechanism, and therefore the choice of 
treatment. This is in particular of interest for FTLD, in which distinct genetic forms and 
molecular pathologies exist. With our increased understanding of gene mutations and 
its underlying disease mechanism, and genetic variations with modifying effect on risk 
of developing disease or disease course, it is conceivable that a pharmacogenomics 
profile may also be implemented in the therapy of AD and distinct FTLD forms in the 
future. Interestingly, a recent paper suggested that a single variant in phospholipase 
C gamma 2 (PLCG2) has a protective role in AD, FTLD and dementia with Lewy bodies, 
suggesting a shared etiology between these diseases and potential target for drug 
therapy.61 
In conclusion, WES has made a major step in the genetic research of AD and FTD by 
identifying rare variants contributing to disease. Despite its advent in the genomics, 
a substantial part of the genetic contribution to AD and FTLD remained unexplained. 
Larger sample sizes for genetic associations studies, accompanying with the combina-
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tion of different omics data will be essential for success in the expedition to identify 
remaining unknown genetic factors. Larger consortia of international research groups 
will be established aiming to collect reasonable sample sizes of cases and controls to 
increase the rate of success. In clinical setting, WES should increasingly be applied in 
diagnostic process, in particularly in patients with uncharacterized dementia and posi-
tive family history, and may replace standard Sanger sequencing in the future. Future 
therapeutic trials should consider determining genetic profiles using NGS data to 
stratify patients based on the presence of genetic factors, and to account for genetic 
modifiers as covariates to investigate the effect of drugs.
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Summary 
Dementia is a disorder characterized by cognitive impairments and behavioral 
disturbances that interfere with ability of daily functioning, with Alzheimer’s disease 
(AD) as the most common form of dementia, and frontotemporal dementia (FTD) as 
the second most common before age of 65. Both disorders are characterized by a 
clinical heterogeneity, in particularly for FTD patients, wherein symptoms suggestive 
for motor neuron disease (MND), corticobasal syndrome or progressive supranuclear 
palsy may occur. Genetic factors are involved in the development of AD and FTD. 
Approximately 5-10% of early-onset AD (EOAD) can be caused by autosomal dominant 
inherited mutations in presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor 
protein (APP). FTD is a highly heritable disorder with familial forms in 30-50% of FTD 
patients. Mutations in microtubule associated protein tau (MAPT), progranulin (GRN) or 
hexanucleotide repeat expansion within the non-coding region of Chromosome 9 open 
reading frame 72 (C9orf72) can be found in up to 60% of familial FTD patients. Although 
a majority of familial forms could be linked to these highly penetrant mutations, a 
substantial part of familial cases still remained genetically unexplained. 
In the last decade, advances in technology have enabled us to further investigate 
rare genetic variations using next-generation sequencing methods. Whole exome 
sequencing (WES), a next-generation sequencing technique, investigating rare variants 
(with minor allele frequency < 1%) in protein coding regions, is a time and cost-
effectively method studying causative genetic mutations in patients with unknown 
genetic defects that are probably related to disease. 
This thesis focuses on the finding of genetic causes of patients with AD and FTD with 
unknown genetic defects using whole exome sequencing, and describes the clinical 
and neuropathological features of these mutation carriers.
Chapter 1 provides the general introduction to the distinct genetic forms of AD and 
FTD with their clinical and pathological features and outlines the aims of this thesis.
Chapter 2 describes the study of underlying genetic factors using WES in patients 
with EOAD and/or familial AD. In Chapter 2.1 we screened a Dutch cohort of 68 EOAD 
on rare variants in AD, FTD and prion disease genes, and found three PSEN1 and two 
PSEN2 variants. Of those, three variants were not reported previously, and were absent 
in control exomes. Although the clinical relevance of one variant was unclear, other 
variants were assumed to be probable pathogenic. Clinical presentation of the mutation 
carriers varied from typical memory complaints to behavioral changes or extrapyramidal 
signs. Our findings underlined the clinical heterogeneity among PSEN1 and PSEN2 
carriers, which makes the clinical diagnosis challenging. In Chapter 2.2 we examined 
eight AD families with suggestive autosomal dominant inheritance, unexplained by 
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mutations in PSEN1, PSEN2 and APP. Using WES, we found two distinct rare variants in 
EIF2AK3 gene, segregating with disease in two AD families, and nominated this gene as 
candidate gene for AD. The association of EIF2AK3 with AD was further supported by an 
enrichment of rare variants in the WES data of Dutch individuals with AD compared to 
non-demented controls. Burden test by collapsing all rare variants in EIF2AK3 showed 
almost two times increased risk of AD. This association was mainly driven by one 
variant p.Arg240His, which was also found in one of our AD family. Although we could 
not replicate the association of this variant with AD in an independent AD cohort, 
there was a trend towards association. EIF2AK3 encodes for protein kinase RNA-like 
endoplasmic reticulum kinase (PERK), which functions as a sensor in the endoplasmic 
reticulum involved in the activation of the unfolded protein response (UPR) that is 
essential for protein homeostasis. PERK has been implicated to play a role in learning, 
memory and pathogenesis of AD. Neuropathological examination of EIF2AK3 carriers 
showed an increased phosphorylated PERK and phosphorylated eukaryotic initiation 
factor-2α compared to non-demented controls, indicating an increased UPR as also 
found in previous studies of AD patients. However, the UPR activation was similar 
between EIF2AK3 carriers and non-EIF2AK3 carriers with AD. This is the first study 
supporting genetic association of rare EIF2AK3 variants with AD. Future studies using 
larger sample sizes are needed to investigate this association. It is unclear how rare 
EIF2AK3 variants contribute to AD. Functional studies are warranted to elucidate the 
exact disease mechanism.
Chapter 3 describes the genetic and pathological features of carriers of genetic variants 
in frontotemporal lobar degeneration (FTLD) identified by WES. In Chapter 3.1 we 
reported two novel and one reported variants in valosin-containing protein (VCP) 
gene identified by WES and targeted sequencing of known causative genes involved in 
neurodegenerative disorders. These mutations were assumed to be pathogenic based 
on: 1) previous reported mutations in the same codons; 2) absence in healthy control 
exomes and public exome databases; 3) neuropathological findings of VCP carriers 
consistent with FTLD- transactive response DNA-binding protein (TDP) type D. Main 
clinical presentation of the carriers was behavioural changes, with additional semantic 
impairment in one patient, concomitant wit clinical diagnosis of behavioral FTD. No 
signs of amyotrophic lateral sclerosis, myopathy or Paget disease were noticed during 
the disease course making the classical VCP-mutation associated phenotype of inclusion 
body myositis with Paget’s disease of the bone and frontotemporal dementia unlikely. 
Large clinical variability including variable age at onset and clinical presentation has 
been frequently found in VCP mutation carriers, even within the same family, and may 
indicate the presence of potential genetic modifiers involved in the disease course. 
In Chapter 3.2 we provided the evidence of co-segregation of a novel heterozygous 
variant in Tubulin alpha 4A (TUBA4A) with disease in a family with FTD phenotype 
unexplained by mutations in known FTD genes. TUBA4A has been implicated to be a 
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rare genetic cause of ALS, but the supported evidence for genetic association with FTD 
was limited. In our FTD family, behavioral FTD without symptoms suggestive for ALS 
was the main clinical phenotype in most patients, except for one with uncharacterized 
dementia and extrapyramidal symptoms. Neuropathological findings corresponded 
with a mixed of FTLD-TDP type A and type B characteristics. Screening of TUBA4A in 
our FTD cohort did not identify additional variants. This is the first study describing co-
segregation of a novel TUBA4A variant with disease in a FTD family with its underlying 
neuropathology. Our study indicates that TUBA4A could be a rare genetic cause of 
Dutch FTD patients. 
Chapter 3.3 describes a large family with neurodegenerative disorder presenting with 
dementia and/or extrapyramidal symptoms. Combining genome-wide linkage analysis, 
WES and proteomic analysis we identified a novel variant (p.Leu50Arg) in protein 
kinase A type I-beta regulatory subunit (PRKAR1B) gene co-segregating with disease 
in the family. The variant is located in the dimerization/docking (D/D) domain of the 
regulatory subunits of the protein, and is predicted to hinder dimerization between 
the D/D domains within the protein kinase A (PKA) holoenzymes, as a result in an 
impaired function of PKA or in aggregation of PRKAR1B protein. Unique pathological 
findings were found in three carriers characterized by abundant neuronal cytoplasmatic 
inclusions positive stained for p62, neurofilament, α-internexin and PRKAR1B, but 
negative for fused in sarcoma (FUS), α-synuclein, and TDP43. Mutations in PRKAR1B are 
assumed to be rare as no pathogenic mutations in PRKAR1B has been identified in a 
cohort of patients with familial Parkinson’s disease or FTD. In Chapter 3.4 we screened 
an additional cohort of patients with clinical diagnosis of FTD (n=74) or AD (n=229) 
below the age of 70 on variants in PRKAR1B gene and known AD and FTD genes. We 
identified two rare nonsynonymous variants in PRKAR1B, probably not pathogenic due 
to benign prediction by in silico prediction tools. In our study, the observed mutation 
frequency in patients with AD was 5%, with PSEN1 as most common. Higher mutation 
frequency of 14% was observed in FTD patients, with C9orf72 mutation as most frequent. 
Mutations in FTD genes were found in patients with clinical diagnosis of AD.
In Chapter 4 we discuss the main findings of this thesis, the clinical recommendations 
of WES and suggestions for future research.
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Samenvatting
Dementie is een aandoening die gekenmerkt wordt door cognitieve stoornissen en 
gedragsveranderingen die interfereren met het dagelijks functioneren. De meest 
voorkomende vorm van demente is de ziekte van Alzheimer (ZvA). Frontotemporale 
dementie (FTD) is de tweede meest voorkomende vorm van dementie voor het 65e 
levensjaar. Beide vormen van dementie worden gekenmerkt door een heterogene 
klinische presentatie. Deze heterogene klinische presentatie is meest kenmerkend voor 
patiënten met FTD, waarin patiënten ook klachten van motorisch voorhoornlijden, 
corticobasaal syndroom of progressieve supranucleaire verlamming kunnen hebben. 
Genetische factoren zijn betrokken in de ontwikkeling van zowel ZvA als FTD. Ongeveer 
5-10% van de preseniele ZvA wordt veroorzaakt door erfelijke mutaties in presenilin 
1 (PSEN1), presenilin 2 (PSEN2) en amyloid precursor protein (APP) genen. FTD kan 
veroorzaakt worden door erfelijke mutaties in microtubule associated protein tau 
(MAPT), progranulin (GRN) and hexanucleotide repeat expansion in het niet-coderende 
deel van het chromosoom 9 open reading frame 72 (C9orf72) genen. In familiaire vorm 
van FTD, wordt tot 60% van de ziekte verklaard door mutaties in MAPT, GRN en C9orf72 
genen. Dit betekent dat er een deel van de ziekte nog geen erfelijke verklaring heeft.
In het laatste decennium hebben ontwikkelingen in technologie ons de mogelijkheid 
gegeven verder te verdiepen in het opsporen van zeldzame genetische varianten 
met behulp van next-generation sequencing technieken. Een voorbeeld hiervan is 
whole-exome sequencing (WES), waarmee men zeldzame genetische varianten (d.w.z. 
varianten met een allelfrequentie van kleiner dan 1% in eiwit coderende delen van het 
DNA kunnen opsporen. WES is een tijd- en kosteneffectieve methode om genetische 
mutaties op te sporen bij patiënten zonder bekende erfelijke defecten.
Dit proefschrift focust zich op het vinden van de genetische oorzaken van patiënten 
met ZvA en FTD zonder aangetoonde genetische mutatie met behulp van WES en het 
beschrijven van de klinische en neuropathologische kenmerken van deze genetische 
mutatiedragers.
Hoofdstuk 1 geeft een algemene introductie over de verschillende genetische 
vormen van ZvA en FTD met de bijhorende kliniek en neuropathologie en beschrijft 
de doelstelling van dit proefschrift.
Hoofstuk 2 beschrijft de studie naar de genetische factoren bij patiënten met preseniele 
ZvA en familiaire vorm van ZvA door middel van WES. In hoofdstuk 2.1 hebben we 
een Nederlandse cohort van 68 patiënten met preseniele ZvA gescreend op bekende 
genen betroffen bij ZvA, FTD en prionziekte. Hierbij vonden we 3 genetische varianten 
in het PSEN1 gen en 2 varianten in PSEN2 gen. Drie van deze varianten zijn niet eerder 
beschreven en zijn afwezig in controles. Hoewel de klinische relevantie van 1 variant niet 
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duidelijk is, zijn de andere 2 varianten waarschijnlijk als pathogeen te beschouwen. De 
klinische presentatie van de mutatiedragers varieerde van klassieke geheugenstoornis 
tot gedragsproblemen of extrapiramidale symptomen. Onze bevindingen benadrukken 
de heterogene klinische presentatie voor patiënten met PSEN1 en PSEN2 mutaties. 
Dit kan het stellen van de juiste klinische diagnose bemoeilijken. In hoofdstuk 2.2 
hebben we 8 families met een waarschijnlijke autosomaal dominante vorm van de ZvA 
onderzocht waarvan de genetische oorzaak niet verklaard werd door mutaties in PSEN1, 
PSEN2 en APP genen. Door middel van WES analyse hebben we 2 verschillende zeldzame 
varianten in het EIF2AK3 gen gevonden. Deze varianten segregeerden met de ziekte 
in deze families. Zodoende hebben we dit gen genomineerd als mogelijke genetische 
oorzaak voor de ZvA. De genetische associatie van EIF2AK3 gen is tevens ondersteund 
door de aanwezigheid van meerdere zeldzame varianten in het EIF2AK3 gen in cohorten 
van patiënten met de ZvA in vergelijking met niet-demente individuen. De burden test, 
die alle zeldzame varianten in EIF2AK3 bij elkaar neemt, toonde een bijna 2x verhoogde 
risico op het krijgen van de ZvA. Deze genetische associatie werd vooral veroorzaakt 
door de variant p.Arg240His, die ook in één van de families met ZvA werd gevonden. 
Hoewel we de genetische associatie van deze p.Arg240His variant niet konden 
bevestigen in een onafhankelijk cohort van patiënten met ZvA, was er wel een trend 
naar associatie. EIF2AK3 codeert voor het eiwit protein kinase RNA-like endoplasmic 
reticulum kinase (PERK). Dit eiwit fungeert als een sensor in het endoplasmatisch 
reticulum, dat betrokken is bij de activatie van de unfolded protein response (UPR) welke 
belangrijk is voor de eiwithuishouding. Het is aangetoond dat PERK een rol speelt bij 
leren, geheugen en de pathogenese van de ZvA. Neuropathologisch onderzoek van 
de dragers met EIF2AK3 varianten toonde een verhoogde fosforylatie van het PERK 
eiwit en het eukaryotic initiation factor-2α eiwit in vergelijking met niet-demente 
individuen. Dit wijst op een verhoogde UPR die eerder ook beschreven is bij studies van 
patiënten met de ZvA. Echter is deze verhoogde UPR vergelijkbaar in dragers en niet-
dragers van de EIF2AK3 varianten. Dit is de eerste studie die de genetische associatie 
van zeldzame varianten in het EIF2AK3 gen met de ZvA ondersteunt. Toekomstige 
studies met grotere aantallen van patiënten en controles zijn nodig om deze associatie 
verder te onderzoeken. Het is vooralsnog niet geheel duidelijk hoe zeldzame EIF2AK3 
varianten betrokken zijn bij het ontstaan van de ZvA. Functionele studies zijn nodig 
om het exacte ziektemechanisme op te helderen.
Hoofdstuk 3 beschrijft de genetische en pathologische kenmerken van dragers 
van genetische varianten voor frontotemporale lobaire degeneratie (FTLD) die door 
middel van WES zijn gevonden. In hoofdstuk 3.1 hebben we middels WES en gerichte 
sequencing (targeted sequencing) van bekende genetische oorzaken betrokken 
bij neurodegeneratieve ziekten een tweetal nieuwe en een bekende mutatie in het 
valosin-containing protein (VCP) gen gevonden. We beschouwen deze genetische 
mutaties als pathogeen op basis van 1) Eerdere mutaties die in het dezelfde eiwitcodon 
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zijn gerapporteerd; 2) afwezigheid van dezelfde mutaties in exomen data van 
gezonde controles en publiek toegankelijke exomen databases; 3) FTLD-transactive 
response DNA-binding (TDP) protein type D bij neuropathologisch onderzoek van de 
VCP-mutatiedragers. De klinische presentatie van gedragsverandering, met tevens 
bijkomende semantische taalstoornissen bij een patiënt, paste bij de klinische diagnose 
van gedragsvariant FTD. Klinische tekenen van amyotrofische laterale sclerose (ALS), 
myopathie of de ziekte van Paget werden niet gevonden in het ziektebeloop. Dit maakte 
de klassieke VCP genmutatie geassocieerde klinische diagnose van inclusion body 
myositis met de ziekte van Paget en frontotemporale dementie minder waarschijnlijk. 
VCP gen mutatiedragers worden gekenmerkt door grote heterogene klinische 
presentatie inclusief de variabele debuutleeftijd en verschillende klinische symptomen, 
zelfs bij individuen binnen dezelfde familie. Dit suggereert de aanwezigheid van 
potentiële genetische factoren die het ziekteverloop kunnen beïnvloeden.
In hoofdstuk 3.2 tonen we bewijs voor de segregatie van een nieuwe variant in 
het Tubuline alpha 4A (TUBA4A) gen in een FTD familie zonder bekende genetische 
oorzaak. TUBA4A is beschreven als een zeldzame genetische oorzaak voor ALS, maar 
het bewijs voor de betrokkenheid van dit gen bij FTD is gering. Gedragsvariant FTD 
zonder klinisch symptomen van ALS was het meest voorkomende fenotype in deze 
familie. Eén patiënt had een niet nader gespecificeerde dementie met extrapiramidale 
verschijnselen. Bevindingen bij pathologisch onderzoek pasten bij een mix van FTLD-
TDP type A en type B. De screening van TUBA4A gen in onze FTD cohort toonde geen 
overige potentiële pathogene varianten. Dit is de eerste studie die de segregatie van 
een nieuwe TUBA4A gen variant met de bijbehorende pathologie beschrijft. Onze 
studie suggereert dat mutaties in het TUBA4A gen mogelijk een zeldzame genetische 
oorzaak is voor FTD. 
Hoofdstuk 3.3 beschrijft een grote familie met neurodegeneratieve ziekte waarbij de 
patiënten zich presenteren met dementie en/of extrapiramidale verschijnselen. Door 
een gecombineerde analyse van familie koppelingsonderzoek, WES en proteomic 
onderzoek hebben we een nieuwe variant (p.Leu50Arg) in het protein kinase A type 
I-beta regulatory subunit (PRKAR1B) gen gevonden wat segregeerde met de ziekte 
in deze familie. De variant bevindt zich in het dimerisatie/docking domein van de 
regulatoire subunit van het eiwit. In silico analyse voorspelt dat deze variant de 
verbinding van de dimerisatie/docking domein binnen de proteine kinase A (PKA) 
holoenzym kan verstoren. Dit kan resulteren in een gestoorde PKA functie of in 
ophopingen van PRKAR1B eiwitten. De unieke neuropathologische bevindingen, 
gekenmerkt door overvloed aan neuronale cytoplasmatische eiwitophopingen die 
een positieve kleuring hebben voor p62, neurofilament en α-internexin eiwitten, 
maar negatief zijn voor fused in sarcoma (FUS), α-synucleine, and TDP43 eiwitten. 
De veronderstelling is dat PRKAR1B gen mutatie zeldzaam is in FTD en de ziekte van 
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Parkinson omdat er geen overige pathogene mutaties zijn gevonden in een cohort 
met FTD en Parkinson patiënten. In hoofdstuk 3.4 hebben we een additioneel cohort 
met patiënten met klinische diagnose van FTD (n=74) of ZvA (n=229) (onder 70 jarige 
leeftijd) getest op varianten in het PRKAR1B gen. Hierbij vonden we tweetal zeldzame 
nonsynoymous varianten in PRKAR1B gen die waarschijnlijk niet pathogeen zijn. We 
vonden een mutatiefrequentie van 5% in patiënten met de ZvA en PSEN1 was de meest 
voorkomende mutatie. De mutatiefrequentie was hoger in FTD patiënten met C9orf72 
repeat expansie als de meest voorkomende mutatie. Mutaties in FTD genen werden 
gevonden in patiënten met klinische diagnose van ZvA.
In hoofdstuk 4 bespreken wij de belangrijkste bevindingen in dit proefschrift, de 
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gnomAD Genome aggregation database 
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GRN Progranulin
GSK3β Glycogen synthase kinase 3β
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HEX Healthy EXomes 
hnRNPA1 Heterogeneous nuclear ribonucleoproteins A1
hnRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2B1
HSP Hereditary Spastic Paraplegia




IRE1 Inositol Regulating Enzyme 1
LB Lewy bodies
LGMD Limb-Girdle Muscular Dystrophy
LOAD Late-onset AD
LoF Loss of function 
LS Low salt
MAF Minor allele frequency
MAPT Microtubule associated protein tau
MLPA Multiplex ligation-dependent probe amplification
MMSE Mini Mental State examination 
MND Motor neuron disease
MRI Molecular mass 
MSP Multisystem proteinopathy 
NCI Neuronal cytoplasmic inclusions
NF Neurofilament
NGS Next-generation sequencing
NIFID Neuronal intermediate filament inclusion disease
NII Neuronal intranuclear inclusions
NOS Not otherwise specified
OPTN Optineurin
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PD Parkinson’s disease
PDB Paget disease of the bone
peIF2α Phosphorylated eukaryotic initiation factor-2α 
PERK Protein kinase RNA-like endoplasmic reticulum kinase
PGRN Progranulin (protein)
PKA Protein kinase A 
PLCG2 Phospholipase Cγ2
PLD3 Phospholipase D3
PNFA Progressive non-fluent aphasia
PPA Primary progressive aphasia
pPERK Phosphorylated pancreatic endoplasmic reticulum kinase
PRKAR1B Protein kinase A type I-beta regulatory subunit
PSEN1 Presenilin 1
PSEN2 Presenilin 2
PSP Progressive supranuclear palsy
PTV Protein truncating variants 




SIFT Sorting Intolerant from Tolerant
SNP Single nucleotide polymorphism 
SORL1 Sortilin-related receptor 1
SPECT Single photo emission computed tomography
SQSTM1 Sequestome 1 
svFTD Semantic variant frontotemporal dementia
TAF15 TATA-binding protein-associated factor 15
TARDBP TAR DNA binding protein 
TBK1 TANK-binding kinase 1 
TDP Transactive response DNA-binding protein
TDP-43 Transactive response DNA-binding protein of 43 kDa
TMEM106B Transmembrane protein 106B 
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TUBA4A Tubulin alpha 4A 
TX TritonTM X-100
UBQLN2 Ubiquilin 2
UNC5C Unc-5 netrin receptor C
UPR Unfolded protein response
UPS Ubiquitin proteasome system
UR Urea
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VUS Variant with uncertain significance 
WES Whole exome sequencing 
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